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Abstract
With increased interest in studying neurodegenerative diseases, data generated is grow-
ing exponentially. The sheer amount of patient data being collected gives rise to the
problem of how it can be stored, represented and classified. The representation of col-
lected data varies from one centre to other, based on several factors such as language,
region, standards adapted, study design. The results of this variation makes it difficult
to study different cohorts by combining or comparing them. Therefore, variables that
are collected in all these cohorts need to be standardised and harmonised for further
re-use and analysis.
Disease maps are another form of knowledge resources collecting existing
biological facts in a single resource. Disease mechanisms are represented visually in
the form of models or maps, capturing the knowledge extracted from the literature.
There are several modelling languages which serve this purpose. Disease maps capture
knowledge about disease related mechanisms at different molecular levels. Compar-
ison of different disease maps can support co-morbidity studies to identify common
disease mechanisms or drug targets. To this end, we developed a method to compare
disease maps. We then compared Parkinson’s and Alzheimer’s disease maps using this
approach.
However, there are several modelling formats available. Therefore, here arises
a need to harmonise and standardise the representation and make the different disease
modelling formats convertible and comparable. For the course of the project, we focus
on Open Biological Expression Language (OpenBEL) and Systems Biology Markup
Language (SBML) modelling languages. A semi-automated convertor from OpenBEL
format to SBML was developed to compare knowledge over heterogeneous systems his
was then used to convert an Alzheimer’s OpenBEL model to SBML format for better
visualization and hierarchical representation and to enable comparison against other
SBML models.
In conclusion, the work presented in the thesis, emphasises the importance of
standards in the representation and modelling of clinical and biological information to
vi
ensure interoperability between tools and models and facilitate data sharing, reusability
and reproducibility.
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Chapter 1
Introduction
A large number of clinical cohorts are set up to study diseases and their mech-
anisms. As of May 2018, Clinicaltrails.gov records 450 clinical studies planned or
currently recruiting subjects with Parkinson’s Disease. Another 100 have completed
recruitment and are still active. During a clinical study, researchers collect diverse data
over several visits, e.g.: clinical assessments, biomarker tests, imaging, genetic tests,
all in various formats. The study design, ontologies used and even the language of the
study may differ. As a support to clinical studies being setup to study diseases, disease
maps offer an approach to collect and integrate existing knowledge about the disease
mechanisms, providing context to the hypotheses about the disease. Disease maps inte-
grate multiple knowledge resources at different molecular levels and also enable visual
exploration.
Current disease classifications rely mainly on the phenotypes of the diseases,
especially in the case of neurodegenerative diseases like Parkinsons and Alzheimers.
This is primarily due to the inherent complexity of the biological systems and partly
because the aetiology of the disease is still unknown to us. Recently projects like AE-
TIONOMY (https://www.aetionomy.eu) and SYSCID (https://syscid.eu/) focus
on capitalising on the knowledge about the underlying mechanisms of the disease to
1
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better explain the pathology of the disease [Hofmann-Apitius et al., 2015a, Schultze and
Rosenstiel, 2018]. Integration of these heterogeneous resources requires a harmonised
format and standards. This also helps to link different tools and subsequent analysis.
Today, the data generated by research grows both in volume and variety. This
data is definitely valuable but mostly unstructured or partially structured. Making data
useful requires cleaning and organising, which is both expensive and time consuming
and adds to the cost at every step of data processing, from analysis to decision making.
Data collected from disparate sources require harmonization for them to provide a
single view, otherwise they will remain separate pieces.
Harmonisation transforms datasets such that different pieces fit together
both in terms of semantics and information. Thus, it improves the power of large
scale studies by facilitating integration of different analyses. Harmonising collected
data increases the quality of data and the precision of resulting analysis. Utilising
standards to harmonise data and knowledge bridges the gap between their representa-
tions and makes the data easily identifiable, sharable, useful and interoperable. Data
sharing is one of the key components of reproducible and efficient research, to maximize
the value of research. To promote good data stewardship, a community of international
stakeholders have developed a set of guidelines to make data Findable, Accessible, In-
teroperable and Reusable, and have been widely accepted by the scientific community,
and various institutions, projects and initiatives to share data and maximise its use
and reuse [Wilkinson et al., 2016].
1.1. Trends in biomedical research and their impact on bioinformatics 3
1.1 Trends in biomedical research and their impact
on bioinformatics
With the advent of high-throughput technologies, the rate at which data
is generated to support translational research and personalised medicine is growing.
These high-throughput technologies are used to investigate distinct aspects of the cellu-
lar processes at several levels such as genome, transcriptome, proteome and metabolome.
To understand complex biological systems, we need to study the effect of alterations
on the genome, transcriptome, proteome and metabolome simultaneously [Horgan and
Kenny, 2011]. Data integration has been reported to be an effective strategy to extract
meaningful biological data from heterogeneous data sets in several fields [Xie et al.,
2017, Huang et al., 2017]. It has been employed to identify candidate genes for further
investigation, thereby scaling down the translation of genome-wide data into smaller
list [Zhong and Sternberg, 2007]
The heterogeneity and inaccessibility across data sources are the major fac-
tors hindering formalized integration. Mandates on data sharing, considerations of
standardized data collection, and mechanisms to integrate heterogeneous data are nec-
essary to address these issues [Allen et al., 2016]. Today several efforts are in place
in the scientific community to enforce and promote the use of a uniform standard, on
data sharing [Wilkinson et al., 2016, McQuilton et al., 2016, Auffray et al., 2016, Wol-
stencroft et al., 2017].
1.2 Standards in biomedical research
Standards are an agreed or compliant term or form of representation. In
other words, standards are essentially a set of rules and definitions that specify how to
name or describe any entity or process. In a data-driven field like biomedicine, stan-
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dards play a major role. While some standards evolve over time, it is also essential to
develop them deliberately. Standards enable diverse research groups to communicate
and work in co-operative and collaborative environments, especially in healthcare do-
main, where different groups of people work towards a common goal. For instance, in a
healthcare environment, diverse groups such as patients, doctors, hospitals, biologists,
statisticians, bioinformaticians, patient organisations need to work together. This re-
quires coordination, communication and transfer of knowledge and data from one group
to another. In addition, medical knowledge is complex. Thus, encoding knowledge and
data using accepted standards and ontologies can reduce both ambiguity and technical
challenges for data exchange and interoperability arising due to the heterogeneity of the
data generated [Oemig and Snelick, 2016, Bodenreider, 2008, Smith and Brochhausen,
2010].
1.2.1 Need for standards
Most biomedical systems and resources are designed and developed indepen-
dently of each other. Therefore, they do not share a common format or structure.
This makes it time consuming and complex to determine the correspondences between
these heterogeneous sources. Challenges arising due to the heterogeneity in the design
of various databases have been previously reported in several biological research do-
mains such as genome wide studies and gene expression studies [Zhong and Sternberg,
2007]. The process is considered both time and computationally exhaustive since dif-
ferent databases use different identifiers, formats and access methods. Therefore, to
overcome such computational challenges researchers have preferred to obtain data from
least number of sources possible [Zhong and Sternberg, 2007].
Standards facilitate re-use of data by enabling easier data sharing and repro-
ducibility. In addition, standards also promotes interoperability across different data
formats and analysis tools. In an ideal biological research environment, standards form
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the base to all the higher layers of the infrastructure [Lapatas et al., 2015]. Therefore,
a strong foundation is necessary to build subsequent integration and analysis tools.
For data driven research goals, integration of results from different bioinformatic tools
or software are required. The first step is to find the specific service or tools which are
necessary to attain this goal. This may be one or more tools required in consecutive or
parallel steps. The results maybe generated through a web service or locally. However,
in several domains including biological research, it is a well accepted fact that these
tools and web services are not expected to be designed or represented using the same
schema or ontologies, since they are most likely developed for different purposes or tar-
get users [Ethier et al., 2018, Shvaiko, 2005]. Henceforth, both for finding the adequate
services and linking them, it will be necessary to establish the correspondences between
the interpretation of the inputs and generated results [Wilkinson et al., 2016, Ham-
mond et al., 2014]. Following standards in the design of the tools, representation and
naming of the inputs, process and outputs play an import role in this process. For
instance, if a service provides its result and description in an ontology and the next
required service or tool uses a different ontology for its input, matching both ontologies
and formats are essential for
a) ensuring what is delivered by the first service, matches what is required by the
second
b) verifying prerequisites of the second service or tool, and
c) creating a middle layer which acts as an interface to transform the output of the
first service such that it can be the input expected by the second service or tool.
Most scientific studies are build on previous findings. The scientific pro-
cess therefore depends heavily on the reproducibility and interoperability of results. In
2011, a team at Bayer Health Care in Germany investigated 67 in-house projects. They
reported that only about 25% of published preclinical studies could be validated for
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further investigation [Prinz et al., 2011]. Ioannidis et al., in 2009 reported the reanal-
ysis of 18 articles published in Nature Genetics on comparative analysis of microarray
experiments. Only two analyses could be reproduced in principle and six partially or
with some discrepancies. The main reason for failure, was reported as data unavail-
ability, incomplete data annotation or specification of data processing and analysis
[Ioannidis et al., 2009]. A lack of transparency and standards leads to loss in resource
and time to replicate these results [Baker, 2016, Begley and Ellis, 2012].
1.2.2 Standardisation efforts
Several initiatives coordinate and collaborate on the consolidation and cre-
ation of standards. They also play a major role to advocate the use of standards in
biological research at all levels. The Findability, Accessibility, Interoperability, and
Reusability (FAIR) principles for scientific data management and stewardship were es-
tablished to enhance the ability of machines to automatically find, access, exchange and
use data. FAIR stands for the four foundational principles Findability, Accessibility,
Interoperability, and Reusability [Wilkinson et al., 2016].
Clinical data interchange standards consortium (CDISC)
The Clinical Data Interchange Standards Consortium (CDISC) works on de-
veloping standards in clinical trials data and metadata (https://www.cdisc.org/). The
CDISC mission is ”to develop and support global, platform-independent data standards
that enable information system interoperability to improve medical research and related
areas of healthcare”. These standards facilitate the acquisition, submission, exchange,
and archiving of clinical trail data. For instance, the CDISC standard for acquisi-
tion, Clinical Data Acquisition Standards Harmonization (CDASH), aims to improve
interoperability in clinical research and drug development processes. The Study Data
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Tabulation Model (SDTM), provides a standard for organising and formatting data
to streamline processes in collection, management, analysis and reporting. Currently,
SDTM is one of the required standards for data submission to FDA (U.S.) and PMDA
(Japan).
MIRIAM and Identifiers.org
In order to ensure re-usability of biological models the computational biology
community proposed a set of guidelines, the Minimum Information Required in the An-
notation of Models (MIRIAM) [Le Nove`re et al., 2005]. These guidelines describe not
only the need to unambiguously and perennially identify components in the model, but
also required meta-information such as provenance and development. The MIRIAM
Registry (currently Identifiers.org), available at http://identifiers.org/registry provides
such a centralised, unique, perennial and location independent identifiers for use in the
biomedical domain. The registry is catalogue of data collections. Each data catalogue
is associated with a unique namespace and extensive metadata. This namespace then
allows the generation of Uniform Resource Identifiers (URIs) to uniquely identify any
record in the collection. To increase usability, Identifiers.org [Juty et al., 2012] pro-
vides a service which provides directly resolvable identifiers, in the form of Uniform
Resource Locators (URLs). The flexibility of the identification scheme and resolving
system allows its use in many different fields, where unambiguous and perennial iden-
tification of data entities is necessary. Many ontologies and databases currently use
these URIs, including Reactome [Croft et al., 2011], BioModels Database [Li et al.,
2010], OpenPHACTS [Williams et al., 2012] and Bio2RDF [Belleau et al., 2008].
8 Chapter 1. Introduction
Computational Modelling in Biology Network (COMBINE)
The growing model sizes and their complexities make it necessary to stan-
dardise forms of representations [Waltemath and Wolkenhauer, 2016a]. Standardising
modelling formats is essential for largescale modelling, eases sharing results and per-
mits other researchers to use, re-use them [Hucka and Finney, 2005]. The Compu-
tational Modelling in Biology Network (COMBINE, http://co.mbine.org), guides the
development of standards for modelling in computational biology. COMBINE helps to
coordinate common activities and to establish a common infrastructure by fostering
communication between the various standardization efforts [Waltemath et al., 2015].
COMBINE supports both, mature standards and emerging efforts, in covering the cur-
rent needs in the interoperability landscape. The network identifies missing standards
and promotes further developments for the exchange of modelling and results [Hucka
et al., 2015]. The COMBINE, currently covers standards for CellML [Lloyd et al.,
2008], SBML [Hucka et al., 2003], SBOL [Galdzicki et al., 2014], BioPAX [Demir et al.,
2010], SEDML [Waltemath et al., 2011], NeuroML [Gleeson et al., 2010] and SBGN
[Nove`re et al., 2009]. In addition, projects such as FAIRDOM (http://fair-dom.org)
develop management guidelines and infrastructure for collaborative modelling. They
also offer curation, training, and run workshops and summer schools to promote these
standard settings within the systems biology community.
Disease Maps Community (DMC)
Disease maps are emerging concept, providing computationally readable yet
comprehensive knowledge-based resource of disease mechanisms. Disease maps visu-
ally represent hallmark pathways and biological processes associated with the disease
[Mizuno et al., 2012, Fujita et al., 2014, Kuperstein et al., 2015]. Disease maps bring
together domain experts from bioinformatics, molecular biology and clinical research.
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To ensure the interoperability of disease maps, it is essential to adopt relevant stan-
dards for knowledge encoding and annotation [Mazein et al., 2018]. Also, appropriate
tools are needed to support creation and use of the maps. The DMC (http://disease-
maps.org/) brings together developers and users of disease maps. The community
was formed to identify challenges by exchanging experiences from the different dis-
ease maps’ projects [Ostaszewski et al., 2018]. The community aims to establish best
practices for creation, maintenance and application of disease maps.
1.3 Disease maps as knowledge resources
Systems biology is a data driven domain, with rapid generation of data about
the individual components such as genes, proteins, chemicals, diseases, cell types and
organs [Greene and Troyanskaya, 2010]. To understand complex biological systems
and diseases, we need to bring into context available data to detect relations, pattern
and links between the individual components, allowing us to formulate and validate
scientific hypotheses [Kitano, 2002]. The existing knowledge is distributed over different
databases. Disease maps are one such method to integrate knowledge about the disease
mechanisms from literature and different databases into a single resource and to add
context to the knowledge, by organising it into a structured and organised network.
Disease maps integrate and annotate knowledge from different molecular mechanisms
and biological pathway relevant to the disease into a computer-readable format and
enable visual exploration.
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1.3.1 Complexities of diseases and their comorbidities
Figure 1.1: Complexity of diseases and their comorbidities
Source: Dr. Reinhard Schneider
Complex diseases like neurodegenerative diseases are affected by several fac-
tors. The Figure 1.1 illustrates the knowledge gap between the high-level medical
ontologies, describing the disease state, and biological models and ontologies, encod-
ing molecular processes, and their perturbation by genomic, environmental or lifestyle
factors. There is a missing link between the way we represent the biological knowl-
edge, diseases and their treatments. To bridge this link, disease maps integrate the
knowledge about disease mechanisms from literature in a single resource.
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1.3.2 Representing diseases as a map
Disease mechanisms can be modelled as a molecular interaction graph, i.e.
nodes that are connected by edges. Each component of the biological system and other
factors contributing to the disease pathology are represented as a node. Each node is
annotated by a unique identifier. Localisation of the interaction and nodes are repre-
sented as clusters or compartments providing the map a hierarchical organisation. The
relationship or interaction between these ”factors” are modelled as edges connecting
the node. Curating a disease-related pathway comprises of identifying and structur-
ing content, mining for information either manually or computationally, or both, and
building a knowledge base using appropriate software [Viswanathan et al., 2008].
Representation of molecular pathways requires a format for modelling that
is computable and allows for exchange, integration. Several such formats exist, varying
in representation depending on their purpose.
1.3.3 Common modelling formats
Most widely used pathway-related formats [Stro¨mba¨ck et al., 2006], are XML-
based. We would like to focus on three important notations, namely Systems Biol-
ogy Markup Language (SBML) [Hucka et al., 2003], Biological Pathways eXchange
(BioPAX)[Demir et al., 2010] and Open Biological Expression Language (OpenBEL)
(http://openbel.org/).
BIOlogical PAthway eXchange language (BioPAX)
BioPAX (Biological Pathway Exchange) is a standard language to facilitate
exchange biological pathway data at the molecular and cellular level. It is defined
in Web Ontology Language (OWL) and represented in XML [Demir et al., 2010].
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BioPAX has a large user base and is supported by many pathway databases such as
Reactome [Fabregat et al., 2018], Panther [Mi et al., 2017] and network visualisation
and analysis tools such as cytoscape [Shannon et al., 2003]. BioPAX was created
through a community process and continues to be an open and collaborative effort.
Systems Biology Markup Language(SBML)
SBML [Hucka et al., 2003] is a software-independent language used to build
models in the computational biology domain. SBML is used mainly for modelling, it
can also be used for pathways representations including metabolic pathways, gene regu-
lation, and cell signalling pathways [Caron et al., 2010]. As of May 2018, SBML is sup-
ported by over 280 software systems (http://sbml.org/SBML Software Guide). With
greater support and interaction between tools, and a common format like SBML, users
would be better able to spend more time on actual research rather than on complying
with data format issues. As of May 2018, the BioModels (https://www.ebi.ac.uk/biomodels-
main/) lists 8428 SBML models.
BioPAX and SBML are two of the most commonly used format in the systems
biology modelling domain and are supported by a wide base of user and developer
community to make them interoperable [Bu¨chel et al., 2012, Rodriguez et al., 2016]
Open Biological Expression Language (OpenBEL)
There exists numerous modelling languages and formats for modelling bio-
logical knowledge as networks. However many require at least a basic understanding
of programming knowledge to use and are generally not adopted by biologists and
clinicians. In recent years, with the explosion of data and knowledge in the biomed-
ical domain, it is important to develop tools that can foster collaboration between
experts in different domains. One of the most important features of OpenBEL is that
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it is both human readable and computable. The subject and object are annotated by
namespaces, in this case MeSH Disease and Gene Ontology respectively. BEL focuses
on representing the causal and correlative relationship between entities. These entities
can be biological entities such as proteins, genes, RNA, etc or chemicals, complexes
or phenotypes. The relationships represent primarily cause-effect events between these
entities. BEL also captures the provenance of the relationships, at the statement level.
BEL statements are modelled as a semantic triple. The subject and object
are connected by the predicate which describes their relationship. In this example (List-
ing 1.1 and Figure 1.2), we can see that from the statement the subject Atherosclerosis
has a positive correlation with the object lipid oxidation.
SET Disease = "Atherosclerosis"
SET CardiovascularSystem = "Arteries"
SET TextLocation = "Review"
SET Evidence = "Oxidation and nitration of macromolecules , such as
proteins , DNA and lipids , are prominent
in atherosclerotic arteries."
SET Citation = {"PubMed","Trends in molecular medicine","12928037",
"","de Nigris F, Lerman A, Ignarro LJ, Williams -Ignarro S, Sica
V, Baker AH , Lerman LO , Geng YJ , Napoli C",""}
pathology(MESHD:Atherosclerosis) positiveCorrelation
biologicalProcess(GO:"lipid oxidation")
Listing 1.1: BEL Statement Example
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Figure 1.2: BEL Statement structure
Representation of BEL terms as functional expressions, helps to make the
language concise. The concept of abundance provides a systematic way to represent an
unknown quantity of biological material or activity and how its activity can increase or
decrease in the system. This allows a qualitative representation of biological knowledge.
OpenBEL is one of the popular modelling languages among biologists pri-
marily due to its simplicity and resemblance to natural language. It has been widely
accepted by the research community especially because of its simplicity and short learn-
ing curve. Although it is close to natural language it is still a computable model. As
a result, it has been adopted by various crowd sourcing challenges to build and gener-
ate networks collaboratively [Namasivayam et al., 2016]. Additionally, in recent years
several text mining and information extraction challenges and tasks have also adopted
OpenBEL [Fluck et al., 2015, Fluck et al., 2016] [Lai et al., 2016].
1.3. Disease maps as knowledge resources 15
SBML BEL BioPAX
Inventors Systems Biology Work-
bench
Selventa: OpenBEL BioPAX group
Focus Process description Entities and causal re-
lationship
More general represen-
tation, Focus on reac-
tion/interaction
Tools Validation, visualisa-
tion, conversion and
modelling e.g. CellDe-
signer, Cytoscape
(BiNoM plugin)
BEL Framework: con-
vertor to XML, Valida-
tion, Visualisation by
Cytoscape, PyBEL
Validation, visualisa-
tion, conversion and
modelling e.g. Protege,
ChiBE, BioLayout,
Cytoscape (BiNoM
plugin)
Interactors Species Subject/Object PhysEntity
Interactions Reactions Relationship Reaction
Role of Interactors Reactants, Products or
Modifiers
Subject, Object Pathway representing
set of interactions
Mathematical rela-
tions
Yes No No
Inheritance Yes No Yes
New entities Unknown type abundance Possible to make ap-
plication specific addi-
tions
Table 1.1: Features of SBML, OpenBEL, BioPAX
Table 1.1 gives a summary of the features of SBML, OpenBEL and BioPAX
(Source: [Stro¨mba¨ck et al., 2007], http://sbml.org/, https://binom.curie.fr/,
http://openbel.org/,http://www.biopax.org/).
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(a) Parkinson’s Disease Map (SBML compliant)
(b) Amyloid Precursor Protein normal physiology model (BEL)
Figure 1.3: Disease models in SBML and OpenBEL formats
Although BEL models, capture the context information, this information is
not utilised for its visualisation via Cytoscape (Figure 1.3b) [Shannon et al., 2003].
SBML, on the other hand can graphically represent cellular location and pathways
with the help of diagram editors like CellDesigner (Figure 1.3a) [Funahashi et al.,
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2003, Funahashi et al., 2008]. Visualising context or location information is essential
to the concept of disease maps for navigational capabilities similar to geographical
maps. Currently, the concept of disease maps is implemented in domains such as
cancer [Kuperstein et al., 2015], influenza [Matsuoka et al., 2013] and neurodegenerative
diseases [Fujita et al., 2014] [Mizuno et al., 2012].
So far all the publicly available maps are constructed using CellDesigner in
SBML and notations based on the process description of Systems Biology Graphical
Notation (SBGN) [Nove`re et al., 2009]. CellDesigner is a diagram editor for drawing
gene-regulatory and biochemical networks. Diagrams are drawn based on the process
diagram, with graphical notation system proposed by Kitano et. al. [Kitano et al.,
2005], and are stored in an SBML-compliant format. To support efficient navigation
and management of community driven curation of these maps platforms such as the
NaviCell [Kuperstein et al., 2013, Bonnet et al., 2015] and MINERVA [Gawron et al.,
2016] are available. NaviCell is a platform for exploring large maps of molecular inter-
actions built in CellDesigner. NaviCell features efficient navigation, semantic zooming
of the map for viewing different levels of details. Additionally, it also provides sup-
port for collecting curation feedbacks from the community. MINERVA [Gawron et al.,
2016] (Molecular Interaction NEtwoRks VisuAlization) platform is a web service sup-
porting curation, annotation and visualization of molecular interaction networks in
Systems Biology Graphical Notation (SBGN)-compliant format. MINERVA also sup-
ports automated content annotation and verification, thereby improving the quality of
the maps. Both these platforms use the Google Maps API for semantic zooming and
navigation of the maps.
All the elements (proteins, genes, RNA, chemicals, metabolites, etc,.) in a
map should ideally be annotated by publicly available databases such as UniProt [Ma-
grane and Consortium, 2011], HGNC [Gray et al., 2015], Ensembl [Yates et al., 2016],
Entrez Gene [Maglott et al., 2011], KEGG [Kanehisa et al., 2012], Reactome [Croft
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et al., 2011], Gene Ontology [Gene Ontology Consortium, 2000], ChEBI [Hastings et al.,
2013]. Annotation of the contents of a map facilitates the knowledge exploration by
providing additional information about the elements and their interactions.
1.3.4 Available data
While several such disease modelling formats are available, for the scope of
this project we focus on the SBML and BEL modelling formats. As an use case for
neurodegenerative diseases we use the Parkinson’s disease (PD) Map [Fujita et al.,
2014] (1.3a), Alzheimer’s disease map (AlzPathway) [Mizuno et al., 2012] and Amyloid
Precursor Protein (APP) BEL model [Kodamullil et al., 2015]).
The AlzPathway and PD Map are both built in CellDesigner and hosted
on MINERVA platform. All the reactions in these maps have evidences referenced by
PubMed identifiers using the MIRIAM uri.
The PD map integrates and visualises molecular interactions within a cellular
context with a focus on processes associated in PD pathology such as synaptic and
mitochondrial dysfunction, α-synuclein pathology, impaired protein degradation, and
neuroinflammation. It is also the first freely accessible and manually curated knowledge
repository of Parkinson’s Disease.
AlzPathway is the first comprehensive and manually curated map of intra,
inter and extra cellular signaling pathways of AD. It is also available as the web ser-
vice (online map) implemented on Payao [Matsuoka et al., 2010], a community-based,
collaborative web service platform for pathway model curation.
The APP model is built in BEL to systematically model causal and cor-
relative relationships between bio-entities. The model was built around knowledge
about physiological functions and pathological responses of amyloid precursor protein
(APP). BEL disease models were also used to perform comorbidity analysis between
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Alzheimer’s disease and Type 2 Diabetes Mellitus based on shared pathways and role
of drugs [Kodamullil et al., 2015, Karki et al., 2017].
20 Chapter 1. Introduction
1.4 Scope and Aim
Imaging Data
Visualisation / 
support of hypothesis
Data Exploration & 
Hypothesis generation
Data
Capture
Public Studies
Extraction 
Transformation 
Loading (ETL)
Hypothesis validation in a prospective clinical study
Mechanism based 
taxonomy to classify subjects
Disease Maps as 
Knowledge resource
BEL
SBGN
Support hypothesis of 
mechanism based 
taxonomy
AETIONOMY
Figure 1.4: Overview of the project
The AETIONOMY project, integrates publicly available data and knowledge
with proprietary data across several scales such as clinical, omics, imaging to identify
candidate mechanisms and propose a mechanism based taxonomy for Alzheimer’s and
Parkinson’s disease, which will be validated in a prospective clinical study (Figure
1.4). As part of the PhD, I will focus on the data harmonisation and linking this
heterogeneous data. This includes the publicly available and clinical data from the
AETIONOMY project with associated transcriptomics data and support the hypothe-
ses generation. In addition to the clinical data, I will also focus on interoperability and
comparison of maps and their application.
The project described in this thesis was built on three main objectives. First,
the integration and harmonisation of heterogeneous publicly available and consortium
data to support hypothesis generation. Second, to implement comparison of two SBML
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maps to enable co-morbidty studies. Third, to implement a convertor from BEL model
to SBML models to take advantage of the hierarchical organisation of SBML maps.
Overall, the thesis will highlight the need to make data generation and sharing standard
and harmonised to facilitate integrative and data-driven research.
1.5 Thesis Overview
Several data and knowledge repositories are constructed to study disease
progression and mechanisms. Such datasets are available in public repositories or as
proprietary datasets. Since, the data collected are from different sources and in different
formats, the data is either unstructured or semi structured.
Chapter 2, describes how publicly available and consortium datasets were
integrated. An ETL (extraction, transformation and loading) pipeline is utilised to
harmonise and integrate into the translational medicine platform, in this case tranS-
MART. The chapter describes how using tranSMART enables to explore and analyse
integrated clinical and associated molecular (-omics) data and facilitates hypothesis
generation.
Contributions: Aishwarya Alex Namasivayam (AAN), curated and integrated all
the datasets, except the proprietary datasets (PPMI and ADNI), and public PD stud-
ies (inkind from eTRIKS). The AETIONOMY consortium provided all other project
datasets. AAN and Adriano Barbosa da Silva (ABS), supported the project with data
acquisition and management and analytical tools integration. Reinhard Schneider (RS)
supervised the project.
Chapter 3, describes the comparison of SBML maps using the PD Map and
AlzPathway. Similarities are discussed with several examples. Also discussed are the
challenges due to differences in annotations and advantages of a harmonisation.
Contributions: AAN, Piotr Gawron (PG), Marek Ostaszewski (MO) and Reinhard
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Schneider (RS) planned and designed the project. The comparison was implemented
by AAN and supported by the MINERVA platform (PG, MO). Stephan Gebel (SG)
contributed to interpreting the biological relevance of the detected similarities.
Chapter 4, describes the conversion of BEL model to SBML maps using
the APP BEL model as a use case. The methods and challenges are discussed. The
converted map was compared to the AlzPathway and PD map using the methods
discussed in Chapter 2.
Contributions: AAN and MO designed and planned the project. The convertor was
implemented by AAN and supported by MO to convert to the Cell Designer format
and hosted on the MINERVA platform.
Chapter 5, discusses the results and lessons learned. Chapter 6 sum-
marises the thesis and provides future directions.
Chapter 2
Integrating heterogeneous data
Biological systems are complex, with many levels of regulation and interac-
tion [Conesa and Mortazavi, 2014]. Large amounts of biological data are generated and
collected to investigate these individual levels, but a more comprehensive understand-
ing of the system requires the integration of these data, allowing analytical approaches
to describe relationships between the components [Gomez-Cabrero et al., 2014].
2.1 Integrative platforms
A large amount of omics data is generated by high-throughput technologies
from a broad spectrum of domains. These omics data need to be considered in the
context of the phenotype and diseases to achieve their full potential.
Translational platforms enable efficient data sharing and integration. More-
over, it increases the quantity of data available in a common format for research fa-
cilitating interoperability and comparability of the data. Efficient data integration
also requires that translational research platforms can utilise existing data collection
processes within the institutions. Platforms should provide reusable ETL pipelines to
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handle not only research data (e.g. text or spreadsheets) but also standard omics and
clinical data formats.
Currently several translational research platforms are available to integrate
clinical and omics data. [Canuel et al., 2015]. The cBio Cancer Genomics Portal (cBio-
Portal) [Gao et al., 2013], is an open-source platform facilitating the access to data sets
generated by large-scale cancer genomics projects, like International Cancer Genome
Consortium (http://icgc.org/) and The Cancer Genome Atlas (http://cancergenome.nih.gov/).
It integrates pseudonymised clinical data with genomics, transcriptomics and pro-
teomics [Cerami et al., 2012]. Integrative analysis approaches have utilised such plat-
forms in several cancer studies [Gao et al., 2013, Rance et al., 2016].
TranSMART [Szalma et al., 2010], is another translational research platform
the integrates powerful visualization and interoperability functionalities of Informatics
for Integrating Biology and the Bedside (i2b2) platform [Murphy et al., 2006]. tranS-
MART is a well-accepted platform in translational medicine research [Athey et al.,
2013, Schumacher et al., 2014, Bauer et al., 2016]. It facilitates integration of low-
dimensional clinical data and high-dimensional transcriptomics data.
2.2 Data acquisition
To address the challenge of ensuring smooth and efficient entry of datasets
into the AETIONOMY knowledgebase (http://aetionomy.scai.fhg.de/, https:
//aetionomy.uni.lu/transmart), the AETIONOMY consortium uses a study request
system (https://aetionomy.uni.lu/StudyRequest/). A user interested in bringing
a specific study into the knowledgebase starts by sending a request to the system,
which then follows several stages. First, the project office approves the inclusion of the
dataset, followed by the legal team’s review of legal and ethical principles concerning the
usage of the dataset. Once the dataset is reviewed for inclusion. The data acquisition
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and curation process is initiated. Finally, the dataset is loaded into the Data Cube
and then the study requester is informed of its availability.
2.3 Data harmonisation
Unstructured data predominantly contains free text and are difficult to anal-
yse, whereas structured data can be easily extracted for analysis and research because
the data elements are comparable. Data can be harmonised using a controlled vo-
cabulary such as CDISC, SNOMED-CT. Lack of harmonised naming conventions and
structured meta-information are the main reasons for the lack of semantic integration
in the life sciences. Data cleansing is often necessary to bring consistency to different
sets of data that have been merged from separate clinical sites or databases. Cleansing
data involves consolidating data within a database by identifying and correcting in-
consistent data and removing duplicates in order to achieve concise and accurate data
resource.
The data sources available to the consortium were systematically explored
and approved for inclusion to the knowledge base. The project data to be integrated
into the platform included CSV (comma-separated values), excel worksheets and addi-
tional non-standardized study data. The raw files retrieved from public databases and
received from data providers undergo a curation and harmonization phase. They were
first converted to a tab separated format. Each dataset, then undergoes a curation and
harmonisation process which involves several steps (Figure 2.1)
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Format conversion Cleansing and QC Transformation Standardisation
● Misspelling
● Out of range
● Type error
● Language
● Data format
● Derived data
● Impute missing data
● Data model
● Variable to ontology
● Value to ontology
● Convert to standard 
unit
Figure 2.1: Curation and harmonisation overview
Integration of omics and clinical research data is not straightforward specif-
ically because clinical research data collection is often non-standardised. Clinical re-
search and cohort data are difficult to handle, mainly due to their non standardised
parameters and varying representations over time and study centres. Careful data
cleaning and preparation are necessary prerequisites to any process involving integrated
biological data. Often the clinical data was not accompanied by a data dictionary and
therefore required constant follow up with the collaborators and additional manual
effort to map the variables and values to a standard ontology.
2.4 Extraction, Transformation and Loading (ETL)
The AETIONOMY project, uses tranSMART to integrate publicly available
omics datasets on Alzheimer’s and Parkinson’s disease from Gene Expression Omnibus
(GEO) and Array Express and consortium datasets [Hofmann-Apitius et al., 2015b].
tranSMART offers visually aided data exploration and drag and drop enabled cohort
selection.
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Integration of heterogeneous datasets require extraction, transformation, and
loading (ETL) processes to harmonise the representation. Data can be added to the
tranSMART database by mapping the variables to a data-scheme via standard tem-
plates or mapping files. The mapping files for the curated data files are then generated.
The mapping files are generated to follow the tranSMART standard files for the ETL
scripts. Additional data can be associated on the subject level data and linked via these
mapping files. For instance, for datasets which include expression data, additional files
for the platforms used for the experiment have to be generated. These platform map-
ping files enable the mapping of probe ids from the platform to its corresponding
GeneID and Gene Symbol.
The ETL process to load data in tranSMART ensures that all integrated
data makes use of unique identifiers and provides a uniform structure. In addition
to the benefits of integrating heterogeneous data it also enables easy sharing of data
in the future. This structured and standardised structure fosters data exchange in
the scientific community, which is also a pre-requisite for many translational medicine
projects and multi-subject expert teams [Maier et al., 2011].
In the example (Figure 2.2), the data collected were in different formats over
different files and languages, etc. Though valuable, they are disparate and provide
no structure. These have to be transformed for further analysis as a single dataset.
After data curation and harmonisation we load them in tranSMART. This then gives
a structure to the dataset, allowing it to be explored and shared easily.
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Figure 2.2: Unstructured or semi-structured to structured data
2.5 From unstructured to structured data
Structured data is data that can be easily stored, queried, exported, and
analysed by computational methods. Clinical research data is often unstructured or
semi-structured data like medical records, handwritten notes. Healthcare applications
require efficient ways to integrate and convert a variety of data including automat-
ing conversion from structured to unstructured data. To take advantage of the various
functionalities of tranSMART, the data sets have to go through extraction, harmoniza-
tion, curation, and quality checking. Data acquired from publicly available databases or
resources are usually structured or semi-structured. However, they may require trans-
formation to retrieve relevant information to be integrated into tranSMART. Next, a
set of standard format files need to be generated to map each subject to sample level
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data. In addition to harmonising the raw data, metadata is also annotated by relevant
ontologies.
Figure 2.3: Harmonised and structured datasets via tranSMART standard format files
Figures 2.3 and 2.4 show the how the ETL process controls the structure
of the variables loaded. These variables, are represented as a hierarchical parent-child
tree (Figure 2.3). This tree structure allows efficient data sets exploration and also the
selection of variables from the hierarchy to build customised patient cohorts by visual
exploration and for further analysis or export. Variables in the dataset, such as age,
gender, or measure of a blood marker could be used as filters to build a sub cohort.
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Raw File
Curated File
Clinical Mapping File
Loaded in tranSMART
Figure 2.4: Extraction Transformation and Loading of datasets
The mapping file generated to load the datasets into tranSMART also gen-
erate the i2b2 tree structure for the study. Therefore, the category for each variable
and the naming of the features are assigned at this stage. The mapping files are hence
responsible for structuring the different studies in the AETIONOMY knowledge base.
Each feature collected across studies should eventually be assigned to the same cate-
gory and leaf node for every study loaded. Features specific to a single study, however
will have a new leaf node, nevertheless the structure of the tree (in terms of category
and branching) can be harmonised to the extent possible.
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2.6 Results
Hypothesis generation / support
Figure 2.5: Linking heterogeneous data in tranSMART
Platforms like tranSMART helps to integrate disparate datasets to analyze
them for support of research hypotheses [Hofmann-Apitius et al., 2015b] (Figure2.5).
tranSMART serves as a collaboration platform by integrating data from heterogeneous
sources. It enables code free data exploration and interactive visual analytics, and thus
brings together researchers from different areas of expertise (biologists or clinicians and
bioinformaticians or statisticians) [Satagopam et al., 2016]. The data can also be easily
exported for further in depth analysis. This chapter demonstrates with two examples,
how the curated and loaded data on tranSMART enables hypothesis generation and
support.
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Figure 2.6: Curated studies loaded in AETIONOMY tranSMART instance
Figure 2.6, shows a number of Parkinson’s disease and Alzheimer’s disease
datasets were curated and loaded into the tranSMART system for the AETIONOMY
project, this includes publicly available studies from Gene Expression Omnibus (GEO)
and Array Express, proprietary datasets such as PPMI and ADNI and studies from
the consortium. The variables include clinical and neuropsychological assessments,
biospecimen analysis results, imaging and transcriptomics data. tranSMART enables
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to bring together these different sources in a common format for exploration, basic
analysis and sharing of data.
2.6.1 Use case 1: Alzheimer’s disease cytokine study
Alzheimer’s disease (AD) is the most prevalent cause of dementia and char-
acterized by cognitive deficits, neuronal death and, ultimately, severe brain atrophy.
At the molecular level, the hallmarks of AD are extracellular plaques of amyloid β
(Aβ) and intracellular tangles of tau protein. Neuroinflammation represents a further
characteristic feature of neurodegenerative diseases. To limit further Aβ accumulation,
the microglia and astroglia are reported to react to Aβ exposure by phagocytosis, and
also by prolonged release of inflammatory mediators creating a neurotoxic environ-
ment. Presuming Aβ aggregation precedes the onset of clinical symptoms by decades,
the innate immune activation may be an early and contributing progress in AD patho-
genesis.
The AD cytokine dataset was collected to determine cerebrospinal fluid
(CSF) levels of interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), monocyte chemo-
tactic protein 1 (MCP-1 / CCL2), and macrophage migration inhibitory factor (MIF) as
biomarkers of neuroinflammation in mild cognitive impairment (MCI) and Alzheimer’s
disease (AD) and to evaluate their diagnostic utility [Brosseron et al., 2014]. The
dataset was curated and loaded in tranSMART and analysed using the visual analyti-
cal plugin smartR [Herzinger et al., 2017].
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Subset 2 : Alzheimer’s Disease
     Non Demented Controls
Subset 1 : Mild Cognitive Impairment
Figure 2.7: Overview of the AD Cytokine dataset loaded in tranSMART
The dataset includes 95 subjects, consisting of 44 subjects diagnosed with
Alzheimer’s Disease, 34 as Mild Cognitive Impaired (MCI) and 17 Non Demented
Controls.
First we compares the distribution of cytokine levels in controls against AD
subjects. Figure 2.8 shows the distribution of MCP-1 and MIF between the subsets.
2.6. Results 35
S2 Alzheimer’s Disease
S1 Non Demented Controls
Monocyte Chemoattractant Protein 1 
(MCP-1) pg/ml S2
Monocyte Chemoattractant Protein 1 
(MCP-1) pg/ml S1
Macrophage Inhibitory Factor 
(MIF) pg/ml S2
Macrophage Inhibitory Factor 
(MIF) pg/ml S1
Monocyte Chemoattractant Protein 1 
(MCP-1) 
Macrophage Inhibitory Factor 
(MIF)
Figure 2.8: Distribution of MCP-1 and MIF levels in AD subjects compared to controls
There were no elevated cytokine levels (MCP-1 and MIF ) in AD compared
to controls. Further we then tested for correlations between cognitive decline and
cytokine levels in AD. The MMSE, Wordlist Recall, Boston Naming Test, Semantic
Fluency and Trail making test were used to score the cognitive decline. Figure 2.9 the
cytokines MCP-1, MIF and IL6 had no significant correlations to cognitive function
in the AD group compared (MMSE shown in Figure 2.9).
MIF with MMSE MCP-1 with MMSE IL-6 with MMSE
Figure 2.9: Correlation of cognitive functions with cytokine levels in AD subjects
To investigate the difference in cytokine level of MCI subjects against both
control and AD. Two subsets were created, subset1 comprising of MCI subjects and
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subset2 comprising of AD and Non demented controls (Figure 2.7). Next we tested for
changes in TNFα levels between subsets 1 and 2 (Figure 2.10)
Figure 2.10: TNF-α was elevated in MCI compared to controls and AD subjects
TNF-α was elevated in MCI compared to controls and AD pValue=0.0202.
Finally we test for correlation between cognitive decline and these elevated levels of
TNFα in MCI subjects.
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TNFα - MMSE TNFα - Wordlist Recall
Figure 2.11: TNF-α in MCI subjects was reported to be negatively correlated with
cognitive scores
TNF-α was reported to be negatively correlated with MMSE with a p=0.03
and r=0.383 and for word list recall word-list recall (p = 0.05, r = -0.343) in MCI
(Figure 2.11). The analysis was performed by Pearson correlation. Levels of TNF-α
has negative correlation with the cognitive functions in MCI.
Common markers of neurodegeneration provided better discriminative power,
as demonstrated by Aβ42, Aβ42/p-tau-181, MMSE or semantic fluency. However, all
standard markers differentiated clinical controls and MCI from AD, but not controls
from MCI, which was in return only achieved by TNF-α. In summary, the data re-
ports elevation of CSF TNF-α levels in MCI accompanied by correlations of TNF-α,
MCP-1 and MIF to cognitive decline in this group of patients. Noteworthy, there
were no elevated cytokine levels and few correlations to cognitive function in the AD
group. Therefore, signaling of MCP-1, MIF and especially TNF-α might be involved
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in pathological inflammatory processes during MCI that impact negatively on cogni-
tion. However, the study may have been biased by a certain degree of inhomogeneity
in patient group size, age and gender. Yet, the collective reflected typical results for
standard AD protein markers from CSF analysis and neuropsychological tests, there-
fore providing a reliable source for comparisons. Furthermore, age or gender driven
effects on cytokine levels were ruled out by ANCOVA and pearson correlation. Assess-
ing neuroinflammation in MCI could therefore be of clinical importance in diagnostic
procedures. CSF cytokines may reflect processes of disease progression and indicate
an impact of innate immune activation on cognitive function in early disease stages. It
is therefore desirable to monitor neuroinflammation, which can be used with the same
routine as the established markers of other key pathological processes of MCI and AD.
Although, Amyloid β pathology is considered the primary hallmark of AD,
recent studies suggest that the disease has a multifactorial origin [Llorens-Mar´ıtin et al.,
2014, Medina et al., 2017, Gong et al., 2018]. Currently, several reports support neu-
roinflammation as a significant contributor to the pathogenesis of Alzheimer’s Disease
[Hong et al., 2016]. As a result of brain damage (e.g., brain trauma, ischemia, Aβ
accumulation, etc,.) microglia and astrocytes acquire reactive phenotype losing their
physiological functions [Karve et al., 2016]. The persistent microglial activation stim-
ulated by Aβ via Toll Like Receptors (TLR) creates a vicious circle between microglia
activation, neuroinflammation, and Aβ accumulation. A crucial role on pathogene-
sis of AD is an absolute culprit for both amyloid plaque and other pathologic change
such as the neuronal damage. Moreover, after activation, these cells produce a wide
range of cytokines and proinflammatory mediators, leading to chronic inflammation
[Heppner et al., 2015]. Even if the initial intent of these modifications is reparative,
such long-lasting and uncontrolled activation causes further neurodegeneration (Figure
2.12) [Heneka et al., 2015].
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Figure 2.12: Role of inflammation in neurodegeneration [Heneka et al., 2015]
Physiological functions of microglia, including tissue surveillance and synap-
tic remodeling, are compromised when microglia sense pathological amyloid β accu-
mulations. Initially, the acute inflammatory response is thought to aid clearance and
restore tissue homoeostasis. Triggers and aggravators promote sustained exposure and
immune activation, which ultimately leads to chronic neuroinflammation. Perpetu-
ation of microglia activation, persistent exposure to proinflammatory cytokines, and
microglial process retraction cause functional and structural changes that result in
neuronal degeneration [Heneka et al., 2015, Brosseron et al., 2014].
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In a follow up study, the AETIONOMY collaborators investigated the utility
of inflammatory biomarkers in diagnostic procedures of AD. This was designed in three
steps: (1) to screen for proteins that are robustly detectable in cerebrospinal fluid;
(2) to explore associations between the analytically robust markers and pathological
features of AD; (3) to determine the discriminative power of these markers in the
clinical diagnosis of AD. 46 proteins were screened, out of which 14 met the criteria for
robust detectability. A subsequent analysis of these markers in a cohort of 399 patients
(non demented subjects, patients with mild cognitive impairment, and patients with
AD, supplemented by smaller cohorts of other diseases) was conducted. Although
a large number of significant associations between clinical cohorts or AD pathology
markers and inflammatory markers were observed, currently, none of the tested proteins
reached a discriminative power as the existing pathological markers for clinical practice.
Implementation of assays with higher sensitivity or investigation of signalling mediators
from alternative pathways could lead to discovery of candidates with higher potential
for use in clinical diagnostic procedures.
2.6.2 Use case 2: Expression data of substantia nigra from
postmortem human brain of PD patients
Figure 2.13: Heatmap generated from curated data (GSE7621) loaded in tranSMART
Here we use a GEO public study GSE7621 [Lesnick et al., 2007]. The study
used microarrays to detail the global program of gene expression underlying Parkin-
son’s disease. Substantia nigra tissue from postmortem brain of normal and Parkinson
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disease patients were used for RNA extraction and hybridization on Affymetrix mi-
croarrays: 9 replicates for the controls and 16 replicates for the Parkinson’s disease
patients were used. Both cohorts included males and females. The heatmap map
workflow was used to retrieve the differentially expressed genes between control and
diseased.
NR4A2 (Nurr1) activity
Dopaminergic transcriptionNormal Parkinson’s Disease
tranSMART
PD Map
Figure 2.14: Overlaying differentially expressed genes on the Parkinson’s disease map
Differential gene expression data comparing post mortem brain tissues from
male PD patients versus controls are overlayed on the PD map blue representing down-
regulated and red representing up-regulated genes (See Figure 2.14). Overlaying the
differentially expressed genes on the PD Map provides context about the pathways and
mechanisms these genes are involved in. These may suggest new targets for further in-
vestigation towards potential treatments. Overlaying the differentially expressed genes
on the PD Map show perturbations in:
• Dopamine secretion and recycling : down-regulation of SLC18A2, RIMS1, SLC6A3
• Dopaminergic transcription : down-regulation of RET, TH, ALDH1A1, DDC,
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SLC6A3, SLC18A2, FOXA2, EN1
• Dopamine metabolism : down-regulation of TH, DDC, ALDH1A1 and SLC6A3
• Post synaptic terminal processes : up-regulation of GRIA4, down-regulation of
SLC6A3, RGS4, ALDH1A1
• Autophagy: up-regulation of AMBRA1
• Calcium signaling and NEF2L2 Activity : up-regulation of CREBBP
• Neuroinflammation : up-regulation of PTGS2, SOCS3 and NCF4
TH, ALDH1A1, SLC6A3, SLC18A2, DDC, RET, EN1, FOXA2 are down-regulated, all
are involved in dopaminergic transcription. Down-regulated genes (SLC18A2, RIMS1,
SLC6A3) are involved in dopamine secretion and recycling. Down-regulated genes (TH,
DDC, ALDH1A1) are involved in dopamine metabolism.
2.7 Summary
A number of public and consortium studies relevant to Alzheimer’s and
Parkinson’s Disease was curated, structured and loaded into tranSMART. Refer Ap-
pendix A.1, for a complete list of studies and data types. This included transcriptomics,
clinical and imaging datasets. The process included several steps from data acquisition,
curation and harmonisation, structuring and loading. The harmonised and structured
data, can then be used for further analysis and sharing. We demonstrate with two
examples how integration of data from heterogeneous sources can support hyphothesis
generation. Translational research platforms like tranSMART provide visual and ex-
ploratory analysis facilitating the identification of patterns in data and the subsequent
hypothesis generation, hypothesis validation. However a major challenge in this pro-
cess is the heterogeneity in data representation and formats. The major effort spent
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in the whole process is to curate and map data to standard ontologies. This process
can be streamlined if data is exchanged in well accepted standards and with adequate
meta-data.
Chapter 3
Comparison of disease maps
There are many disease maps and pathways publicly available [Kuperstein
et al., 2015, Matsuoka et al., 2013, Fujita et al., 2014, Mizuno et al., 2012, Oda and Ki-
tano, 2006] and several others currently in development (http://disease-maps.org/
projects). In addition to serving as a single point to access the existing knowledge,
comparison of disease maps have a number of possible benefits. Comparison of two
disease maps shed light on the underlying mechanisms which are common or specific to
each disease. Several diseases may have common mechanisms that affect the pathology
and progression of each other and therefore is important to study the comorbidity of
diseases. Apart from this, comparison of a disease models against normal biological
state models can help understand the disease pathology and progression. Another po-
tential use case of comparing maps and pathways is to enrich the knowledge in disease
maps and understand how the pathway plays a role in the aetiology of diseases.
Pathguide [Bader et al., 2006] is a meta-database that provides an overview
of web-accessible biological pathway and network databases. These include databases
on metabolic pathways, signalling pathways, transcription factor targets, gene regula-
tory networks, genetic interactions, protein-compound interactions, and protein-protein
interactions. As of May 2018, Pathguide (http://pathguide.org) contains 702 biolog-
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ical pathway and molecular reaction related resources, this includes several organism
models in standards such as BioPAX, CellML, PSI-MI or SBML. Since many different
models in different formats exist, the ability to compare these models is important,
both to compare models of different systems and to compare different versions of the
same model. Comparison of maps highlights the similarities and differences in the
context of the diseases, how the identified elements relate to the interacting elements
and their role in the disease mechanism. This chapter describes the comparison of two
disease models and how such methods can add context to the comorbidity of diseases
and their pathology. We use the MINERVA platform to visualise the results using
its graphical layout and the PD Map Spring 2018 edition and AlzPathway April 2015
edition as use cases.
3.1 Overview of existing comparison methods
The comparison of systems biology models gained interest in recent years.
In 2017, Scott-Brown and Papachristodoulou presented a tool sbml-diff, that is able
to read synthetic biology models in SBML format and produce a range of diagrams
showing different levels of detail [Scott-Brown and Papachristodoulou, 2017]. Each of
these diagram type can then be used to visualize a single model or to visually compare
two or more models. However, in addition to their focus on mathematical models, the
web service could not handle large models like the AlzPathway and PD Map. Moreover,
species and reactions are compared based on their identifiers (ID) and two elements
are treated as the same only if both share the exact same set of MIRIAM identifiers.
BiVeS [Scharm et al., 2015], another tool for comparing SBML models can
track changes in a model over time. Although it produces outputs in a different formats,
the visualisation abilities are limited. The main focus of the BiVeS is to provide
version control for model repositories to accurately detect and describe differences
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between versions of model depending on the encoding, mathematical expressions and
the structure of the networks.
Another approach by Calderone et al., to compare Alzheimer and Parkin-
son’s disease networks, uses AlzPathway and PD Map [Calderone et al., 2016]. The
authors considered direct comparison of SBML models not feasible due to level of de-
tails and differences in entities and annotations. Nevertheless, they extracted the genes
and proteins from the two SBML models and complemented the lists with genes and
proteins from the KEGG database. The AD and PD lists were then used as seeds to
extract two subnetworks from Mentha [Calderone et al., 2013] a human interactome
database. In order to generate the networks, all the genes and proteins were translated
to UniProt identifiers, since the Mentha uses UniProt accession numbers. A graph-
communities-based similarity matrix method was implemented to cross-compare two
networks to highlight differences and similarities in terms of network topology and func-
tions. Entities that were detected as similar in both network and clustered according
to their Gene Ontology overlap form a community. Each Communities present in both
networks signify common biological processes and on the other hand the communities
unique to each network may signify characteristics of the specific pathology.
3.2 Methods for comparison
Although several methods attempt to compare disease maps or models, no
direct comparison of such models were previously reported especially to visualise the
comparison. Therefore, in order to compare two maps directly, an algorithm was
implemented that parses two models and identify similar reactions and entities with
respect to the context in terms of cellular localisation or mechanism. For each map
pair, lists of node and reaction identifiers detected in both maps, as well as a list of
reaction pair, describing their similarity are generated.
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The reaction and node lists can then be visualised on the corresponding map
using the MINERVA platform. The PD Map and AlzPathway hosted on the MINERVA
platform were used as use-cases. The comparison required mapping of annotation for
entities, this was complemented by the annotators in the MINERVA platform.
To compare two maps, we need to compare both reactions and their inter-
acting elements. In order to compare reactions, we take into account the neighbouring
participants of the reactions i.e. the reactant(s), product(s), and modifier(s). Addi-
tionally, to compare the elements we require measures to uniquely identify the elements
irrespective of how they may be named or represented. For this, we use MIRIAM iden-
tifiers, with which the elements are annotated. The algorithm parses the models, and
updates the annotation if required. For instance, if the models use different databases
to annotate elements, the annotator using the name or MIRIAM identifiers to extract
other annotation from corresponding databases.
Figure 3.1 summarises the process to identify similar elements. To match en-
tities, the MIRIAM annotations were used. The MIRIAM Registry and Identifiers.org
system are a set of services and resources that provide support for generating, inter-
preting and resolving MIRIAM URIs. The annotation will help to identify the same
elements even if they may be named differently. If the type of the element/node, e.g.:
protein, gene, RNA, etc. matches, then the annotations are checked for a match. Once
the annotation also match, the localization information i.e. the compartment the ele-
ment is in is matched. If the entity is a complex itself, or part of the complex is also
taken into account i.e. if the entity is annotated as the same complex or if it is part of
the same complex in both maps.
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Figure 3.1: Element Match Decision Diagram
The reactions are matched by checking for i) the reaction type ii) the entities
involved in the reaction. The reactions have more than one reactant and product.
Additionally, reactions may involve one or more modifiers as well. The matches for
reactions were categorised into the following categories:
1. All Products, Reactants, Modifiers, annotation and compartment match
2. All Products, Reactants, Modifiers match
3. All Products and Reactants match
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4. All Products and Reactants match and model1 has no Modifiers
5. All Products and Reactants from model1 match and at least 1 Modifier match
6. All Products and Reactants from model1 match and no modifiers match
All Reactants, Products and Modifiers Match
All Reactants and Products Match
Figure 3.2: Examples of reaction match
The reaction pair i.e. the corresponding reaction identifiers that matched
in both models, and the above categories are saved in a ReactionPair table. This
table provides additional information that can supplement a closer examination of
the relevance of the match in the disease mechanism context. Figure 3.2 shows two
example of reaction pairs. Each reaction involves at least one reactant and one product.
However, reactions may have more than two participating elements.
Another challenge in the comparison is the representation of complexes. Of-
ten in cases when the relevant scientific literature does not provide enough information
to annotate the complex itself, curators have to resort to create complexes which are
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not annotated by a unique identifier. Therefore complexes cannot be compared di-
rectly if they are not annotated. We need to approach the comparison of complexes at
a content level i.e. two unannotated complexes are identical if they have exactly the
same content.
(a) Example of an annotated complex
(b) Example of an unannotated complex
Figure 3.3: Representing complexes in disease maps
For instance in Figure 3.3a is annotated by the GO identifier GO:0031931.
TORC1 complex is a protein complex that contains at least TOR (target of rapamycin)
and Raptor (regulatory-associated protein of TOR), or orthologs of, in complex with
other signalling components. Whereas the DDB1:CUL4A complex in Figure 3.3b is
not annotated. This may be due to several reasons such as the relevant article did not
provide enough information about all the contents of the complex, or such a complex
could not be mapped to a unique entry in corresponding databases like Gene Ontology.
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3.3 Results
For each map pair that is compared, three result tables are generated. Two
lists for overlay on the map i) List of element identifiers in model1 which have a
counterpart that was matched in model2 ii) List of reaction identifiers in model1 which
have a counterpart that was matched in model2. The third table ReactionPair, lists
each pair of reaction, reaction identifiers from model1 and model2 and the match type
as discussed before. The result tables for AlzPathway and PD Map are also included
in the Appendix A.2.
3.3.1 Comparison of AlzPathway and PD map
The AlzPathway and PD Map were compared using this method. Because
PD map has a number of submaps, their contents were compared, one by one, with
the contents of AlzPathway. The supplementary ReactionPair table, makes it easier to
compare the reactions side by side on both maps, to give a context to the identified
reaction in both diseases.
MINERVA enables updating the model with additional annotations which
are used for comparison. Currently MINERVA supports HGNC and BioCompendium
to extract by name and Uniprot, Gene Ontology, Ensembl, Entrez Gene, and ChEBI for
update by MIRIAM identifiers [Gawron et al., 2016]. Different maps may use different
namespaces to annotate their entities with a unique identifier. The AlzPathway uses
Uniprot to annotate the proteins, genes and RNA. Whereas the PD Map uses HGNC
to annotate these species. Therefore, it requires a conversion between Uniprot and
HGNC. The annotator extracts the HGNC symbol and identifier from the correspond-
ing Uniprot identifier. Drugs and chemicals are annotated by ChEBI in the PD Map,
while AlzPathway uses PubChem. Since MINERVA does not currently support Pub-
Chem and this mapping has not been implemented, drugs and chemicals comparisons
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are not considered unless they are annotated by the same database in both models.
The following database identifiers are used to annotate the entities in the PD Map.
• Protein, Gene and RNA: HGNC, HGNC symbol, Uniprot, InterPro, Entrez Gene,
Ensmbl, GO
• Drugs, chemical, ion, simple molecule : ChEBI, Reactome
• Phenotype : GO, MeSH
• Complex : GO, Reactome, MeSH, InterPro
• Compartment: GO, MeSH
If one or more of the MIRIAM annotation of the elements match, the elements are
considered a match.
Map/submap Elements Reactions
AlzPathway 2464 979
PD map - main diagram 5444 2416
Ubiquitin-proteasome system 100 18
PRKN substrates 75 64
Fatty acid and ketone body metabolism 194 75
Iron metabolism 557 183
Table 3.1: Number of elements and reactions in the AlzPathway Map and PD Map
and submaps
Table 3.1, summarises the number of elements and reactions in each map.
To retrieve elements and reactions in AlzPathway Map that are present in the PD
Map, the models were updated using the MINERVA automatic annotators. Since the
AlzPathway and PD Map utilise different namespace to annotate the entities, updating
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the annotation was essential to identify similar entities which would otherwise not be
detected.
Figure 3.4: Increase in matched elements and reaction by updating model annotation
Figure 3.4, depicts the increase in identified elements and reactions when the
models annotations were updated by additional identifiers. Comparing models with-
out updating the annotation returns 48 elements, from 2464 elements in AlzPathway
(Table 3.1). No reactions were identified. Since the PD Map uses HGNC to anno-
tate the Protein, Gene and RNA, the HGNC annotator was used to fetch the Uniprot
identifiers (used by AlzPathway). This increased the number of elements identified
to 649. Although 31 Reactions were also identified, none of these reactions were a
perfect match, signifying that there were changes in number of reactants, products or
modifiers. This may be due to the fact that similar entities were still not detected due
to no namespaces or different database used for annotation. Using all the annotators
(HGNC, Uniprot, Entrez, Ensembl, GO, and bioCompendium) increased the number
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of entities identified to 762 and reactions to 40. Six of these reaction were a perfect
match. The low number of perfect matches could also be a result of different litera-
ture source used for curation, different scope (disease) of the maps or expertise of the
curator.
No. of species No. of reactions
PD neuroinflammation 310 209
AlzPathway 1312 979
PD Map-main 2606 2416
Table 3.2: Summary of model sizes
Figure 3.5: Time taken per comparison
To estimate the time taken for comparing smaller models, a smaller section of
the PD map was used, PD neuroinflammation (Table 3.2). The comparison of models
takes about 10-30 seconds depending on the size of the model (Figure 3.5).
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Highlights on PD Map, similarities from AlzPathway
PD Map Submap
Elements from
AlzPathway
Reactions from
AlzPathway
Perfect matches:
reaction
Possible
reaction pairs
PD map - main diagram 163 39 5 61
Iron metabolism 20 2 0 2
Ubiquitin-proteasome
system
3 0 0 0
Fatty acid and ketone
body metabolism
6 0 0 0
PRKN substrates 1 0 0 0
Table 3.3: Number of elements and reactions identified from AlzPathway in PD Map
Figure 3.6 shows the reactions and elements found in AlzPathway and high-
lighted on the PD Map. Table 3.3 shows the number of reactions and elements detected
in the PD Map submaps. The matches can be further investigated to understand the
mechanisms that may result in the comorbidity of these diseases.
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Highlights on AlzPathway, similarities from PD Map
PD Map Submaps
Elements from
Submap
Reactions from
Submap
Perfect matches:
reaction
Possible
reaction pairs
PD map - main diagram 181 31 5 57
Iron metabolism 21 2 0 2
Ubiquitin-proteasome
system
3 1 0 2
Fatty acid and ketone
body metabolism
9 0 0 0
PRKN substrates 1 0 0 0
Table 3.4: Number of elements and reactions identified from PD Map in AlzPathway
Map
Figure 3.7 shows the reactions and elements found in PD Map and high-
lighted on AlzPathway. Table 3.4 shows the number of reactions and elements detected
in the PD Map submaps. From Figure 3.7 and 3.6, we can see that in general the re-
actions identified on the AlzPathway Map are more centralised around a specific node,
whereas in the PD Map they are more distributed in terms of different processes they
are involved in.
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3.3.2 AKT1 Activity
The serine/threonine kinase (Akt), has been widely research for their in-
volvement in several cellular processes, including insulin metabolism and diseases like
PD, AD and cancer. The isoforms of Akt- Akt1, Akt2, and Akt3 are reported to be
involved regulation of the apoptopic machinery [Vivanco and Sawyers, 2002, Reddy,
2013, Greene et al., 2011]. In the developing nervous system AKT is reported to be
important mediator of growth factor-induced neuronal survival. Activation of AKT1
can suppress apoptosis and oxidative stress by inactivation and phosphorylation of pro-
apoptotic targets, including BAD and FOXO1 and FOXO3 [Zhang et al., 2011, Hers
et al., 2011].
One of the matches detected in AlzPathway and PD Map is shown in Figure
3.8. While in the PD Map (Figure 3.8b) AKT1 moderates the phosphorylation of BAD,
Phosphorylated AKTI1 inhibits the transition of BAD in AlzPathway. Other similar
reactions found in the PD Map are shown in Figure 3.9. In Figure 3.8a, PDK1, WNT
and WISP1 are shown mediating the phosphorylation of AKT1 in the AlzPathway.
Whereas in Figure 3.9a ROCK2, mTORC2 and PDPK1 mediate the phosphorylation
in PD. It is also interesting to note that PDK1 in AlzPathway is PDPK1 in PD Map,
but they were not detected as identical since the PDK1 in AlzPathway was annotated
as pyruvate dehydrogenase kinase 1(PDK1) instead of 3-phosphoinositide dependent
protein kinase 1 (PDPK1) Another downstream target of AKT1 is the TSC1, TSC2
complex which is reported to inhibit mTOR activity (seen also in Figure 3.10b) which in
turn regulates cell growth and protein degradation [Olney et al., 2017]. TSC1:TSC2 (in
PD Map) and TSC in AlzPathway are seen to be mediated by several entities including
AKT1 and MAPK1/3 in both AD and PD, but they were not identified since TSC was
not annotated in AlzPathway, additionally MAPK1/3 was annotated as MAPK3 in
AlzPathway. However, downstream reactions of TSC mediating RHEB were identified
in both AlzPathway and PD Map. To summarise, several of the downstream targets
of AKT1 are similar, but the modifiers of the phosphorylation are different.
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(a) AlzPathway Map: BAD modulation by AKT1
(b) PD Map: BAD modulation by AKT1
Figure 3.8: Perfect match in AKT1 activity in PD Map and AlzPathway Map
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(a) PD Map: Modulators of AKT1 Phospho-
rylation
(b) PD Map: Phosphorylated AKT1 me-
diating FOXO3
Figure 3.9: AKT1 activity in PD Map
(a) AlzPathway: Downstream targets of AKT1
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(b) PD Map: Downstream targets of AKT1
Figure 3.10: TSC1:TSC2 activity in AlzPathway and PD Map
3.3.3 TAU (MAPT) hyper-phosphorylation
Microtubule-associated protein tau (MAPT ), promotes microtubule assem-
bly and stability, is supposed to be involved in the establishment and maintenance of
neuronal polarity [Gendron, 2009]. Tau hyper-phosphorylation is one of the patholog-
ical hallmarks of Alzheimer’s Disease. MAPT is also a risk factor in PD [Noble et al.,
2013, Lei et al., 2010]
Although there were several reactions that were detected similar in PD and
AlzPathway, they all differed in the modifiers involved (Figure 3.11). The only com-
mon modifier between all three reaction identified in the PD Map and the reaction in
AlzPathway is GSK3. To summarise, although the Tau pathology plays a role in both
diseases, the post translational modifications may be induced by different factors.
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(a) PD Map: Tau Phosphorylation
(b) AlzPathway: Tau Phosphorylation
Figure 3.11: MAPT activity in AD and PD Map
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3.3.4 MAPK signalling
Mitogen-activated protein kinases (MAPK s) are serine-threonine kinases
that mediate intracellular signalling associated with cellular activities including cell
survival, death, proliferation, and differentiation. MAPK signalling is reported to be
involved in neuronal apoptosis in both AD and PD [Kim and Choi, 2010].
In PD, oxidative stress is a prominent cause of neuronal death. Studies have
shown that ROS production induced by the toxins results in the activation of microglial
cells, which subsequently attack neighbouring dopaminergic neurons. Amplified levels
of α-Synuclein activates the MAPK pathway, resulting in subsequent inflammatory
response [Fadaka et al., 2017]. This can also be observed in the PD Map in neuroin-
flammation, as seen in Figure 3.12)
In AD, Amyloid β aggregation triggers the activation of microglial macrophages,
which then produce reactive oxygen species (ROS) and pro-inflammatory cytokines
such as TNF-α and IL-1β. These cytokines then stimulate the MAPK signalling path-
way [Correˆa and Eales, 2012]. This was also observed in AlzPathway, as shown in
Figure 3.13a.
MAPK8 in the AlzPathway was incorrectly annotated by mitogen-activated
protein kinase 8 interacting protein 1 (MAPK8IP1) in addition to MAPK8. However,
the MAPK8 was detected as a match by updating the model annotations. The MAPK8
transition in both AlzPathway and PD Map are modified by MAP2K7 and MAP2K4.
While in the PD Map, the reaction has only two modifiers, the AlzPathway has sev-
eral other modifiers mediating the activation of MAPK8. Additionally, the reactions
highlighted in Figure 3.13b were all in Apoptosis in the PD Map and mediated by
activation of entities in neuroinflammation.
These observations support the current knowledge that MAPK signalling
pathway contribute to neuroinflammatory responses and neuronal death and functional
deficiencies in neurodegenerative diseases. Recently, many studies investigate possible
role of MAPK as an attractive therapeutic target against neuroinflammation in AD, PD
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and several chronic inflammatory diseases [Yarza et al., 2016, Fadaka et al., 2017, Lee
and Kim, 2017]. Moreover, in recent years efforts have been made towards targeting
the inhibition of MAPK pathways in AD and PD [Munoz and Ammit, 2010, Gehringer
et al., 2015, Leonoudakis et al., 2017, Shah et al., 2017]
Figure 3.12: PD Map: MAPK cascade triggered by ROS and α synuclein fibrils
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(a) MAPK cascade in AlzPathway highlighted in red are reactions found similar to PD Map
(b) PD Map: MAPK cascade in autophagy. Highlighted in red are reactions found similar
to MAPK cascade in AlzPatwhay Map.
Figure 3.13: MAPK8 signalling in AD and PD
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3.3.5 Endoplasmic Reticulum Stress
Endoplasmic reticulum is responsible for the synthesis and folding of trans-
membrane and secretory proteins. In neurodegenerative disorders like AD and PD pro-
gressive loss of neuronal functions leads to accumulation of damaged proteins, which
results in Endoplasmic Reticulum (ER) Stress. To restore homoeostasis by clearance
of misfolded proteins the unfolded protein response (UPR) pathway is activated. The
UPR signalling mechanism improves the efficiency of protein folding and clearance of
the abnormally folded proteins. However, under chronic ER stress, UPR fails to restore
homoeostasis and triggers apoptopic processes through alternate pathways to eliminate
permanently damaged cells [Mercado et al., 2016, Urra et al., 2013].
ER stress is modelled in both diseases maps. Several overlapping elements
were found including EIF2AK3 (PERK), ERN1 (IRE1), ATF6, EIF2A, XBP1, and
HSPA5. Moreover, one of the perfect matches in the comparison was involved in ER
stress mediated transcription/translation Figure 3.14. Activated EIF2AK3 (PERK)
mediates the activation of EIF2A in both AD and PD.
While ER stress in PD is mediated by SNCA fibril, in AD it is mediated
by mutated presenilin. Although presenilin 1 was incorrectly annotated as PSEN,
the algorithm could identify the entity as PSEN1. UPR is regulated by the three
master regulators, IRE1, PERK, and ATF6. All the three proteins were found in both
AlzPathway and PD Map. Further downstream, ERN1 (IRE1 activates XBP1 which
then induces ER-associated degradation (ERAD) [Cai et al., 2016], this can be seen in
the PD Map (not shown here).
The second regulator, PERK, on activation induces phosphorylation of EIF2A
causing translational arrest. Phosphorylated EIF2A activates ATF4 increasing the lev-
els of the transcription factor CHOP. CHOP then triggers the expression of several
pro-apoptotic proteins [Urra et al., 2013]. This can also be identified in the PD Map
(Figure 3.14b, and downstream reactions) and selective chaperone translation in Alz-
Pathway (Figure 3.14a)
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ATF6 traffics to Golgi apparatus where it is cleaved and fragment named
ATF6. ATF6 then translocates to the nucleus regulating the transcription of genes
involved in ER homeostasis [Urra et al., 2013]. This is modelled in the PD Map (re 4212
and downstream, not shown here) and ATF6 mediating selective chaperone translation
in AlzPathway (Figure 3.14a).
These similarities identified, reveal a complex scenario in which the ER stress
response can have distinct downstream effects in both diseases and when different
signalling components are manipulated. Moreover, as discussed earlier, the UPR can
have different effects depending on the stage of the disease, initially working towards
a pro-survival factor to restore homeostasis, but later triggering apoptosis to clear
irreversibly damaged proteins.
Although response to ER stress were similar in both AD and PD leading
to apoptosis in distinct regions of the brain, however the upstream triggers were dif-
ferent and alternate pathways leading to apoptosis exist in both diseases. Moreover,
alterations in the function of the ER also play a major role in the aetiology of diseases
like diabetes, cancer, heart diseases, inflammation and several other neurodegenerative
[Hetz and Saxena, 2017, Oslowski and Urano, 2011, Sano and Reed, 2013]. Together,
studies of inflammatory disease and neuronal injury also support that persistent ER
stress represents a more general mechanism of neurodegeneration that is triggered not
only by the accumulation of disease-related damaged proteins but also by the pro-
inflammatory environment that is observed in neurodegenerative diseases. Therefore,
further efforts are needed to define the components of the ER stress response that could
be specifically targeted for optimal disease interventions for distinct diseases.
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(a) AlzPathway: ER stress induced by mutated presenilin
(b) PD Map: ER stress mediated by α synuclein toxicity
Figure 3.14: ER stress signalling in AD and PD
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3.3.6 Inflammation
Inflammation is a natural response of the immune system to restore tissue
homoeostasis. Inflammation is triggered by stressful stimuli such as tissue damage
and infections. The inflammatory response kills pathogens, repairs injured tissue and
removes abnormal metabolite deposits. Neuroinflammation is reported in many neu-
rodegenerative diseases and in some of them not only considered to be a consequence
but also could trigger the pathology. Moreover, in many neurodegenerative diseases,
inflammation markers are being investigated as diagnostic measures [Andreasson et al.,
2016, Wang et al., 2015] (also discussed in section 2.6.1).
Three of the matched reaction were involved in neuroinflammation in both
AD and PD. Figure 3.15, shows the transport of TNF and IL1B from the astrocyte
in both AD and PD Maps. Also detected as similar was the transport of IL6 from
the microglia triggered by their inflammatory response (reaction 779 in AlzPathway,
reaction 5241 in PD Map (not shown here)).
In many cases, AlzPathway entities were identified only after updating the
annotations. For example, nuclear factor kappa B subunit 1 was annotated as NFKB
instead of NFKB1, although named as subunit1. Similarly IL6 in many instances were
annotated as IL6R and annotated by two Uniprot identifiers. Several other cytokines
including AP1, TNF, IL6, and IRF were also incorrectly annotated. No other reactions,
other than discussed above were identified as similar in the neuroinflammation pathway,
suggesting that the consequence of neuroinflammatory responses may be similar in both
disease but the trigger could be distinct.
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(a) AlzPathway: Transport of TNF and IL1B from astrocyte
(b) PD Map: Transport of TNF and IL1B from astrocyte
Figure 3.15: Inflammation triggering transport of TNF and IL1B from astrocyte
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3.3.7 Wnt signalling
Figure 3.16 shows common reactions detected in Wnt signalling in AlzPath-
way highlighted on PD Map. Wnt signalling regulates several aspects of development
including organogenesis, mid brain development especially in dopaminergic neurons and
stem cell proliferation [Berwick and Harvey, 2014]. In PD, Wnt and β catenin signalling
serves as the common final pathway for neuroprotection and self repair [Marchetti et al.,
2013].
On the other hand, a variant of Wnt signalling pathway co-receptor LRP6
is associated with late-onset of AD and presents low level of Wnt signalling activation.
Wnt signalling is a neuroprotective mechanism against Amyloid β toxicity. With the
increase in Aβ aggregates, levels of Dkk1 increases. Dkk1 is a negative regulator of
Wnt signalling, resulting in higher GSK-3β activity. GSK-3β activity is reported to
be involved in several hallmark signatures of AD like the hyperphosphorylation of
tau, increased memory impairment and increased production of Amyloid β [Inestrosa
and Varela-Nallar, 2014, De Ferrari et al., 2007]. Also as discussed section 3.3.3, we
identified GSK3 as the only common modifier between all reactions matches in context
to tau hyper-phosphorylation.
Similar to several other mechanisms discussed here, the reaction identified
as similar are mediated by different modifiers signifying the upstream triggers in both
disease are distinct.
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Figure 3.16: Reactions identified from AlzPathway highlighted in PD Map
3.3.8 Synaptic area
The synaptic area does not show much similarities. This is primarily due
to the fact that the common receptors are represented as complexes without single
proteins. Since the complex comparison is not robust, these entities could not be
compared. Additionally, several entities in the AlzPathway were annotated. For in-
stance, Calmodulin in the AlzPathway was annotated as ”PICALM ” (Uniprot identi-
fier:Q13492), which is Phosphatidylinositol-binding clathrin assembly protein instead
of ”CALM1 ”. Glutamate was annotated as ”glutamate(2-)” in the AlzPathway and
as ”L-glutamic acid” in the PD Map.
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3.4 Summary
Comparison of disease maps to detect similarities and differences was imple-
mented and demonstrated using PD map and AlzPathway. Although many elements
and reactions were found similar in many hallmark neurodegenerative pathways they
were potentially triggered by different upstream events and cause different down stream
effects.
In AKT1 activity, TSC complex mediating activation of RHEB was detected
as a similar downstream reactions of phosphorylated AKT1 in both AD and PD.
Although TSC was not annotated in AlzPathway, the RHEB activation by
TSC was identified as a match. GSK3 was identified as the only common modifier
for Tau hyperphosporylation in both AD and PD maps. Additionally, in AlzPathway
Dkk1 negatively regulates Wnt signalling resulting in higher GSK3 activity.
Although there were incorrect annotations for MAPK cascade elements in
AlzPathway, several reactions were identified as similar with the PD Map. In the PD
Map SNCA triggers the MAPK signalling pathway in the PD map, whereas Amyloid
β aggregates trigger the MAPK cascade.
Similarly, while ER stress response has several alternate paths leading to
apoptosis in both AlzPathway and PD map, it is mediated by SNCA in PD and mutated
PSEN1 in AlzPathway. Presenilin 1 was incorrectly annotated as PSEN in AlzPathway
instead of PSEN1.
NFKB1 was annotated by two Uniprot identifiers and IL6, TNF, etc., were
not annotated. However, the annotated based comparison could identify several reac-
tions involving these cytokines as similar in inflammatory responses in both AD and
PD.
Several entities in the AlzPathway were annotated by two Uniprot identifiers,
leading to ambiguity in the identity of the elements . The annotation-based compari-
son could overcome the issues of multiple annotation, missing annotations and different
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encodings (HGNC and Uniprot) of various proteins between PD and AD maps. How-
ever, incorrect annotation of entities, for instance, PICALM for Calmodulin, could not
be detected automatically. Such errors in the model generation will limit the inter-
operability of models. The results of comparison between AlzPathway and PD Map
emphasise the need for curation standards to ensure higher quality and interoperability
of disease maps.
Chapter 4
Comparison of different disease
models
As discussed earlier, all the published disease maps are built in CellDesigner.
However, such maps are only a part of the knowledge landscape. Other formats like
BioPAX and OpenBEL are also used to built disease models ( Section 1.3.3) While
SBML and BioPAX have several software packages and packages for visualisation and
analysis, the framework and environment supporting OpenBEL is much more limited.
For instance, while OpenBEL captures the context of the relationship, this information
is not used for visualisation in cytoscape. This limits the re-usability and interoper-
ability of OpenBEL models [Hoyt et al., 2017].
System Biology Format Converter (SBFC) provides a generic framework
to includes several converters translating between several formats including SBML,
BioPAX, and SBGN-ML [Rodriguez et al., 2016]. Knowledge assemblers, like INDRA,
provide support for import of many formats and PyBEL [Hoyt et al., 2017] enables
the import of OpenBEL documents into a common format in INDRA. However, there
exists no converter from OpenBEL to SBML. Therefore, a converter from OpenBEL
to CellDesigner format was implemented. The converter was used to generate a node
file and reaction file from an XBEL file. The converter is available at https://git-
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r3lab.uni.lu/aishwarya.alex/xBELtoCellD. The list of nodes and reactions can then be
used to generate an CellDesigner model. The generated CellDesigner model can then
be visualised using the MINERVA platform.
4.1 Interoperability between models
The previous chapter details the comparison between two CellDesigner maps.
The next step was to convert OpenBEL models to the CellDesigner format. As a use
case, we convert the APP OpenBEL model. The species and reactions in CellDesigner
and their corresponding representation in OpenBEL are represented in the Appendix
A.2. The namespaces listed in the table are limited to the ones used in the APP model.
Since both modelling language have different purposes the conversion is lossful.
Each OpenBEL statement records a biological fact and can be annotated
with references, typically a PubMed ID. Additionally, each statement can also be asso-
ciated with a set of annotation that describes the context in which the statement was
observed. This adds to the knowledge associated with the statement being captured.
The additional information about the encoded statement such as the tissue, species,
and cell line can then be used for hierarchical organisation of the map. However, these
annotations are optional.
SET Disease = "Atherosclerosis"
SET CardiovascularSystem = "Arteries"
SET TextLocation = "Review"
SET Evidence = "Oxidation and nitration of macromolecules , such
as proteins , DNA and lipids , are prominent
in atherosclerotic arteries."
SET Citation = {"PubMed","Trends in molecular medicine","
12928037","","de Nigris F, Lerman A, Ignarro LJ, Williams -
Ignarro S, Sica V, Baker AH , Lerman LO , Geng YJ , Napoli C",""
}
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pathology(MESHD:Atherosclerosis) positiveCorrelation
biologicalProcess(GO:"lipid oxidation")
Listing 4.1: BEL Statement Example
An example of a OpenBEL statement and associated annotation is shown in
Listing 4.1. The statement with the biological fact is provided as the evidence. The
statement is accompanied by the citation and additional information e.g. the disease
and tissue. These information provided is essential to annotate the entities and reac-
tions in the context in which they should be added to the model. The subject (pathol-
ogy(MESHD:Atherosclerosis)) and object (biologicalProcess(GO:”lipid oxidation”)) in
OpenBEL, are translated to reactants and products (or modifiers) in CellDesigner.
Relationships in OpenBEL are converted to reactions in CellDesigner.
To identify each element (subject or object) is annotated by a namespace.
While the OpenBEL Language Documentation [BEL v2.0 Language Documentation,https:
//github.com/OpenBEL/language, Date Accessed: 30 May 2018], recommends as best
practice the use of well defined domains, external vocabularies and public ontologies
to define entities, it must be noted that the users are free to define and use their own
vocabularies to refer to entities.
Legacy and custom namespaces
OpenBEL also provides a list of legacy namespaces for domains such as
chemical, protein families, etc. These are lists of accepted names for chemicals, protein
families, etc., and also allows entities with no namespace. The legacy namespaces cover
each of the OpenBEL function types. These namespaces are available through their
resource framework at http://resources.openbel.org/belframework/. However, this has
not been updated to reflect the changes in the underlying resources. Additionally,
most of these resources identify entries by name and not a unique identifier. Due to
the large number of terms across many namespaces, the main challenge was to extract
the namespace and corresponding identifiers to generate a MIRIAM uris.
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For entities that are not annotated or use the OpenBEL legacy namespace,
we use the MeSH dictionary and reflect-client [O’Donoghue et al., 2010] to query GO
and Ensembl to try to extract the identifiers. This approach was also used to extract
the entities which where annotated by namespace and name alone, to extract the
corresponding identifier. E.g.: abundance (amyloid betapeptides). Such terms were
looked up in GO, MeSH and Ensembl. If not retrieved, they were set to unknown
species in CellDesigner.
Missing Namespaces and Improper Names
OpenBEL facilitates the use of openly shared controlled vocabularies (names-
paces) to promote exchange and consistency of information. Finding an appropriate
namespace-identifier pair is often an essential part of the curation process. An impor-
tant point to be noted is the element ”abundance which can represent any entity which
does not fit any of defined species like protein, gene etc,. OpenBEL uses this element
to encode elements of unknown quantity like chemicals, metabolites, ion, and peptides.
An overview of the conversion process is given below. The algorithm takes as
input the OpenBEL model in .XBEL format. The OpenBEL framework provides tools
to convert the OpenBEL document into .XBEL, a parsable xml format. The converter
extracts the relationships and involved subject and object to return two list, a node
and a reaction list. The node list, contains the elements, their unique identifier as
miriam uris, and location information. The reaction list contains reactants, products
and modifiers (if any) and the corresponding citation from which the reaction was
extracted. The reaction lists refers to the elements involved by the identifier used in
the node list. The elements in the node list can be reactants, products or modifiers in
one or more reactions. Therefore, we create a list of nodes with unique identifiers which
is used to refer to the same element as a participant of multiple reactions. An extract
of the result tables generated during the conversion of the APP OpenBEL model are
attached in the Appendix.
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Algorithm 1: Converting XBEL to nodes and reactions
Data: OpenBEL model in .XBEL
Result:
nodes list (nodes with annotation and location information)
reactions list (reactions, with nodes referring to nodes list and annotation)
for Each statement in file do
Extract annotations : citation, cell, cell line, tissue, disease, etc., ;
for Each relationship in statement do
if valid relationship then
get subject ;
if object is nested then
modifier ← subject ;
modifying relationship ← relationship ;
repeat section for relationship in object ;
else
get object ;
end
if subject, object and modifier exists in nodes then
retrieve identifiers ;
else
create nodes for subject, object and modifiers ;
retrieve identifiers ;
end
add new relationship with subject, object and modifier to reaction ;
else
skip to next relationship ;
end
end
end
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While CellDesigner is a process focused representation, the information cap-
tured is detailed based on interaction between entities rather than directly on entities.
OpenBEL on the other has its focus in relationship between entities and has specifics
representation for such relationships which are missing in CellDesigner.
OpenBEL allows nested statements. They are translated as reactions with
modifiers in CellDesigner. Figure 4.1, the subject of reaction1 acts as a modifier to the
nested reaction in CellDesigner.
Subject1 Object2Subject2
Object2Subject2
Subject1
Object1
(Modifier)
Reaction1 Reaction2
Reaction1
Reaction2
BEL nested statement
 As hypergraph in CellDesigner
Figure 4.1: Nested statements in OpenBEL
However, this is only done for reactions which allow modifiers like state
transition and transport. For reaction types that do not permit modifiers, the reactions
are converted to two separate reactions:
1. modifier(subject1) -modifying relationship (reaction1)- reactant (subject2)
2. reactant(subject2) -relationship (reaction2)- product(object2)
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Currently the converter handles the OpenBEL predicates following the map-
ping shown in Table 4.1.
OpenBEL predicates CellDesigner reaction
increases UNKNOWN POSITIVE INFLUENCE
directlyIncreases POSITIVE INFLUENCE
directlyDecreases NEGATIVE INFLUENCE
decreases UNKNOWN NEGATIVE INFLUENCE
positiveCorrelation UNKNOWN REDUCED MODULATION
negativeCorrelation UNKNOWN REDUCED MODULATION
translocation STATE TRANSITION
MODIFIER increases UNKNOWN CATALYSIS
MODIFIER directlyIncreases CATALYSIS
MODIFIER directlyDecreases INHIBITION
MODIFIER decreases UNKNOWN INHIBITION
Table 4.1: OpenBEL predicates and corresponding representation in CellDesigner
As mentioned earlier, due to the differences in the language structure we
expect a loss of information upon conversion. Some of the predicates in OpenBEL
do not have a corresponding equivalent representation in CellDesigner, e.g. nega-
tiveCorrelation, positiveCorrelation, association, biomarkerFor, hasComponents, prog-
nosticBiomarkerFor, complexAbundance. These relationships are not represented in
CellDesigner since they do not directly describe a process, and add no mechanistic
value to the model. Such relationships in OpenBEL are ignored by the converter.
OpenBEL captures the context of the reaction using the ”SET” statements (See listing
4.1). The converter extracts this information to organise the model hierarchically into
compartments for better visualisation and context. The cell and cell line information
provides the context in which the reaction occurs and are represented as compartments
in CellDesigner.
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OpenBEL activity term GO annotation
catalyticActivity urn:miriam:obo.go:GO:0003824
chaperoneActivity urn:miriam:obo.go:GO:1903332
gtpBoundActivity urn:miriam:obo.go:GO:0008277
chaperoneActivity urn:miriam:obo.go:GO:1903332
kinaseActivity urn:miriam:obo.go:GO:0016301
peptidaseActivity urn:miriam:obo.go:GO:0008233
phosphataseActivity urn:miriam:obo.go:GO:0016791
ribosylationActivity urn:miriam:obo.go:GO:1990404
transcriptionalActivity urn:miriam:obo.go:GO:0006355
transportActivity urn:miriam:obo.go:GO:0005215
degradation urn:miriam:obo.go:GO:0009056
Table 4.2: OpenBEL activity terms and corresponding GO annotation
To specify distinct molecular activity of protein, complex, and RNA, Open-
BEL uses the ”activity” functions providing distinct terms that differentiate these
activity from the abundance.
For example, kinaseActivity(proteinAbundance(HGNC:AKT1)) directlyDecreases tran-
scriptionalActivity(proteinAbundance (HGNC:FOXO1)), indicates that the kinase ac-
tivity of AKT1 directly decreases the transcriptional activity of FOXO1. These func-
tions are annotated as GO terms (Table 4.2) and added as additional information to
the specific node (Protein, Gene, etc.) by the converter.
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4.2 Results
The APP OpenBEL model was converted in to an CellDesigner format using
the converter and visualised using the MINERVA platform. The conversion process
consists of several steps. First, the OpenBEL model in .XBEL format was parsed by
the converter and the entities and their annotations were extracted to generate a nodes
list. At this stage , the converter also extracts annotation for unannotated elements
and legacy namespaces. Next, the relationships in OpenBEL are translated to reaction
types in CellDesigner and a reaction list was generated referring to elements from the
node list and also the cellular location extracted from the OpenBEL model. The node
and reaction list were then converted to an SBML format. Finally, to provide a layout
to the model, the SBML was converted to CellDesigner format.
EVIDENCE: Recent studies have shown independently that presenilin-1 (PS1) null mutants and familial 
Alzheimer's disease (FAD)-linked mutants should both down-regulate signaling of the unfolded protein response 
(UPR)
proteinAbundance (HGNC: PSEN1)   decreases    biologicalProcess (response to unfolded protein)
SUBJECT: proteinAbundance (HGNC:PSEN1)
OBJECT: biologicalProcess (response to unfolded protein)
RELATIONSHIP: decreases
REACTANT :   s22          PROTEIN      PSEN1                                         urn:miriam:hgnc.symbol:PSEN1
PRODUCT   :   s3721    PHENOTYPE      response to unfolded protein    urn:miriam:obo.go:GO:0006986
REACTION : 
r4235 UNKNOWN_NEGATIVE_INFLUENCE s22 s3721      urn:miriam:pubmed:11551913
BEL
Nodes and Reaction
Figure 4.2: Example of a lossless statement conversion
Figure 4.2 shows an example of a statement that could be translated without
any loss of knowledge. Moreover, the object in the OpenBEL statement biologicalPro-
cess (response to unfolded protein) had no annotation associated with it. This term
was retrieved as a GO term. From a total of 7083 statements in the APP OpenBEL
model 4347 were partially or completely converted to the CellDesigner model. Table
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4.3 gives a summary of the relationships that were ignored or partially translated.
Relationship Count Partially converted
Association 1445 9
Decreases 17 17
Increases 86 86
directlyIncreases 1 1
biomarkerFor 19 0
causesNoChange 54 0
ComplexAbundance 1014 0
hasComponents 2 0
hasMember 1 0
hasMembers 54 0
isA 56 0
negativeCorrelation 1 1
rateLimitingStepOf 1 0
translocation 52 4
Table 4.3: OpenBEL statements lost in conversion
Some statement with the following relationships: decreases, increases, direct-
lyIncreases, translocation and negativeCorrelation were partially converted because
they were a nested statements with a modifying relationship that did not have any
equivalent. In such cases, only the nested statement was translated. In the case of
translocation, statements which were missing either a from or to location were also
ignored.
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Figure 4.3: A version of the APP OpenBEL model converted to CellDesigner visualised
using the MINERVA platform.
In Figure 4.3, each box represents the context (cellular location or mech-
anism) where the reactions occur. The top left box represents the synapse. The No
compartment box had no context (no tissue, cell type or compartment) associated with
it. This is an example of how a model built without required standardized notation
for context would be visualised. There is a very dense network, but offers very little
use in any knowledge exploration, or data interpretation.
The generated model that had proper context annotation was quite large and
therefore was split into five maps depending on the cell type of the reactions involved.
Table 4.4 shows components of each of the smaller maps.
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Celltype group Components
Blood Blood Cells, Blood Platelets, Lymphocytes, Erythrocytes, Leukocytes
Neurons
Neurons, primary neuron, Dopaminergic Neurons, Pyramidal Cells,
Motor Neurons, primary cortical neuron, Interneurons
Only tissue
Bone Marrow Cells, Beta cell, INS-1 cells, Myocytes, Smooth Muscle,
Endothelial Cells, Human Umbilical Vein Endothelial Cells, Fibroblasts, Neural Stem Cells
Glial cells Astrocytes, Microglia
Others (Model systems) Neuroblastoma cell, CHOAPPsw, N2a695 cell, 293, NT2N cells, PC-12
Table 4.4: Submaps components based on cell type
The only tissue map comprises of reaction and nodes which had no precise
inter cellular location information associated to them, but only tissue information.
Many statements tagged only with tissue information, were pertaining to literature
about cerebrovascular diseases, Diabetes Mellitus Type 2, etc., investigating cross-
talk with significant pathways of AD [Ubeda et al., 2004, Freude et al., 2009, Jung
et al., 2003]. These interactions may not be specific to AD, but are interesting for
co-morbidity studies. Additionally, several statements were extracted from literature
reporting results from model systems and cell lines, such reactions were included in the
model system map.
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APP BEL (Cystoscape)
APP SBML (MINERVA)
Blood
Brain
Neurons
Glia
Other cell lines
Only tissue
Figure 4.4: APP OpenBEL model converted to CellDesigner, visualised in MINERVA
Figure 4.4 highlights the difference in visualisation using contextual infor-
mation. The map provides an easily navigable, hierarchical and compartmentalised
structure as opposed to the dense ”hairball” of the OpenBEL model. Moreover, the
community support for SBML compatible software is much larger than the OpenBEL
community, providing better analytical and exploratory tools for the SBML network.
4.3 Comparison of APP map to PD map
The converted APP submodels were compared to the PD Map with methods
described in Chapter 3. Figure 4.5 shows the matches highlighted on the PD map.
Although all the submaps identified many elements in common with the PD Map only
one reaction was identified as similar; the transition of APP to Amyloid β 42. This
reaction was identified both in the APP blood and APP neuron maps.
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Figure 4.5: Elements and reaction from APP model on PD map
The identified elements were mainly concentrated around the neuroinflam-
mation, cell death and ER stress signalling neighbourhood on the PD Map. ROS
activity and the iron metabolism submap also detected matches in the PD Map. The
Alzpathway also detected similarities in these regions.
However, the absence of similar reactions is evident. This may be primarily
due to the fact that the distribution of reaction types in both the maps are consid-
erably different. Table 4.5, shows all the reaction types in the APP map and the
number of such reactions in the PD Map. It is evident that the APP model has larger
number of reaction of type modulation and influence, arising from the ”increases” or
”decreases” relationships in OpenBEL. The greater number of such interactions is be-
cause OpenBEL aims to capture causal and correlative relationships between entities.
Additionally, unlike the AlzPathway, the APP model is primarily focused around the
Amyloid β Pathology, therefore it is not surprising that there were not many reaction
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similarities with the PD Map.
Reaction type Count (APP Map) Count in PD Map Count in AlzPathway
NEGATIVE INFLUENCE 25 206 2
STATE TRANSITION 49 678 380
POSITIVE INFLUENCE 76 1060 9
UNKNOWN REDUCED MODULATION 525 13 1
UNKNOWN NEGATIVE INFLUENCE 1059 26 10
UNKNOWN POSITIVE INFLUENCE 2498 2 14
Table 4.5: Reactions in the APP Map
4.4 Comparison of APP map to AlzPathway
On comparing the APP maps with the AlzPatwhay, 308 elements were found
in common, out of which only 125 unique elements. The blood and brain submap had
the maximum number of matches. Figure 4.6 show the elements from APP maps
highlighted on AlzPathway.
The matched elements from APP are spread out on the Alzpathway, except
around the region of cholesterol metabolism. Interestingly, none of the elements of
type ”phenotype” were matched, although both APP and AlzPathway have a large
number of elements of type ”phenotype”. This could be due to the fact that phenotypes
elements were not annotated in AlzPathway. On the other hand, phenotypes like ”long-
term memory”, ”astrocyte activation”, ”neuroinflammation” ,”ER stress response”,
etc., were detected as matches between the PD Map and APP maps. Therefore, we
could expect an increase in the number of matches, if phenotypes were accounted for.
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Figure 4.6: Elements from APP model highlighted on AlzPathway
Figure 4.7 shows the results for a search for ”APP” on the AlzPathway, the
results include ”APP, APP (Abeta), APP (Abeta 40), APP (Abeta 40, APP (c99))”.
The distribution is similar to all matches detected from the APP maps, since the APP
map was built around the Amyloid Beta pathology.
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Figure 4.7: APP and Aβ highlighted on AlzPathway
Similar to the reactions detected in comparison to the PD Map, number of
reactions detected as matches was lower than expected based on the fact, that both
resources are models of Alzheimer’s disease pathology. Only 5 reactions, were detected
as similar in the AlzPathway. All five reactions were involving APP. As discussed
earlier, this was primarily due to the reaction type, the APP map has greater reactions
of unknown influence or modulation (Refer Table 4.5). Next, we identified the reactions
that have the same interacting elements i.e. reactants and products but not necessarily
the same reaction type. This approach detected 31 reactions. Figure 4.8 shows these
reactions highlighted on the AlzPathway.
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Figure 4.8: Reactions from APP model highlighted on AlzPathway
However, the majority of the reactions were still involved with APP, Abeta
peptides and BACE. Also detected was the activation of GSK3B and transport of
inflammation markers TNF-α, IL6, IL1B.
Figure 4.9, shows reactions found similar in APP and AlzPathway. BACE
(BACE1) is reported to cut APP to generate the N terminus of Aβ producing a C-
terminal fragment called C99 [Tanzi and Bertram, 2005]. BACE is also a known drug
target for the therapeutic inhibition of Aβ production in AD [Vassar et al., 2009].
In AD, GSK3β serves as a functional link between Amyloid β and Tau pathol-
ogy [Llorens-Mar´ıtin et al., 2014](also discussed in section 3.3.3 and 3.3.7). This was
also detected as common in the comparison between APP and Alzpathway map. Shown
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in Figure 4.10, activated GSK3β, modulates the phosphorylation of MAPT, which fur-
ther downstream results in production of Neurofibrillary Tangles.
Although in recent decades, Amyloid β was considered the primary hallmark
of AD pathology, the present consensus is that the disease has a multifactorial origin
[Llorens-Mar´ıtin et al., 2014, Medina et al., 2017, Gong et al., 2018]. Currently, several
reports support neuroinflammation as a significant contributor to several neurodegen-
erative pathogenesis including Alzheimer’s Disease [Hong et al., 2016] (also refer section
3.3.6).
GSK3β is also known to play regulatory role in the inflammatory response
[Sudduth et al., 2013, Llorens-Mar´ıtin et al., 2014]. Reactions involving inflammatory
markers IL6, IL1B and TNFα were detected in the astrocyte and microglia in both
APP and AlzPathway (See Figures 4.11 and4.12, also discussed in section 3.3.6 )
Figure 4.9: BACE and APP activity in Alzheimer’s Disease
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Figure 4.10: GSK3β as a functional link between Amyloid β and Tau pathology
Figure 4.11: IL6, IL1B and TNFα transported to microglia
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Figure 4.12: IL6 and IL1B transported to astrocyte
4.5 Summary
The converter extracted the nodes and reactions from the OpenBEL model.
This was then converted to the CellDesigner format for layout. The converted model
were divided into five smaller maps based on cell type or tissue context. The converted
maps were then used to compare against the AlzPathway. Although many elements
were identified as similar between the maps, due to the differences in reaction types,
only five reactions were identified as similar. It was evident that identified reactions
were involved in the Amyloid β pathology. Next, we performed a comparison not
strict on the reaction type, but considering the reactants and products involved in
the reaction. 31 reactions were identified as similar. While several additional reaction
involving APP or Aβ were identified, similarities in inflammation and Tau pathology
were also identified. However, as discussed earlier both maps have several elements
as phenotypes, and several of them were not annotated in AlzPathway. Although
unannotated genes or proteins are handled by the comparison, the current version of
does not handle unannotated phenotypes. Overall, we demonstrate that annotations
and modelling standards are essential for interpretability of the models. Moreover,
4.5. Summary 97
these standards can facilitate re-use and easier interoperability of different modelling
formats for further investigation.
Chapter 5
Discussion
Data heterogeneity is one of the biggest challenge in data integration . This
particularly dominant in data driven domains like systems biology and translational
medicine since many researchers with different areas of expertise work together. The
difficulties in data integration have only increased with the advent of high throughput
technologies. Moreover, interdisciplinary research brings together different experts such
as clinicians, biologists, bioinformaticians, and software developers together. Therefore,
it is particularly important for these diverse groups to use, share and exchange their
data and results. This is only possible if they speak the ”same language”.
Today, an increasing amount of data is available in databases that are main-
tained by different organizations for different purposes and therefore are often designed
independent of each other. The increase in amount of data does not necessarily signify
increase in the amount of knowledge. Data and resources are useful when they are
understandable and interpretable [Panahiazar et al., 2014, Wang et al., 2018]. Appli-
cations can then integrate, search and extract information from interpretable data to
support clinical decision making. Due to the volume and complexity of data available
today, traditional methods of analysing such a large amount of data are not feasible
[Raghupathi and Raghupathi, 2014].
With increasing power of computers resources we can now look for ”infor-
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mation” and ”relationships” that were not obvious. In 2013, healthcare expense of
the United States was estimated at 17.6 percent of GDP (nearly $600 billion) [Groves
et al., 2013]. Despite the significant funding spent on healthcare, the main challenge
of interoperability still remains [Kruse et al., 2016]. In 2011, dirty data was estimated
to cost the US healthcare industry over $300 billion every year and 60% of estimated
time spent on cleaning and organising data [Redman, 2016, Tibbetts, 2011]. Over the
last decades, the failure to organise and standardise the rapidly generated data makes
it an increasingly costly effort to make use of this data today [Attwood et al., 2009].
In order to use and reuse the data, it is storage and communication should be in a
structured and standardized format.
5.1 Integrating Heterogeneous Data
Research approaches today rely heavily on information available through
public databases. These datasets are often inconsistent, not standardized, or properly
annotated. Moreover, the quality of the data is also uncertain [Wolstencroft et al.,
2015, Comber et al., 2006]. Despite several normalisation efforts and initiatives, data
standardization still remains an open issue. There is a need to define standard formats
for every data type. Several domains already have such efforts which has been at least
partially successful (e.g. MIAME). However, the metadata, i.e. information describing
the provenance and structure of the data, design of experiment, is still neglected in
many cases and are not comprehensive enough to support large scale data integration
approaches [Bagewadi et al., 2015].
Chapter 2 details, the curation, harmonisation and integration of publicly
available studies from GEO and Array Express and datasets generated within the AE-
TIONOMY consortium. Data access, acquisition, curation and integration is tracked
through a study request system to address the challenge of ensuring smooth and effi-
cient entry of datasets into the AETIONOMY knowledgebase. Each dataset undergoes
a curation and harmonization process. The standard format files are generated for each
curated dataset. Following the ETL process, the datasets are loaded in tranSMART
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to enable further visual and exploratory analysis. Section 2.6, discuss how these har-
monised and integrated datasets support hypothesis generation in AD and PD. While
datasets from public repositories such as GEO and Array Express were standardised
to large extent, clinical data from collaborators was far more challenging.
When it comes to clinical data collection, data harmonisation and standard-
isation is not a trivial task [Hudson et al., 2018]. Standards harmonise meaning across
different studies and even sites within studies. This will enable individual elements to
be aggregated into a larger picture. Often data collection involves more than one per-
son and is carried out over a considerable period of time, without guidelines and agreed
upon standards, the process will vary from person to person and over time [Dickersin
and Mayo-Wilson, 2018, Leroux et al., 2017]. As discussed in Chapter 2, this variance
in data representation and sharing is the biggest challenge to the integration process.
Representations varying between study centre and often within the same centre. There-
fore, standards will ensure the uniformity and additionally facilitate the compatibility
between different systems. Collaborating with the CDISC, the Consortium for Preven-
tion of Alzheimer’s Disease (CPAD, https://c-path.org/programs/cpad/) mapped
the data from nine different organizations to create an openly available database con-
taining individual records of 6,500 Alzheimer patients from 24 clinical studies [Neville
et al., 2015].
Traditionally, clinical research studies relied on collecting data with case
report forms. These were subsequently entered into a database by a double data entry
to generate electronic records. This method is time-consuming and error-prone. Today,
electronic case report forms (eCRFs) and electronic data capture (EDC) solutions are
available to reduce the duration of data capture and increase accuracy. [Rorie et al.,
2017, Walther et al., 2011]
Creating and revising the EDC and accepted set of arguments along with the
different target groups is crucial to accommodate the requirements and potential use
cases of the data generated. Minimising free text fields for data input or provide free
text fields in addition to mandatory fields with select or multiple select variables will
accommodate the needs of both data collector and processor. For instance, although a
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data processor would prefer strict data representations to reduce ambiguity and errors
that can be caused due to uncontrolled data entry, a medical researcher or data collector
may find it difficult to restrict certain inputs to limited set of values. Therefore, it is
particularly important to consider the needs of both the data collector and processor.
Following standards in data collection and data representation at early stages
of the data collection will ensure harmonised data capture and reduce errors and ambi-
guity that may arise if there are no strict rules [Bellary et al., 2014, Cowie et al., 2017].
Therefore, it is necessary to bring together several groups of users when creating and
designing the study. Data integration should rely on bioinformaticians and software
engineers, but it also needs to be driven by the people involved directly or indirectly
with the data i.e. research communities, clinicians, informaticians and analysts.
5.2 Comparison and Conversion of Maps
Comparing of disease maps is a crucial element in biomedical research. Dis-
ease maps integrate current knowledge about disease mechanisms in a context of hier-
archical organisation representing the different layers of biological complexity. Disease
maps help to visually represent extensive knowledge about a disease integrated in a
single resource. The usefulness of disease maps, largely depend on their quality. As
discussed in Chapter 3, the results of comparison between AlzPathway and PD Map
emphasise the need for curation standards. For instance, several entities in the Alz-
Pathway were annotated by two Uniprot identifier, leading to ambiguity in the identity
of the elements. However, many elements were identified by extending the model anno-
tation to additional namespaces and detecting unannotated genes and proteins. This
improved interoperability between two maps and facilitated their comparison. Initia-
tives like COMBINE and FAIRDOM coordinate and promote the adoption of standards
and ontologies in disease modelling through the experience of the community [Wols-
tencroft et al., 2017, Waltemath and Wolkenhauer, 2016b, Stanford et al., 2015]. Such
initiatives
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Although there has been considerable efforts in ensuring model sharing and
reusability in disease maps using widely used languages like SBML and BioPAX, Open-
BEL still remains a challenge [Hoyt et al., 2017]. It is important for languages like BEL
to adopt and promote standards and ensure best practices in modelling particularly
because it has been adopted by communities for crowd sourcing challenges and com-
munity built maps. Moreover, from Chapter 4 we see that while BEL is very flexible
and allows to generate large networks, the quality and consistency of the network may
vary depending on the curator. Since, there are no strict rules for the adoption of
standards, over time the curator could potentially capture the same knowledge in dif-
ferent representations. This could also rise if more than one curator is involved in
adding knowledge to the model, since they bring different perspective of modelling the
disease. While OpenBEL suggests best practices to follow, it does not impose any
strict consistency checks to ensure them. Moreover, OpenBEL is a relatively new and
evolving language, hence it could be potentially useful to coordinate modelling and an-
notation standards in OpenBEL to ensure better model and data exchange and reuse
in the community.
While standards in modelling may differ with different formats, annotation
standards could be unified. However, development model annotation standards and ad-
vocating the benefits is not a trivial task. The absence of such annotation standards,
makes linking data and knowledge from different model and interoperability of models
a difficult task. Although it is understandable that making different modelling lan-
guages interoperable requires considerable effort, a unique format for representation of
annotation could facilitate the process. Such an approach could address the challenges
discussed in Chapter 4 arising due to differences in element annotation in OpenBEL
and CellDesigner. Currently, no such standard protocols for model annotation exists
in biological modelling community [Neal et al., 2018]. [Neal et al., 2018] propose an
interesting approach to address this issue by storing annotations in a separate file,
thereby the possibility to harmonise annotation standards across different formats.
Recent works, like the SemanticSBML [Liebermeister et al., 2009] allow merging two
SBML models. However, a computer software can only support, but not replace the
modeller in building biochemically meaningful models, because it cannot handle the
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assumptions and intentions on which all models are based.
Models may naturally differ in assumptions and intentions when built by
different researchers. Therefore comparison or merging them can be tedious process.
However, the standards both in modelling and annotation can reduce ambiguity and
bridge this gap. A major challenge in extracting information from publications is the
identification of entities within the article [Mons, 2005]. The usage of unique identifiers
and standards in the form of controlled vocabularies and ontologies is essential for a un-
ambiguously identifying and annotated entities. As a solution, journals and databases
should not only encourage but also mandate the use of complete, standardized and
structured data in their submissions.
Using integrative systems biology approaches, we can leverage the existing
knowledge and large-scale data to add to our limited understanding of unknown fac-
tors and disease mechanisms [Greene et al., 2011]. Hypotheses generated from these
approaches can support clinical decision making and targeted approaches in a cost-
effective manner [Castaneda et al., 2015, Auffray et al., 2016, Wang et al., 2018].
Although, integrative approaches are limited by the semantic disparity between com-
ponents standardising data and results will help us achieving this goal. However, it is
not straightforward, but it is not impossible. Several initiatives and consortia advo-
cating the FAIR principle is a step forward in this direction [Sansone et al., 2018].
Chapter 6
Summary and Outlook
6.1 Summary
In the last year alone, 88 new biomolecular-related databases were listed
in the latest Nucleic Acids Research database issue [Rigden and Ferna´ndez, 2018].
Researchers require tools to identify relevant information in the maze of biological
data. Several systems have been developed to address this need and help scientists
work with omics data, e.g. Gene Expression Omnibus, Array Express, etc,. However,
omics data have to be analysed together with clinical data to be useful for translational
research. We use tranSMART, a translational medicine platform to curated, harmonise
and integrate publicly available datasets and datasets from the AETIONOMY project.
These datasets were then used to support hypotheses generation, demonstrated with
examples.
Disease maps support hypothesis generation by providing context to the dis-
ease mechanism. The concept of shared mechanisms and underlying co-morbidity is
common in complex disease like Parkinson’s and Alzheimer’s. This can be investi-
gated by comparing disease maps. To this extent, comparison of CellDesigner maps
was implemented. The comparison takes into account the annotation, translation of
namespaces, and localisation of the entities and reactions. This was demonstrated us-
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ing AlzPathway and PD Map. The elements and reactions found in both maps were
highlighted on the PD Map, detecting similarities in both disease mechanisms, but
potentially triggered by different upstream events. Comparison of maps could there-
fore support identification of disease specific drug targets and support clinical decision
making.
Several disease modelling formats are available today. To enable comparison
of disease models, they should first be interoperable. In the scope of this project, we
implemented a converter from OpenBEL to CellDesigner. The converter takes into
account mapping of the representation and tries to extract unique identifiers for all
the entities and the context of the reaction. As a use case, the APP BEL model was
converted to the CellDesigner format. The converted APP map was then used to
compare against the PD Map and AlzPathway. Standardising semantic annotations
in models eliminates the bottlenecks and helps researchers to easily locate models,
automate and translate between modelling formats. This supports the integration of
biological knowledge encoded in different models and resources.
Overall, we demonstrate how harmonised and curated data makes heteroge-
neous datasets and formats interoperable, bridging the gap between data and knowl-
edge.
6.2 Outlook
Although we have successfully integrated several heterogeneous sources and
making them interoperable, the process could be further stream lined by reducing
manual efforts if the input data formats are harmonised. Furthermore, to maximize
data sharing, the use standards for data collection and modelling should be mandatory
for funding support. A prerequisite for data-driven analytics is a data sharing culture.
To address this issue, we require significant efforts in adopting standards at all stages
of healthcare data life cycle. This will significantly improve the quality of data and
the accuracy of analysis and prediction. CDISC being widely accepted by the several
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consortia and funding agencies is a big step forward to facilitate efficient data sharing
and interoperability in the clinical data domain.
In addition to comparison of maps, visualising the results are of great im-
portance. Additional scoring mechanism to the matches and intuitive visualisation
methods need to be developed for e.g. a colouring scheme, which signifies the confi-
dence on the match. Currently, we have been successful in highlighting the identified
similarities. In addition to highlighting the similarities, more intuitive would be to
superimpose both the compared maps and visualising both similarities and differences.
The conversion from OpenBEL to CellDesigner loses some information, but
this is expected due to the difference in the objectives of the languages. However, there
are many tasks that can improve this converter, but this largely depends on the different
models. For instance, in the APP model SNP were encoded as genes with the dbSNP
identifiers, the current version of the converter ignores these entities. This could be
converted as gene with the corresponding HGNC identifier and additional annotation of
the mutation. Expanding to additional namespaces, could improve entity recognition
for unannotated elements.
One of the challenges in front of the scientific community today is to change
how knowledge is organized and communicated. Several of the knowledge resources
overlap in content [Perez-Riverol et al., 2018, Masseroli et al., 2014, Williams et al.,
2012]. New resources are being created in parallel, whether they should be a novel
resource or could be integrate into an existing resource is debatable. Moreover, there is
no broad consensus about which resources should be used for an annotation in an ideal
scenario. Therefore, the same concept could potentially be represented in two different
scenarios might be annotated by different knowledge resources. This adds additional
efforts to the community to compare and compose models or integrate resources in an
automated fashion, as well as convert between standard formats. In an ideal case, the
content of the models should be annotated using the same set of reference terms and
qualifiers. However, the choice of knowledge resources for annotation may vary from
group to group. Therefore, it cannot be defined by strict rules. On the other hand,
making these specifications publicly available with along with the model will make the
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model much more interoperable and re-usable.
Data is an essential part of research today, therefore it is also necessary to
maintain standards for data annotation. With initiatives like the FAIR and COMBINE,
linking annotations in models and data sources is foreseeable in the future. In this era
of big data, data-driven analytics has the potential to transform the technologies used
by healthcare providers by gaining insight from clinical and public data repositories
and supporting decision making. The rapid, widespread implementation and use of big
data analytics in the healthcare industry is challenged by the volume and heterogeneity
of relevant data. Harmonised and standardised data and representation can accelerate
the development of such analytical tools to support clinical decision making.
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Partner Name of Cohort Subjects Biospecimen Type Comments
UL
ADNI ADNI1 1386 Completed Closed
ADNIMERGE 1779 Completed Public
FhG SCAI AD Public studies Demographic+Clinical+mRNA/miRNA Expression 43 Studies Completed Public
EMC Imaging ADNI 57 Completed
IDIBAPS
Screening CSF 17 Completed
Validation CSF 34 Completed
AD  Dementia Stage CSF 164 Completed
UKB  (AD) AD  Inflammation Consecutive Preclinical AD 30 CSF
399
Completed
AD Cytokine CSF 95 Completed Closed
Total 
Received
Data access after 
AETIONOMY (+5 years): 
Public, closed, deleted, data 
access committee
Plasma
CSF
Demographic
Clinical
Neuropsychological
ADNIMERGE: Alzheimer's Disease 
Neuroimaging Initiative. R package 
version 0.0.1.
Plasma
CSF
Demographic
Clinical
Neuropsychological
4 GEO Studies
39 AE Studies
BIGR
Connectome
Freesurfer
BIGR
Connectome
Freesurfer
Control 9
AD Moderate Cognitive Decline 6
Prodormal AD 2
Demographic
Clinical
Neuropsychological
MRNA/miRNA Expression
Restricted (Data Access 
committee)
Control 20
AD Moderate Cognitive Decline 11
Prodormal AD 4
Demographic
Clinical
Neuropsychological
MRNA/miRNA Expression
Restricted (Data Access 
committee)
Control 68
AD Moderate Cognitive Decline 26
Preclinical AD 23
Prodormal AD 39
SNAPS 8
Demographic
Clinical
Neuropsychological
Restricted (Data Access 
committee)
Demographic
Clinical
Neuropsychological
Restricted (Data Access 
committee)
AD 44
MCI 34
Control 17
Demographic
Clinical
Neuropsychological
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A.1 Alzheimer’s and Parkinson’s Disease datasets integrated in AETIONOMY
Partner Name of Cohort Subjects Biospecimen Type Total Received Comments
UL
PPMI eTRIKS (in Kind) 813 Completed Closed Closed
PD Public studies eTRIKS (in Kind) 16 Studies Completed Public Public
FhG SCAI AD Public studies 43 Studies Completed Public Public
ICM
GenePark Blood 360 Completed Data Access Committee Closed
NGC/ PD Repository 5011 Completed Data Access Committee Closed
DIGPD 416 Completed Data Access Committee Closed
PD Transcriptomic data Fibroblasts 36
Completed.
Data Access Committee Closed
UKB (PD)
DNA (Blood)
1057
Completed.
Data Access Committee
Public
UCB
Kings College London Demographic Completed Data Access Committee Data Access Committee
D13B Tubingen plasma and CSF Proteomics and methylation studies
Completed Data Access Committee Data Access Committee
EFPIA PD Clinical Studies 14 STUDIES
Curation Data Access Committee
BI
BI001 76 IDS Aggregate Datasets
Completed Data Access Committee
BI002 7 IDS Aggregate Datasets
Completed Data Access Committee
BI003 6 IDS Aggregate Datasets Completed. Data Access Committee
KI
AETIONOMY
ICEBERG
Data access during AETIONOMY: Public, 
closed, deleted, data access committee
Data access after AETIONOMY (+5 
years): Public, closed, deleted, data 
access committee
Demographic
Clinical
Neuropsychological
Demographic
Clinical
mRNA/miRNA Expression
4 GEO Studies
39 AE Studies
Demographic
Clinical
MRNA/miRNA Expression
IPD (156)
LRRK2 Relative (1)
Parkin Relative(4)
Parkinson Disease Asymptotic Carrier(1)
Genetic(27)
MSA (10)
PSP (11)
Healthy  controls  (150)
Demographic
Clinical
Neuropsychological
At Risk 1082
Control 578
Diseased 3331
Unknown 20
Demographic
Clinical
Neuropsychological
Consecutive  idiopathic PD
  
DNA
Plasma
Demographic
Clinical
Neuropsychological
Genetic Data Results
Control 10
LRRK2 12
Parkin 14
Demographic
mRNA/miRNA Expression
Epigenetics Data PD
(CpG data)
Control 521
PD 536
Demographic
Clinical
Neuropsychological
Control 161
Parkinson's Disease 40
DNA
CSF
CSF
Plasma
PD 100
Control 50
DNA
Plasma
CSF
PD 240
Genetics 65
Control 90
IRBD 70
PD 53
Control 10
iRBD 17
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A.2 AlzPathway overlayed on PD Map
Summary of performance with different annotators
Existing Annotations HGNC annotator All annotators
Elements
(Annotation)
48 649 762
Elements
(Annotation+Compartment)
25 430 528
Perfect Element
(Annotation+Compartment+Complex)
25 291 325
Reactions 0 31 40
Perfect Reaction
(Reactants+Products+Modifiers)
0 5 6
Table A.1: Summary of performance with different annotators
Elements from AlzPathway found in the PD Map
name lineWidth Color
ATG10 10 #FF0000
IL1B 10 #FF0000
SNCA 10 #FF0000
VPS35 10 #FF0000
BCL2 10 #FF0000
ATG13 10 #FF0000
BAX 10 #FF0000
PPARG 10 #FF0000
GSK3B 10 #FF0000
TXN 10 #FF0000
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XBP1 10 #FF0000
NFKB1 10 #FF0000
BAD 10 #FF0000
TLR2 10 #FF0000
multivesicular body 10 #FF0000
NGFR 10 #FF0000
PPP2CA 10 #FF0000
ULK1 10 #FF0000
FAS 10 #FF0000
P2RX7 10 #FF0000
CXCL1 10 #FF0000
CYCS 10 #FF0000
NFKBIA 10 #FF0000
glutathione disulfide 10 #FF0000
EIF4EBP1 10 #FF0000
CAMK2B 10 #FF0000
TNF 10 #FF0000
ATG12 10 #FF0000
CTNNB1 10 #FF0000
RELA 10 #FF0000
mitochondrion 10 #FF0000
HSPA5 10 #FF0000
CASP8 (p10) 10 #FF0000
CASP9 10 #FF0000
PRKAA2 10 #FF0000
CAT 10 #FF0000
ubiquitin 10 #FF0000
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NGF 10 #FF0000
MAPK8 10 #FF0000
PIP2 10 #FF0000
astrocyte 10 #FF0000
APC 10 #FF0000
TNFRSF1A 10 #FF0000
STXBP1 10 #FF0000
CCL2 10 #FF0000
TLR3 10 #FF0000
ATG3 10 #FF0000
FYN 10 #FF0000
peroxynitrite 10 #FF0000
RPS6KA1 10 #FF0000
BCL2L1 10 #FF0000
APAF1 10 #FF0000
AKT1 10 #FF0000
ATG16L1 10 #FF0000
AKT1S1 10 #FF0000
RAC1 10 #FF0000
CASP3 10 #FF0000
AGER 10 #FF0000
VPS26A 10 #FF0000
RYR3 10 #FF0000
FADD 10 #FF0000
ATG7 10 #FF0000
JUN 10 #FF0000
PDP1 10 #FF0000
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MAPK1 10 #FF0000
RHOA 10 #FF0000
EIF2AK3 10 #FF0000
GSR 10 #FF0000
PTGS2 10 #FF0000
WNT1 10 #FF0000
NEDD8 10 #FF0000
CD36 10 #FF0000
EIF2A 10 #FF0000
ERN1 10 #FF0000
early endosome 10 #FF0000
DLG4 10 #FF0000
CSNK1A1 10 #FF0000
CASP6 10 #FF0000
IKBKB 10 #FF0000
CASP8 (p18) 10 #FF0000
CDK5 10 #FF0000
GAPDH 10 #FF0000
TRAF2 10 #FF0000
Golgi 10 #FF0000
RHEB 10 #FF0000
late endosome 10 #FF0000
HSPD1 10 #FF0000
IGF1R 10 #FF0000
IRS1 10 #FF0000
IL4 10 #FF0000
BID 10 #FF0000
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BACE1 10 #FF0000
PPARA 10 #FF0000
NTRK2 10 #FF0000
HMGB1 10 #FF0000
MAPK12 10 #FF0000
trans-Golgi network 10 #FF0000
ER 10 #FF0000
BDNF 10 #FF0000
MAPT 10 #FF0000
IFNG 10 #FF0000
MAP2K7 10 #FF0000
MTOR 10 #FF0000
PGK1 10 #FF0000
APP 10 #FF0000
TRADD 10 #FF0000
KCNIP3 10 #FF0000
IL6 10 #FF0000
TP53 10 #FF0000
VPS29 10 #FF0000
BTRC 10 #FF0000
TH 10 #FF0000
WISP1 10 #FF0000
NLRP3 10 #FF0000
GTP 10 #FF0000
MAPK14 10 #FF0000
FOXO1 10 #FF0000
TLR4 10 #FF0000
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MMP3 10 #FF0000
advanced glycation end-products 10 #FF0000
LRP6 10 #FF0000
GNAQ 10 #FF0000
NTRK1 10 #FF0000
C3 10 #FF0000
SLC2A1 10 #FF0000
exosome 10 #FF0000
PTEN 10 #FF0000
CASP7 10 #FF0000
MAPK cascade 10 #FF0000
mitochondrial matrix 10 #FF0000
VCAM1 10 #FF0000
ATG5 10 #FF0000
CASP2 10 #FF0000
MAPK pathway 10 #FF0000
CASP8 10 #FF0000
MAP2K3 10 #FF0000
JAK2 10 #FF0000
PRKCI 10 #FF0000
CHRM1 10 #FF0000
LAG3 10 #FF0000
STK11 10 #FF0000
NTF3 10 #FF0000
MAPK13 10 #FF0000
MMP9 10 #FF0000
CD14 10 #FF0000
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PDK1 10 #FF0000
MAP2K4 10 #FF0000
CDC42 10 #FF0000
PSEN1 10 #FF0000
resting microglia 10 #FF0000
ATF6 10 #FF0000
NCOR2 10 #FF0000
CAPN2 10 #FF0000
LRP5 10 #FF0000
TREM2 10 #FF0000
SKP1 10 #FF0000
S100B 10 #FF0000
GABARAPL2 10 #FF0000
CASP1 10 #FF0000
ICAM1 10 #FF0000
blood vessel 10 #FF0000
MAPK3 10 #FF0000
MAP2K6 10 #FF0000
Table A.2: Submap PD 180412 2 alzpath 8APR Element
reactionIdentifier lineWidth Color
re629 7 #FF0000
re5103 7 #FF0000
re4885 7 #FF0000
re3346 7 #FF0000
re3352 7 #FF0000
re5314 7 #FF0000
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re5188 7 #FF0000
re5153 7 #FF0000
re4341 7 #FF0000
re5044 7 #FF0000
re5336 7 #FF0000
re5221 7 #FF0000
re2858 7 #FF0000
re624 7 #FF0000
re4330 7 #FF0000
re3344 7 #FF0000
re2869 7 #FF0000
re5241 7 #FF0000
re478 7 #FF0000
re5415 7 #FF0000
re919 7 #FF0000
re2850 7 #FF0000
re5305 7 #FF0000
re5077 7 #FF0000
re4343 7 #FF0000
re505 7 #FF0000
re5342 7 #FF0000
re2865 7 #FF0000
Table A.3: Snapshot of reaction matches in PD Map and Alzpathway
CELLDESIGNER BEL
Species Notation Namespaces BEL species Notation/Function Namespaces BEL Example
Protein HGNC Protein proteinAbundance, p HGNC, SPAC, MGI, RGD proteinAbundance(HGNC:AKT1)
Receptor HGNC Receptor proteinAbundance, p HGNC, SPAC, MGI, RGD
Ion Channel HGNC Ion Channel proteinAbundance, p HGNC, SPAC, MGI, RGD
Truncated Protein HGNC Peptides abundance, a no namespace a("Amyloid beta-Peptides")
Gene HGNC Gene geneAbundance, g
HGNC, SPAC, EGID, MGI, 
RGD geneAbundance(HGNC:AKT1)
RNA HGNC RNA rnaAbundance, r HGNC, SPAC, MGI, RGD rnaAbundance(HGNC:AKT1)
Anti Sense RNA HGNC RNA rnaAbundance, r HGNC, SPAC, MGI, RGD
miRNA HGNC miRNA microRNAAbundance, m HGNC, SPAC, MGI, RGD microRNAAbundance(HGNC:MIR21)
Phenotype GO:Biological Process Disease pathology, path MESHD
Bioprocesses biologicalProcess, bp GO, MESHPP
Ion CHEBI Ion abundance, a CHEBI, CHEBIID, SCHEM
Simple Molecule CHEBI Simple Molecule abundance, a CHEBI, CHEBIID, SCHEM
Unknown GO, CHEBI, Interpro Unknown abundance, a no namespace
Drug CHEBI, PubChem Drug abundance, a
CHEBI, CHEBIID, SCHEM, 
or custom namespaces like 
DrugBank
Hypothetical Protein Protein family: Interpro ProteinFamily proteinAbundance, p PFR, PFH, PFM
Complex GO: Cellular Component Complex complex()
Compartment
GO:Cellular components, 
MeSH
Cellular Component abundance, a
GOCCACC, GOCCTERM, 
MESHCL
Reaction Notation Additional notes BEL reaction Notation
BASIC
State Transition
Reaction+Translocation, 
Refer supplemenatry 
document 
Known Transition Omitted
Uknown Transition
Transport Translocation tloc
Transcription Transcription transcription(A)
Translation Translation translation(A)
Add reactant reactants()
Add product products()
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A.3 Semantic Mapping: CellDesigner (SBGN)-BEL
Heterodimer association
Dissociation
Truncation peptidaseActivity() pep()
Reaction Notation Additional notes BEL reaction Notation
MODIFIERS
Catalysis Catalysis cat(example)
Inhibition directlyIncreses() =|
Physical Stimulation directlyIncreses() =>
Modulation increases() ->
Trigger directlyIncreses() =>
Unknown Catalysis extended by CellDesigner increases() ->
Uknown Inhibiton extended by CellDesigner decreases() -|
Reaction Notation Additional notes BEL reaction Notation
REDUCED
Positive Influence directlyIncreses() =>
Unknown positive influence increases() ->
Negative Influence directlyDecreases() =|
Unknown negative influence decreases() -|
Reduced Trigger increases() ->
Unknown Reduced Trigger increases() ->
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Abstract Identifying accurate biomarkers of cognitive decline is essential for advancing early diagnosis and
prevention therapies in Alzheimer’s disease. The Alzheimer’s disease DREAM Challenge was de-
signed as a computational crowdsourced project to benchmark the current state-of-the-art in predict-
ing cognitive outcomes in Alzheimer’s disease based on high dimensional, publicly available genetic
and structural imaging data. This meta-analysis failed to identify a meaningful predictor developed
from either data modality, suggesting that alternate approaches should be considered for prediction of
cognitive performance.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
The Alzheimer’s disease DREAM challenge (http://dx.
doi.org/10.7303/syn2290704) was designed to provide an un-
biased assessment of current capabilities for estimation of
cognition and prediction of cognitive decline using genetic
and imaging data from public data resources using a crowd-
sourced approach. The ability to predict rate of cognitive
decline—both before and after diagnosis—is essential to
effective trial design for the development of therapies for Alz-
heimer’s disease (AD) prevention and treatment. Major
collaborative efforts in the field are assessing the association
of genetic loci with ADdiagnosis and the application of struc-
tural imaging for development of early biomarkers of diag-
nosis, but the utility of these approaches to estimate
cognition or predict cognitive decline is not well established.
This project was designed under the advisement of a panel of
experts in the field to evaluate whether these questions could
be meaningfully addressed with current methods given exist-
ing public data sources. To ensure that these questions were
tested across a broad spectrum of the latest analytical
approaches, the study was designed as a crowdsourced,
community-based challenge in which participants were
invited to address one or more of the following three
questions [1]: The prediction of cognitive decline over time
based on genetic data [2]. The prediction of resilience to
cognitive decline in individuals with elevated amyloid burden
based on genetic data [3]. The estimation of cognitive state
based on structural magnetic resonance (MR) imaging data.
2. Results
2.1. Study design and data harmonization
To ensure that predictors were detecting true biological
variation rather than study-specific technical variation, this
project required inclusion of data frommultiple study sources.
Although genetic and imaging data have been generated
withinmany rich longitudinal cohorts across the field, the pro-
curement and harmonization of these data sets were a
nontrivial problem that required solutions to overcome polit-
ical, ethical, and technical barriers. For example, the genera-
tion of whole genome sequencing data across multiple AD
cohorts within theNIH-fundedAD sequencing project has re-
sulted in a powerful resource for genetic analysis in the field
but longitudinal information on cognitive traits is not readily
available in those data sets. Despite limitations on data acces-
sibility, multiple relevant data sources were identified and
used in this project including the Alzheimer’s Disease Neuro-
imaging Initiative (ADNI) [1], the Rush Alzheimer’s Disease
Center Religious Orders Study [2], Memory and Aging Proj-
ect (ROS/MAP) [3], and the European AddNeuroMed [4]
study, which is part of InnoMed, a precursor to the innovative
medicines initiative. Data selection and processing were per-
formed based on data availability across these three data sets.
As such, cognition was defined using mini mental state exam-
ination (MMSE) scores [5], genetic data were provided based
on imputation across array-based genotype data, and struc-
tural MR imaging data were reprocessed in each cohort using
a common processing pipeline. Genetic and imaging data
were supplemented with a limited set of covariates including
diagnosis, initial MMSE score, age at the initial examination,
years of education, gender, andAPOE haplotype. Participants
were providedwith data fromADNI to train algorithms over a
4-month period and to ensure that participation was not
limited by access to compute resources, they were offered
use of the IBM zEnterprise cloud to perform analyses. The
challenge generated significant interest with 527 individuals
from around theworld registered to participate. A leaderboard
displayed accuracy of submissions throughout the duration of
the challenge: 1157 submissions were made for question 1,
478 submissions for question 2, and 434 submissions for
question 3. Thirty-two teams submitted final results that
were scored based on prediction and/or estimation of blinded
outcomes within ROS/MAP for genetic predictions and
AddNeuroMed for imaging-based estimations (Fig. 1).
2.2. Genetic prediction of cognitive decline
The first challenge question assessed the ability of current
methods to predict change in cognitive examination perfor-
mance based on genetic data. High prediction accuracy
would signal the potential for noninvasive biomarkers of
cognition to have a major clinical impact on early AD diag-
nosis and prevention. Previous efforts to develop predictors
of change in cognitive function have not succeeded in
providing robust and replicable models [6–8]. Genetic
variation has been demonstrated to influence AD status:
rare genetic mutations at several loci are implicated in
familial forms of early-onset disease [9], whereas common
variation contributes 33% to variance in sporadic AD, and
22 loci have been implicated by large-scale genetic associa-
tion analyses [10,11]. However, with the exception of the
APOE ε4 haplotype, there has been little success in
transforming these genetic associations into meaningful
clinical predictions of cognitive decline. For this purpose,
participants were challenged to predict 2-year changes in
MMSE scores based on genotypes imputed from SNP array
data. Participants trained their algorithms with 767 ADNI
samples, and the algorithms’ predictions were evaluated on
a test set of 1175 ROS/MAP samples with blinded outcome
measures. The algorithm with the best predictive perfor-
mance at the midpoint of the challenge did not contain any
genetic features beyond APOE haplotype. As the goal of
this question was to assess genetic contribution to prediction
of cognitive decline, this top-ranked algorithm was openly
shared across teams as an interim baseline on which to incor-
porate additional genetic predictors (http://dx.doi.org/10.
7303/syn2838779). Eighteen teams submitted final predic-
tions. Most methods performed significantly better than a
permutation-based random model prediction (Fig. 2A). A
cluster of six methods performed significantly better than
the others (including the interim baseline model) but were
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statistically indistinguishable among themselves (Fig. 2D).
Of these, the prediction with the best overall score (team
GuanLab_umich from the University of Michigan) achieved
a Pearson correlation of 0.382 and a Spearman correlation of
0.433 (the overall score was a rank-based combination of
these two measures of performance; see online Supplement
and Supplementary Methods: http://dx.doi.org/10.7303/
syn3383106). However, no significant contribution of ge-
netics beyond APOE haplotype to predictive performance
was observed across any of the submissions. Given the small
sample size, no conclusions can be inferred from this analysis
regarding the existence of genetic loci associated with cogni-
tive decline. Rather, these observations suggest that predic-
tors of cognitive decline developed based on genetic data
will not be useful within the clinical setting.
2.3. Genetic prediction of cognitive resilience
The second question challenged participants to identify
genetic predictors that could distinguish individuals who
exhibit resilience to AD pathology as defined by minimal
change in cognitive function despite evidence of amyloid
deposition [12,13]. Identification of genetic signatures
predictive of cognitive resilience would aid in the
elucidation of mechanisms that may confer resilience,
providing a powerful tool to help advance AD prevention
Fig. 1. Challenge overview. The top schematic summarizes the three challenge questions on the left column, the training data in the middle, and the test data on
the right, including numbers of subjects. The symbols represent sources of data (demographic, ROS/MAP genetic, and ADNI or ANM brain images and shape
information). The bottom panel provides example brain image labels and shape information derived from the Mindboggle software (http://mindboggle.info)
provided to the participants for question 3. Anatomic labels for left cortical regions are shown on the left and just a couple of the cortical surface shape measures
are shown on the right (travel depth on top and mean curvature below), for both uninflated and inflated surfaces (top and bottom rows, respectively).
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Fig. 2. Performance evaluation results. (A), (B), and (C) report the P values (in negative log 10 scale) for intersection union tests investigating which teams per-
formed better than random for questions 1, 2, and 3, respectively. Explicitly, for question 1 (A), we tested the null hypothesis that at least one of the four correlation
coefficients (namely Pearson/clinical, Pearson/clinical1 genetics, Spearman/clinical, and Spearman/clinical1 genetics) is equal to zero, against the alternative
that all four correlation coefficients are larger than zero. Adopting a 0.05 significance level, 26 of the 32 submissions were statistically better than random, after
Bonferroni multiple testing correction for 32 tests (submissions crossing the black vertical line). For question 2 (B), we tested the null hypothesis that balanced
accuracy 5 0.5 or AUC 5 0.5, against the alternative that balanced accuracy . 0.5 and AUC . 0.5. In this case, no model performed significantly better than
random, and, therefore, no best performer was declared. For question 3 (C), we tested the null hypothesis that Pearson’s correlation (COR) or Lin’s concordance
correlation coefficient (CCC) are equal to zero, against the alternative that both COR and CCC are larger than zero. Adopting a 0.05 significance level, all 23
submissions were statistically better than random, after Bonferroni correction. For all three questions, the P values were computed from an empirical null distri-
bution based on 10,000 permutations. (D) and (E) report the bootstrapped assessment of ranks for questions 1 and 3, respectively. Samples were resampled with
replacement from the original data (true outcome and team’s predictions), and the ranks of the different teams were reassessed in each of 100,000 resamplings.
Submissions were sorted according to themedian of their bootstrapped average ranking distributions. The black horizontal line represents the posterior odds cutoff
from the Bayesian analysis. Teams above the black line are statistically tied to the top-ranked model, according to a posterior odds threshold of 3.
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strategies and treatment development. Eleven teams
submitted predictions of resilience based on a training set
derived from 176 ADNI subjects. Evaluations were made
using data derived from 257 individuals from the ROS/
MAP data. Despite using the largest such public data set
assembled to date, participants were unable to develop
algorithms with predictive performances significantly
better than random (see Fig. 2B, online Supplement and
Supplementary Methods in Synapse: http://dx.doi.org/10.
7303/syn3383106). Although it is likely that the study
was underpowered due to small sample size and trait het-
erogeneity, this result suggests that information about
cognitive resilience is not easily discoverable from SNP
analysis.
2.4. Structural imaging-based estimation of cognition
The third question challenged participants to estimate
cognitive state using structural brain image data (Fig. 1, lower
panel). Brain imaging has emerged as a powerful method for
monitoring neurodegeneration, and there is a great enthu-
siasm in the field tomake use of images for diagnosis and pre-
diction. There have been many attempts in the past to
correlate changes in brain shape with disease progression
and/or diagnosis, conventionally using measures of volume
for a given brain region [14,15]. More detailed shape
measures of image features including cortical thickness,
curvature, and depth have also been found to be relevant to
a variety of neurologic conditions [16]. Participants were
challenged to estimate MMSE scores based on structural
brain images, or shape information derived from these im-
ages. Participants trained algorithms using ADNI data
(N 5 628) and were evaluated using AddNeuromed data
(N 5 182) for which they were blind to outcome measures.
To engage as many participants as possible from both within
and beyond the neuroimaging community, the data were pro-
vided both as raw MR images and as tables containing shape
measures (volume, thickness, area, curvature, depth, and so
forth) for every labeled brain region. Thirteen teams submit-
ted estimates for final evaluation, and all teams performed
better than a random model (see online Supplement and Sup-
plementary Methods in Synapse: http://dx.doi.org/10.7303/
syn3383106). Three teams performed significantly better
than the others (teams GuanLab_umich from the University
of Michigan, ADDT from the Karolinska Institute and Pythia
from the University of Pennsylvania; Fig. 2C) but were statis-
tically indistinguishable from one another and tied for top
average rank (Fig. 2E). The algorithm that generated the
best absolute mean combined rank (Team GuanLab_umich)
achieved a concordance correlation coefficient of 0.569 and
Pearson’s correlation of 0.573 (the overall score was a
rank-based combination of these two measures of perfor-
mance). The most common features that contributed heavily
to the MMSE estimates across the algorithms were hippo-
campal volume and entorhinal thickness, corroborating prior
work [17–19]. The top three teams also found that inclusion
of shape measures of the entorhinal cortex (volume,
curvature, surface area, travel, and geodesic depth)
improved overall estimation. Other features that contributed
to predictions within the top three teams’ results included
volume of inferior lateral ventricle and amygdala (see
online Supplement and Supplementary Methods in
Synapse: http://dx.doi.org/10.7303/syn3383106). These
results validate an established relationship between
structural imaging data and cognition. However, the
correlative performance of these estimators was low
suggesting that their application in the clinical setting may
not be sufficient to inform patient care.
3. Discussion
The AD DREAM challenge provided a formalized
assessment of the ability to develop meaningful predictions
of cognitive performance from public genetic or imaging
data using contemporary state-of-the-art predictive algo-
rithms. Predictive performance across all three of the
questions was modest, and most methods performed roughly
equivalently. Given this uniform performance, we do not
expect that the presented results are a failure of current
modeling methods. A more likely explanation is that the
data used to address these questions were inadequate to sup-
port these tasks. We also note that most research teams that
participated in this challenge did not have expertise in the
field of AD. Although the few teams that did possess this
knowledge did not do better than the others, there remains
the possibility that performance would have been improved
by the inclusion of more domain experts.
3.1. Use of genetic information for cognitive prediction
The modest performance observed in the 3 questions
focused on genetic analysis demonstrated that contemporary
algorithms were not able to leverage genetic signal to make
useful predictions for cognition. These results support the
prevailing expectation that genetic variants of moderate to
high frequency will not support viable biomarker develop-
ment in AD [9–11]. Although heritability estimates and
linkage studies have demonstrated that there is a
considerable estimated genetic contribution to AD onset
and progression [11,20,21], evidence both within the AD
field and across other complex disease [22] traits has indi-
cated that this overall genetic contribution is the aggregated
compilation of a large number of loci with small—indepen-
dent or epistatic—effects. Historically, this type of signal is
difficult to capture in predictive models and unlikely to be
useful in a diagnostic setting [23]. Furthermore, cognition
is highly influenced by a host of nongenetic factors relating
to lifestyle choices and accumulated exposures that were
not represented across all these data sets and, in fact, are
not fully captured in most cohorts [24–27]. Nongenetic
contributions to cognitive performance may themselves
provide an important base for successful predictions.
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Within the context of genetic analysis, the absence of these
factors from models confounds the ability to detect real
genetic signal and impacts the ability to accurately model
state-specific genetic contributions. As such, future inquiry
into the use of genetic testing for prediction of cognitive per-
formance and AD risk assessment may be better served by
focusing on the contribution of rare genetic variation.
Recently discovered disease-associated rare variants have
larger effect sizes than common variants and confer 2- to 5-
fold greater risk or protection in carriers relative to the general
population [28–30]. Ongoing large-scale sequencing ana-
lyses will identify additional associated rare risk variants.
In sufficient numbers, the aggregate prevalence would sup-
port the development of a genetic diagnostic containing a li-
brary of rare variants.
3.2. Use of structural imaging data for cognitive
estimation
Although the inexpensive and noninvasive nature of ge-
netic testing make this approach amenable to population-
level disease screening, the resource-intensive nature of
image-based testing is better positioned for careful evalua-
tion of high-risk individuals. As such, these approaches are
needed to provide a higher confidence estimate of cognitive
performance. Although a variety of methods developed
within the context of this challenge were able to success-
fully estimate cognition, none of these methods were suffi-
ciently accurate to merit clinical consideration. These
observations support previous work in the field [17,19]
and highlight the imperfect relationship between brain
structure and function. Newer imaging modalities that
focus on brain function and/or pathology—such as FDG-
PET [31] or tau imaging [32]—may prove more successful
for assessing cognitive dysfunction.
3.3. Effective performance of meta-analysis across diverse
cohorts
A major consideration for any meta-analysis is the issue
of appropriate harmonization of data across disparate sour-
ces. Despite leveraging several of the most deeply pheno-
typed cohorts in the field, this challenge limited analysis to
those traits that were in common across cohorts. Although
this approach to data harmonization is standard practice
for meta-analyses [10], it greatly reduced the depth of the in-
formation available for modeling and influenced the selec-
tion of cognitive measures for use as prediction outcomes.
Because each cohort had performed a battery of study-
specific tests, this greatly limited the ability for finer grained
assessment across cognitive processes. A more sensible
approach for future analyses may be to focus effort on
more sophisticated methods to calibrate disparate cognitive
phenotypes across cohorts [33]. Another undesirable conse-
quence of the focus on traits measured in common was the
inability to incorporate into model development the full
spectrum of nongenetic and nonimaging factors that are
known to influence cognitive performance [24–27]. This
suggests the need for development of different approaches
for integrating heterogeneous data and/or assessing
replication across cohorts. Alternatively, smaller scale
analyses that prioritize phenotypic depth over sample size
may afford a more refined view of disease.
In summary, this challenge demonstrated that predictions
of cognitive performance developed from genetic or struc-
tural imaging data were modest across a diverse set of
contemporary modeling methods. Future efforts to identify
clinically relevant predictors of cognition will benefit from
a focus on alternative data sources and methods that work
to incorporate greater phenotypic complexity.
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RESEARCH IN CONTEXT
1. Systematic review: Extensive literature searches us-
ing PubMed establish this as the largest study to
date using demographic, clinical, imaging, and ge-
netic data to predict cognitive decline and the first
major instance of crowdsourcing analysis in AD.
2. Interpretation: Over 500 scientists worldwide in the
analytical portion of the challenge, demonstrating
the viability of crowdsourced approaches in AD
research. Unfortunately, we were unable to detect
meaningful predictors of either cognitive decline or
resilience through this effort.
3. Future directions: This experiment in crowdsourcing
AD analyses is an invaluable first-of-its-kind
contribution that provides a snapshot of both the
strengths and limitations in big data analytics in AD
research. The relative inaccessibility and heteroge-
neity across data sources severely limits formalized
integration. Mandates on data sharing, consider-
ations of standardized data collection, and mecha-
nisms to integrate heterogeneous data are necessary
to address these issues. We anticipate that this work
will initiate those discussions across the community.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive 
chronic inflammatory lung disease characterized by persistent 
limited airflow caused by various environmental exposures 
such as cigarette smoke (CS), occupational hazards, and air 
pollution.1 Mechanisms underlying the disease include a com-
plex interplay of inflammation, proliferation, oxidative stress, 
tissue repair, and other processes driven by various immune, 
epithelial, and airway cell types.2,3 Understanding the 
molecular mechanisms associated with COPD is important for 
preventing disease onset, slowing down disease progression, 
and managing treatment. Biological network models offer 
a framework for understanding disease by describing the 
relationships between the molecular mechanisms involved 
in the regulation of a particular biological process. Kyoto 
Encyclopedia of Genes and Genomes (KEGG) and Reactome 
are open access pathway databases widely used by the scien-
tific community.4–7 They describe signaling in various areas 
of biology and can be used to interpret large-scale molecular 
data through integration and overlay on pathways to assess 
pathway overrepresentation. In contrast to these general 
pathway databases, we have developed a set of networks within 
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defined boundaries relevant to COPD that are available to the 
public on the Bionet website at https://bionet.sbvimprover.
com, where they can not only be viewed and downloaded but 
can also be actively commented on and edited.8,9 These net-
works can also be used to interpret large-scale molecular data 
to a fine-grained degree, due to their construction in Biologi-
cal Expression Language (BEL), a human-readable comput-
able language with the ability to capture precise biological 
information and associated context (www.openbel.org). The 
networks were based on a set of previously published lung-rel-
evant healthy biological networks, which along with the most 
current network versions are available for download at http://
www.causalbionet.com/.10–14
To ensure a comprehensive and up-to-date set of bio-
logical network models that cover a wide range of biological 
signaling, crowdsourcing can be used to gather input from 
the scientific community. Crowdsourcing is a powerful tool 
to efficiently gather feedback from a wide audience that cov-
ers expertise in many biological areas. Crowdsourcing efforts 
in biology are useful in the collection of creative solutions to 
challenging problems in various fields of biology such as sig-
naling networks, protein folding, RNA design, and sequence 
alignment.15–18 Crowdsourcing has also been harnessed to 
accomplish a large amount of manual work in annotation 
projects including disease-related genes, interactome path-
ways, and PubMed abstracts.19–21 We have previously reported 
the creation of a set of biological networks describing COPD 
processes that were improved by the scientific community 
during the first Network Verification Challenge (NVC).8,9 In 
this study, we show that the networks were further improved 
during a second NVC (NVC2), in which the crowd added 
mechanistic details in the form of new nodes and edges.
We illustrate possible network applications for the 
crowd-improved set of networks using network scoring by 
TopoNPA, a method to infer mechanism and network per-
turbation based on transcriptomics data and known activators 
and inhibitors of gene expression reported in the literature.22 
Quantitative scoring of networks is enabled by BEL, an open 
platform technology, where cause and effect relationships 
from the literature are described and annotated using a pre-
cise language and collected in a knowledgebase. This knowl-
edgebase is used to predict upstream regulators of measured 
transcriptomics data.23 This backward reasoning approach 
differs from other gene set enrichment approaches using gene 
sets defined as KEGG pathways or Gene Ontology (GO) 
classes for example,24 which make the assumption that RNA 
expression is equivalent to protein activity. Another limitation 
of methods such as gene set enrichment analysis (GSEA)25 
is that they do not take direction into account for each gene 
within the gene set. TopoNPA scoring of networks allows for 
quantitative scoring of inferred mechanisms and networks 
based on signed fold changes in the dataset. Using TopoNPA 
on a set of networks enables quantitative comparison between 
different compounds, disease subtypes, or other perturbations 
of interest.22 We describe here one application for how the 
improved set of 46 computable BEL-encoded NVC network 
models can be used by the scientific community for toxicology 
and drug discovery applications.
Materials and Methods
biological expression language. BEL is a triple-based 
language, where statements consist of two biological entities 
connected by a relationship (for causal statements: cause, rela-
tionship, and effect). The BEL framework, including a data-
base of BEL statements and other tools to be used with BEL, 
is an open-platform technology available for download at 
http://www.openbel.org/. BEL captures specific entities from 
chemicals to proteins to biological processes and relationship 
links that are directional, providing information on activation 
or inhibition. Statements within BEL are derived from the 
published literature and are compiled together to express the 
existing causal knowledge in a graph-based, computable format. 
These entities connected by relationships are represented 
as nodes and edges within a BEL graph network and are 
linked to metadata such as literature support, which contains 
PubMed ID, tissue, disease, cell type, and species. A BEL 
node consists of a function, namespace, and entity. The func-
tion gives information about the type of entity (eg, abundance 
and activity), and the namespace is a standardized ontology 
that defines the entity that each node represents (eg, MeSH, 
ChEBI, GO, and HGNC). See Supplementary File 1 for a 
list of BEL functions and namespaces. Just as the networks 
are continuously improved by the crowd, the BEL language 
evolves based on suggestions made by the OpenBEL commu-
nity. Namespaces in the NVC networks version 2.0 reported 
here were updated from v1.0 BEL Namespaces to the most 
recent version (v20150611), which includes additional and 
refined namespaces.
Network building
Networks were constructed in a three-phase process, as 
described previously.8 Briefly, networks were built using 
data and literature during Phase 1, enhanced with lung- and 
COPD-relevant mechanisms (represented by nodes in the 
networks) by the crowd during Phase 2 on the Bionet web-
site (https://bionet.sbvimprover.com/), and discussed during a 
jamboree meeting during Phase 3 in which the best perform-
ers were invited based on their point totals from the online 
phase. Networks with high crowd activity or interest were 
selected for discussion during the jamboree. Phases 2 and 3 
were repeated in NVC2. Fifteen networks were discussed 
during the NVC1 jamboree (apoptosis, cell cycle, dendritic 
cell signaling, growth factor, hypoxic stress, macrophage 
signaling, neutrophil signaling, NFE2L2 signaling, nuclear 
receptors, oxidative stress, response to DNA damage, mecha-
nisms of cellular senescence, Th1 signaling, Th2 signaling 
[Th1–Th2 signaling were merged as a result of the jamboree], 
and xenobiotic metabolism response) and nine networks were 
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discussed during the NVC2 jamboree (calcium, epigenetics, 
macrophage signaling, necroptosis, neutrophil signaling, 
oxidative stress, senescence, Th1–Th2 signaling, and xenobi-
otic metabolism response). After the NVC2, it was decided 
to merge the four senescence-related models (mechanisms 
of cellular senescence, regulation of CDKN2A expression, 
regulation by tumor suppressors, and transcriptional regula-
tion of the SASP) into one model called senescence. In both 
NVC1 and NVC2, changes were implemented by the orga-
nizers and new versions were uploaded to the Bionet website. 
The latest versions edited after the NVC2 jamboree are the 
version 2.0 networks.
Network statistics
Network statistics and metrics were calculated on the net-
works presented to the crowd at the start of the NVC (v1.1) 
and on the most recent networks containing the outcomes of 
NVC1 and NVC2 (v2.0). Basic network metrics such as num-
ber of nodes, edges, activation edges, inhibition edges, and 
the proportion of inhibition edges were calculated. In addition 
to these basic network characteristics, the following metrics 
were computed:
•	 Mean degree: the average of node degrees. This metric 
informs the overall topology of the network. A low aver-
age degree (,2) is typically observed in linear networks.
•	 Max degree: the maximum degree in the network, repre-
senting the size of the largest hub.
•	 Mean node betweenness (MNB) or betweenness cen-
trality: the number of shortest paths between pairs of 
other nodes that go through that node. Nodes with high 
betweenness centrality are considered as high traffick-
ing nodes. This metric characterizes the centrality of the 
nodes and hence the topology of the networks (for exam-
ple, bottlenecks for the paths in the network). A complete 
graph has a vanishing (=0) MNB.
•	 Largest clique size: the number of nodes in the largest 
complete undirected subgraph in a network. This num-
ber is expected to be low because complete subgraphs 
that are not triangles are not expected to be biologically 
meaningful.
•	 Mean path length (MPL): the average of the shortest 
path length between all pairs of nodes. This metric gives 
an indication of the density of the network. A low MPL 
characterizes networks for which the shortest path of 
causal statements, from one node to another, are made of 
few edges; for example, in a complete graph, this equals 1. 
It does not necessarily imply that the mean degree is 
high. A typical cascading signaling pathway with little 
feedback would be expected to have a high MPL.
•	 Frustration: the minimum number of edges that should 
be removed to make the network balanced. Balance in a 
signed graph is characterized by the property that every 
path between two nodes has the same sign (the sign of 
a path is the product of its edge signs). Equivalently, 
a graph is balanced if and only if every cycle is positive. 
A negative feedback loop contributes to the network 
frustration. For example, tightly regulated processes such 
as cell cycle or apoptosis are expected to have a high frus-
tration metric.
•	 # connected components: number of connected compo-
nents, that is, the number of disjoint (ie, not sharing any 
edge) subnetworks within the network.
For all of these network metrics, the differences 
between the pre-NVC networks (v1.1) and post-NVC2 
networks (v2.0) were calculated to understand crowd con-
tribution effects on the networks. For the Th1–Th2 signal-
ing and senescence networks, both of which were integrated 
from separate networks following jamboree discussions, 
the individual pre-NVC networks (v1.1) were combined for 
comparison with the already combined post-NVC2 net-
works (v2.0).
datasets Analysis
The three datasets that were analyzed are shown in Table 1.
Network perturbation amplitude. The Network Pertur-
bation Amplitude (NPA) methodology aims at contextualiz-
ing high-dimensional transcriptomics data by combining gene 
expression (log2) fold-changes into fewer differential node 
values (one value for each node of the network), represent-
ing a biological entity (mechanism, chemical, biological pro-
cess).22,26,27 A node can be inferred as increased or decreased 
based on gene expression data, because there are signed rela-
tionships (increase or decrease) between the node and down-
stream mRNA abundance entities.23,27 The differential node 
values are determined by a fitting procedure that infers values 
that best satisfy the directionality of the causal relationships 
(positive or negative signs) contained in the network model, 
while being constrained by the experimental data (the gene 
log2-fold-changes, which are described as downstream effects 
of the network itself).
The differential values of the network are then used to cal-
culate a score for the network as a whole, called the TopoNPA 
score.22 For these network scores, a confidence interval 
accounting for the experimental variation and the associ-
ated P-value are computed. In addition, companion statistics 
are derived to inform the specificity of the TopoNPA score 
with respect to the biology described in the network model. 
These are depicted as *O and K* if their P-values are below 
the significance level (0.05). A network is considered to be sig-
nificantly impacted if all three values (the P-value for experi-
mental variation, *O, and K* statistics) are below 0.05.22
Leading nodes are the main contributors to the network 
score, making up 80% of the TopoNPA score. These nodes 
can be useful for interpreting the data to predict mecha-
nisms that might be driving the biological process that the 
network represents.22
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To increase the specificity and relevance of node scores 
and network scores, we consider only the nodes in the net-
work that are bounded by experimental evidence in the fol-
lowing sense: for any given node, at least one ancestor node (ie, 
a node from which a directed path to the node under consid-
eration exists) and at least one child node (ie, a node to which 
a directed path from the node under consideration exists) in 
the directed graph must have downstream RNA abundance 
nodes: their values can be directly inferred based on experi-
mental mRNA data. After removing the nodes that do not 
satisfy the above criteria, the largest connected component is 
kept (if the resulting network is not connected). Finally, the 
“causeNoChange” edges are disregarded for scoring. Selec-
tions of these simplified networks that have been scored using 
these criteria are shown in the results.
results
Network resource comparison. We previously described 
novel aspects of the NVC networks compared with other net-
work resources.8,9 Herein, we select a particular network, cal-
cium signaling, to further illustrate the differences between 
the NVC networks constructed using BEL (https://bionet.
sbvimprover.com) and the pathways available in the KEGG 
(http://www.genome.jp/kegg/pathway.html) and Reactome 
Pathway Databases (http://www.reactome.org) (Fig. 1).
Network boundaries. The NVC Calcium Network (v2.0) 
is an example of a network with similar content and size as 
the KEGG Calcium Signaling pathway map (map04020) and 
Reactome Calmodulin pathway (R-HSA−111997.1). All three 
networks describe the increase of calcium as a result of inositol 
1,4,5-triphosphate activation (Fig. 1, box 1 highlighted in 
yellow) and the role of calcium in activating calmodulin kinase 
(CAMK) (Fig. 1, box 2 highlighted in yellow). However, the 
BEL network was constructed specifically to describe calcium 
signaling that leads to cell proliferation in the lung, while the 
KEGG and Reactome pathways describe calcium signaling in 
a more general manner that is tissue agnostic and can lead to 
proliferation as well as, for example, contraction, metabolism, 
apoptosis, and exocytosis in the KEGG pathway.
Network resource comparison. The NVC Calcium Net-
work (v2.0) contains 47 nodes (35 unique concepts when genes, 
proteins, and activity nodes are flattened together) and 52 edges, 
the KEGG pathway map contains 48 nodes/unique concepts 
and 60 edges, and the Reactome pathway contains 46 nodes 
(34 unique concepts) and 49 edges (Table 2). The NVC2 net-
work is supported by 38 unique literature references for specific 
edges, while there are 20 references for the KEGG pathway 
and 28 references for the Reactome pathways. There is no over-
lap in references between the three resources and the average 
date of publication for the NVC2 references is 2006, whereas 
the KEGG and Reactome average dates are 2002 and 2000, 
respectively. The NVC2 and Reactome refe rences support a 
particular edge, whereas the KEGG references are not specific 
to a particular edge. The NVC2 network contains multiple node 
functions such as abundance, activities, and phosphorylations 
that have been specifically tested in the literature, while the 
KEGG pathway depicts a single layer of gene symbol nodes 
that could represent RNAs, proteins, modified proteins, or pro-
tein activities. Reactome contains nodes that reflect activities 
and phosphorylations that can be repeated throughout the dia-
gram to indicate location.
The cellular localization graphics in KEGG and Reactome 
give a second layer of information, with inositol 1,4,5-triphos-
phate (IP3 in KEGG, I(1,4,5)P3) in Reactome activating 
inositol 1,4,5-trisphosphate receptor (IP3R) depicted on the 
endoplasmic reticulum (ER) membrane, increasing calcium 
in the cytoplasm (Fig. 1, box 1 highlighted in yellow). From 
the KEGG and Reactome diagrams, IP3R/IP3 receptor can 
be inferred to be a calcium channel transporting calcium 
across the ER, although it is not explicitly stated. In BEL, 
this relationship is described explicitly in the NVC network 
as three different family members defined by the HUGO 
Gene Nomenclature Committee (HGNC) database (http://
www.genenames.org/) with transporter activities (tport): 
tport(p(HGNC:ITPR1)), tport(p(HGNC:ITPR2)), and 
tport(p(HGNC:ITPR3)) that activate the bp(GOBP:“store-
operated calcium entry”) node defined by the GO biologi-
cal process database.28 The nodes in the NVC network have 
more granularity than the Reactome and KEGG networks, 
specifying the type of activity and particular residues that 
are phosphorylated.
Along with the IP3 receptor, another process that is 
described by all three network resources is CAMK activa-
tion by calcium (Fig. 1, box 2 highlighted in yellow), although 
the NVC2 network describes CAMK2 while KEGG and 
Reactome pathways describe CAMK4 (only obvious for the 
Table 1. dataset overview.
DATA iDa TiSSuE TREATMENT ENDPoiNT
GSe28464 Human fibroblasts oncogenic Ras (H-RasV12) expression 4 days model of senescence; autophagic markers
e-mtaB-3150 mouse lung Reference cigarette (3R4F) smoke, prototype  
modified risk tobacco product (pMRTP),  
switch, cessation for 7 months
lung function; immune cell numbers and  
inflammatory markers in bronchoalveolar  
lavage fluid (BALF); lung macrophage counts;  
pulmonary morphometry
GSe52509 mouse lung Reference cigarette (3R4F) smoke for 4,  
6 months
B and t-cell counts and histology in lung; immune 
markers in bronchoalveolar lavage (Bal) and lung
Notes: athe GSe datasets are from the nCBi Geo database and the e-mtaB dataset is from the emBl-eBi arrayexpress database.
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figure 1. Comparison of the nVC (A), KeGG (B), and Reactome (C) calcium/calmodulin signaling pathways. Shared portions highlighted in yellow with 
corresponding numbers.
KEGG pathway after clicking on the node within the online 
pathway). The final group of overlapping nodes between NVC 
and KEGG networks include stromal interaction molecular 1 
(STIM1) and calcium release-activated calcium channel 
protein 1 (ORAI1), describing store-operated calcium entry 
(Fig. 1, box 3 highlighted in yellow), a concept that the Reac-
tome network does not cover due to its focus on calmodulin 
signaling. Despite the differences in biological content, these 
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networks illustrate the similarities in causal, computational 
formats and differences in detail and visualization features 
in the NVC, KEGG, and Reactome networks. The edges 
in the NVC, KEGG, and Reactome networks are similar in 
that they can represent causal increase or decrease relation-
ships and can be downloaded for computational use. However, 
the NVC networks contain more layers of information, with 
direct causal, indirect causal, correlative, and other noncausal 
relationships (eg, member, biomarker, and component).
Network crowd verification. Participant feedback. Scien-
tists had many options for engagement during the NVC, 
including commenting on networks, voting for or against 
the validity of evidence for specific edges, adding evidence 
to existing edges, or adding new edges (in order of easiest to 
most challenging according to a participant survey). The most 
impactful, but most challenging (and highest point value), 
action was to add new edges that represented missing biology 
in the networks. This action required participants to perform 
a sophisticated set of tasks beyond identifying relevant papers, 
namely, identify the correct network to include the paper and 
translate the biology to correct BEL statements in a format 
that contained direct, mechanistic biology relevant to the 
boundaries of the particular network. Most participants had 
expertise in identifying relevant papers that included biology 
that was missing in the network and overall, participants were 
able to easily learn BEL and construct correct statements that 
depicted the biology from the papers they identified. The most 
challenging task was assembling these statements into direct, 
mechanistic edges to integrate into the boundaries of a par-
ticular network. Participant feedback indicated that improved 
ways were desired to view networks, particularly to highlight 
areas of the networks that needed more development. Feed-
back also indicated that clearer network boundaries were 
necessary, highlighting the challenges that working with 
networks entails. With regard to participant engagement, 
feedback showed that participants were motivated by learning 
about biology in the networks, the BEL language, and about 
biological networks in general.
Network changes. The latest version of the NVC net-
works edited by the crowd during the NVC2 is available 
as version 2.0 at www.bionet.sbvimprover.com. These net-
works were changed in various ways throughout the two 
NVC challenges, as summarized in Figure 2. Networks 
before the NVC (v1.1) were compared with networks 
changed at the end of NVC2 (v2.0). Network statistics for 
each network version are available in Supplementary File 2. 
The largest amount of new biology in terms of new nodes 
that was added during NVC2 by the crowd and resulting 
from the jamboree was to the epigenetics, xenobiotic metab-
olism response, and calcium networks (Fig. 2). COPD- and 
lung-relevant contexts were added to the epigenetics and 
xenobiotic metabolism response networks, and cancer- 
and liver-related contexts, respectively, were removed. In 
the calcium network, growth factors and smoke-relevant 
mechanisms that lead to calcium signaling were added, as 
well as mechanisms of store-operated calcium entry.
Overall during the NVC1 and NVC2, the size of the 
networks (number of nodes and edges) grew, as seen in the 
four left columns of the heat map (Fig. 2). While the total 
number of edges increased, the proportion of negative edges 
also increased slightly, with a few exceptions such as Wnt and 
epigenetics signaling. This increase may reflect the addition of 
regulatory mechanisms to the networks.
Mean node betweenness (MNB) did not change substan-
tially, with noticeable exceptions for the cell cycle, autophagy, 
and Th1–Th2 signaling networks. For both cell cycle and 
autophagy, the number of nodes and edges stayed relatively 
constant. A difference in MNB may be indicative of a reor-
ganization of the network topology. These networks were all 
discussed during the jamborees where network topologies 
could more easily be changed than on a per user basis dur-
ing the open phase. For Th1–Th2 signaling, MNB went up 
tenfold from 15 to 152. This may be because these networks 
were originally two separate networks with linear (tree-like) 
structures that were then integrated after the jamboree.
The sizes of the largest cliques did not change, which 
suggests that the crowd did not add feedback loops. A clique 
of size 3 is a triangle that may be a simple positive or negative 
feedback of the form A→B→C→A (A→B→C-|A, respec-
tively). Most of the networks exhibit this property, while only 
eight networks have a clique of size 4 or more, the maximum 
being 5 (neutrophil signaling, after verification). A clique 
between four nodes implies that the set of nodes all regu-
late each other; for example, in the epithelial mucus hyper-
secretion network, the nodes A = cat(p(HGNC:ADAM17)), 
B = kin(p(HGNC:EGFR)), C = p(HGNC:MUC5AC), and 
D = bp(GOBP:mucus secretion)) are all related to each other 
as A→B,C,D; B→C,D; C→D.
The mean degree stayed stable while some maximum 
node degrees increased (ie, some nodes are stronger hubs). As a 
case in point, for the megakaryocyte differentiation network, 
the maximum degree went from 12 to 34. The MPL stayed 
stable for all networks, meaning that, on average, the shortest 
path between two nodes did not change (eg, no long hanging 
linear paths).
The frustration, representing the complexity of autoregu-
lation of a network, increased in half of the networks. After 
verification, only eight networks have a decreased frustration.
Table 2. network resource comparison.
ATTRiBuTE NvC KEgg REACToME
# nodes 47 48 46
# unique concepts 35 48 34
# edges 52 60 49
# References 38 20 28
average date of references 2006 2002 2000
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The number of connected components increased in the 
following networks (usually from one to two components): 
mTor, Mapk, Hox, growth factor, cell interaction, osmotic 
stress, NFE2L2 signaling, epithelial innate immune acti-
vation, wound healing, fibrosis, and ECM degradation. 
However, the ratio of the size of the second largest component 
to the size of the largest is less than 5% (except for cell inter-
action 12%, cytotoxic T-cell signaling 15%, and Hox 66%), 
meaning that, except for the Hox network, the largest com-
ponents comprise almost all the nodes. The extra components 
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figure 2. Changes in network statistics as a result of nVC activity. differences between the latest version of the networks and the original networks have 
been posted to the Bionet website.   
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added during network verification may be a starting point for 
further extending the biggest component. However, in the 
case of the Hox network, two components describing sepa-
rated processes are described in the context of this network. 
Besides the metrics discussed above, a scale-free property 
(ie, the degree distribution follows an exponential distribu-
tion) was tested. None of the networks (v1.1. and v2.0) exhibit 
a significant scale-free property (Supplementary File 2).
Network applications. Because the networks were con-
structed in BEL, they can be shared within the scientific 
community and used to understand data through overlay on 
to specific pathways of interest or implementing a more global 
process overview using computational inference approaches. 
We illustrate a few cases of how the networks could be used in 
toxicity assessment and drug discovery for network computa-
tion using the TopoNPA approach. This approach employs the 
two-layer network model to infer the activation or inhibition of 
model backbone nodes based on gene expression data.22 Using 
these inferences and the network model topology, TopoNPA 
computes the perturbation of the network as a whole. The 
approach differs from traditional pathway analyses, because 
it is quantitative and it uses backward reasoning instead 
of assuming that changes in gene expression directly imply 
changes in protein activity. The comparison of TopoNPA with 
other methods was described in detail by Martin et al.22
In vitro treatment effects on transcriptomics data are reflected 
in TopoNPA network scores. The NVC2 networks were scored on 
the in vitro dataset GSE28464 from the NCBI GEO database 
to illustrate that expected pathway activation can be inferred 
from transcriptomics data using network scoring.29 In this 
dataset, HRASV12 was expressed in fibroblasts, as a model for 
oncogene-induced senescence and cell cycle arrest. Consistent 
with the expectations, the senescence and cell cycle networks 
scored significantly in the HRASV12 dataset (Fig. 3). Within 
the senescence network, leading nodes that contribute to 80% 
of the senescence network score were predicted to be increased, 
including bp(GOBP:oncogene-induced cell senescence), repre-
senting oncogene-induced cell senescence, and p(HGNC:HRAS 
sub(G, 12, V)), representing HRASV12 mutation, ranking 
first and eighth in their contribution to the significant senes-
cence network score (Fig. 3A, boxed in yellow). Many nodes 
representing RAS, RAF, and MAPK mechanisms also scored 
highly and/or were high contributors to the network score as 
leading nodes. The relationship from angiotensin II activating 
CDKN1A protein is an example of an edge added to the senes-
cence network during the NVC process.
The cell cycle network also had a significant network 
score with cell cyclins and E2Fs inferred as decreased lead-
ing nodes (Fig. 3B, highlighted in yellow), while inhibitors 
of cyclins and E2Fs (CDKN1A and RB1) were inferred as 
increased leading nodes (Fig. 3B, highlighted in blue). NVC 
contributions include RRM1, MAD2L1, SIRT1, and TP53 
acetylation, which adds more detail to the role of THAP1 
and TP53 in regulating cell cycle. The nodes predicted in 
the senescence and cell cycle networks are consistent with an 
expected decrease in cell cycle due to HRASV12 signaling.
Quantification/comparison of toxicity in two related data-
sets using the network suite. Networks were used to evaluate 
and compare two recently published mouse lung datasets 
(E-MTAB-3150 and GSE52509), in order to quantify the 
effects of different exposures on biological processes at dif-
ferent time points.30 In the first study (E-MTAB-3150), mice 
were exposed to CS or aerosol from a prototype modified risk 
tobacco product (pMRTP). After two months, mice were 
switched from CS exposure to pMRTP or fresh air (cessa-
tion) for an additional five months and compared with mice 
subjected to CS for the whole duration (seven months). In the 
study reported in the GSE52509 dataset, mice were exposed 
to smoke for four or six months.31
Macrophage signaling is of particular interest in the first 
study (E-MTAB-3150). The NPA score for the macrophage 
signaling network significantly increased with smoke expo-
sure for all time points and decreased with switch and cessa-
tion (Fig. 4A). This trend matched the measured end points 
of macrophage count in bronchoalveolar lavage fluid (BALF) 
and pigmented macrophages in lung tissue (Fig. 4B).30 Lead-
ing nodes within the macrophage signaling network that con-
tributed most to the score are depicted by relative contribution 
to network scores in Figure 5. The Il1r1 protein and activity 
were top contributors to the network score for the first four 
months of smoke exposure, after which Irak4 and Myd88 
activity were top scoring contributors. These nodes also con-
tributed most to the five-month pMRTP, switch to pMRTP, 
and cessation scores. Irak4 and Myd88 act in the TLR path-
way that leads to macrophage activation induced by smoke for 
six months (Fig. 6, boxed in yellow). A number of new nodes 
were added during the NVC2 process, including detail around 
the TLR pathway and effects of macrophage activation. Two 
of these new nodes, prostaglandin E2 and nitric oxide, were 
leading nodes that contributed highly to the macrophage sig-
naling network score.
NPA scores can be calculated for the whole suite of net-
works and also allow to compare different datasets, as the rela-
tive signal compared with a control is used. Figure 7 shows that, 
as expected, most of the networks were predicted to be sig-
nificantly impacted with CS exposure in the E-MTAB-3150 
dataset, with an increasing impact over time. In contrast, 
most of the networks were predicted to be not impacted sig-
nificantly with pMRTP exposure. Upon cessation or switch to 
pMRTP from smoke exposure, the network scores decreased. 
Interestingly, this approach also proves powerful when applied 
to a dataset with fainter signal, as judged by the number of 
differentially expressed genes. Indeed, the number of differ-
entially expressed genes in GSE25209 is low (hundreds) com-
pared with those in the E-MTAB-3150 dataset (thousands) 
for smoke-exposed mice (Supplementary File 3). Despite the 
low signal, TopoNPA still detected a signal and predicted 
activation of key networks known to be involved in smoking, 
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was inferred and contributed to the significant Th17 signaling 
network score (Fig. 8, boxed in yellow). These network infer-
ences match measurements from the study, reporting a higher 
number of Th17 cells and IL17-positive cells in the six-month 
smoke-exposed lung tissue.31 Additionally, the study reported 
enrichment of innate and adaptive immune cell communica-
tion pathways by Ingenuity Pathway Analysis of transcrip-
tomics data, which matches the significant network scores in 
T-cell and other immune networks (Fig. 7).
discussion
Network resources have different strengths. Many dif-
ferent network resources are available online, with different 
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figure 3. Senescence (A) and cell cycle (B) networks scored with GSe28464 HRaSV12 data from the nCBi Geo database. a selection from the 
toponPa-scored version is shown. arrow edge indicates a positive relationship while ball and stick edge indicates a negative relationship (includes 
causal and correlative statements). nodes are colored by their nPa score; yellow/orange indicates inferred increase and blue indicates inferred decrease 
in activity or abundance. darker colors denote higher magnitude scores. leading nodes contribute to 80% of the network score and are denoted by their 
shapes outlined in gray. nodes added within this section of the network during the nVC are labeled in red. (A) Senescence network. nodes boxed in yellow 
reflect experimental HRASV12 mutation, resulting in oncogene-induced senescence. (B) Cell cycle network. Predicted upregulated nodes (yellow) contain 
cell cycle inhibitors RB1, e2F4, and CdKn1a predicted increased. Predicted decreased nodes (blue) contain cell cyclins and e2Fs predicted decreased.
including the inflammatory, cell stress, cell proliferation, 
and tissue repair networks (Fig. 7). The networks that score 
significantly in GSE52509 were similar to those in the 
C57BL6-pMRTP-SW dataset, sharing 24 significant and 11 
nonsignificant networks out of the 46 total networks. Note 
that scores cannot be compared across datasets.
One of the networks that scored significantly for the 
impact of six-month smoke was the Th17 signaling net-
work. The network shows mechanisms that can contribute to 
Th17 signaling and were predicted to be increased or decreased. 
Il17 differential gene expression was not statistically signifi-
cant based on the microarray data; however, evidence of Il17a 
and Il17f activation from the overall transcriptomics signal 
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language formats, visualization, and download application 
capabilities.32,33 Out of these, we chose to compare two of the 
most widely used network resources, KEGG and Reactome, 
to the NVC networks focusing on the calcium signaling net-
work as a point of comparison. BEL networks enhanced in 
the NVC cover 46 different COPD-relevant processes. The 
KEGG pathway database is a well-known resource in the sci-
entific community that can be used to interpret data.4,5 Cre-
ated by a select team of biologists, KEGG contains hundreds 
of pathways covering a wide variety of processes including 
metabolism, cellular processes, diseases, and more. Reactome 
is an open-source, open-access collection of manually curated 
and peer-reviewed pathways and suite of data analysis tools 
to support pathway-based analysis.6,7 Similarly, the NVC 
networks are manually curated by a team of scientists and 
organized into discrete subject areas. However, unlike the 
KEGG and Reactome pathways, these network graphs are 
open to the crowd for editing and each of the edges that make 
up the network is supported by literature source(s) along with 
a quotation from the paper that supports the edge and experi-
mental context. The ability for the crowd to edit the networks 
facilitates a peer-review process, which ensures comprehensive 
and current networks.
The NVC networks have different edge and node types 
that describe the relationships between nodes in great detail 
to reflect exactly what was proven in the experiment the 
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figure 4. macrophage signaling network scores in the e-mtaB-3150 dataset and pigmented macrophage counts in the same study. (A) macrophage 
signaling network score increased with time with smoke exposure and decreased with switch or cessation. pMRTP did not have significant macrophage 
signaling network scores at any time point. Green, blue, and red asterisks indicate significant O, K, and experimental P-values, respectively. (B) Pigmented 
macrophage in the alveolar lumen increased with smoke exposure over time and decreased with switch or cessation. pmRtP did not induce an increase in 
pigmented macrophages. 
Notes: *P , 0.05 compared with sham. #P , 0.05 compared with smoke exposure.
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figure 5. leading node contribution for macrophage signaling network in the e-mtaB-3150 dataset. Word size indicates relative contribution to 
network score. 
Notes: *significant score; (+) inferred increase; (−) inferred decrease.
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figure 6. macrophage signaling network scores for seven-month smoke vs seven-month fresh air using the e-mtaB-3150 dataset. a selection from 
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Namasivayam et al
62 Gene ReGulation and SyStemS BioloGy 2016:10
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* * *
*
*
* * *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Apoptosis
Autophagy
Necroptosis
Response to DNA damage
Senescence
Cell cycle
Cell interaction
Epigenetics
Growth factor 
Hedgehog
Jak stat
Mapk
mTor
PGE2
Wnt
Endoplasmic reticulum stress
Hypoxic stress
NFE2L2 signaling
Osmotic stress
Oxidative stress
Xenobiotic metabolism response
B−cell signaling
Cytotoxic T−cell signaling
Dendritic cell signaling
Epithelial innate immune activation
Epithelial mucus hypersecretion
Macrophage signaling
Mast cell activation
Megakaryocyte differentiation
Neutrophil signaling
NK signaling
Th17 signaling
Th1−Th2 signaling
Tissue damage
Treg signaling
Angiogenesis
ECM degradation
Endothelial Innate immune activation
Fibrosis
Immune regulation of tissue repair
Wound healing
Relative NPA
Normalized Network perturbation amplitude scores
E-MTAB-3150GSE52509
4mo 6mo 1mo 2mo 3mo 4mo 5mo 7mo
CS CS
1mo 2mo 3mo 4mo 5mo 7mo 3mo 5mo 7mo 3mo 5mo 7mo
pMRTP Cessation Switch
Tissue R
epair
a
nd Angiogenesis
 
Inflam
m
ation
Cell stress
Cell fate
Cell proliferation
0 1
figure 7. Heat map of network scores comparing the impact of CS exposure, pmRtP, and cessation in the e-mtaB-3150 and GSe52509 datasets. each 
treatment is compared to fresh air at the same time point. Scores are normalized to the maximum scores for each network. a network is considered 
impacted if, in addition to the significance of the score with respect to the experimental variation, the two companion statistics (O and K) derived to inform 
the specificity of the score with respect to the biology described in the network, are significant.  
Note: *o and K statistic P-values below 0.05 and NPA significantly nonzero.
annotated reference describes. Nodes defined by a namespace 
serve to standardize the language and multiple functions such 
as abundance, activity, modifications (ie, phosphorylation), 
biological process, and pathology to describe the biology in a 
fine-grained manner. Edges are defined by causal, correlative, 
and other numerous noncausal relationships and each causal/
correlative edge is based on a literature reference containing 
tissue, species, disease, and experimental metadata. Like the 
NVC networks, KEGG and Reactome describe biological 
processes in a causal manner, though they have less granu-
lar information about the nodes and edges and, for the case 
of KEGG, no specific literature reference was found for each 
relationship. Reactome has references by edge in the net-
work downloads but not in an easily viewable format on the 
Biological network models for toxicology and drug discovery applications
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graph itself. References for the NVC calcium network were, 
on average, more recent than the KEGG and Reactome net-
works, implying that the NVC network contains more up-to-
date information, most likely because of the crowdsourcing 
effort. Among the 86 references used to support the calcium 
pathways across all three resources, all references were unique. 
This illustrates the range of literature and boundaries that were 
used to build the calcium pathways across the three network 
formats. The visualization of the KEGG and Reactome path-
ways allows the viewer to easily traverse the networks within 
a graphical representation that includes cellular localization 
of the nodes. KEGG and Reactome pathway diagrams have 
detailed cellular localization information that the BEL net-
works do not show graphically. However, this information can 
be described in the edge annotation or the node label.
Many analysis tools are available to use with the KEGG 
and Reactome pathways to interpret data. NVC networks also 
support analytics for mapping nodes in a dataset as well as 
taking into account the relationships between the nodes with 
the exact edge data. NVC networks can be downloaded in 
JSON graph format (JGF) and viewed and applied to data 
using Cytoscape or other JGF-compatible network visualiza-
tion software. Edge information can be used to filter and com-
pute on the networks.
Other network resources that are geared toward a 
community-driven approach include WikiPathways34 and 
the Cell Collective.35 These resources do not have a calcium 
pathway appropriate for comparison, but like KEGG and 
Reactome, they are limited by less granular information about 
the nodes and edges compared with NVC networks and, like 
KEGG, no specific literature reference is given for each rela-
tionship. However, they do benefit from the contribution of 
information from the scientific crowd, where WikiPathway 
users can edit and contribute to existing pathways and Cell 
Collective users can contribute information to the Knowledge 
Base, collaboratively build models and simulate and analyze 
them in real time. Like KEGG and Reactome, WikiPathways 
provides a graphical representation, containing cellular locali-
zation information.
Each of these network resources offers advantages for 
viewing and interpreting biology. The NVC networks cover 
lung- and COPD-relevant processes in a very detailed and 
granular manner and are open to public feedback, and the data 
can be computed at the node and edge level. The KEGG and 
Reactome pathways cover a wide range of biology with many 
widely used node-centric analysis tools, the Cell Collective 
allows for quantitative computation of networks, and KEGG, 
Reactome, and WikiPathways provide a simplified represen-
tation for easy visualization.
NVc crowd excels at identifying and encoding lite­
rature. A review of the crowd changes and participant sur-
vey feedback after two iterations of the NVC allowed for an 
understanding of aspects that worked well and aspects that 
can be improved for subsequent challenges. One important 
finding was that the crowd was able to identify relevant lit-
erature that contained COPD mechanisms missing from the 
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figure 8. th17 signaling network scored with GSe52509 mouse lung exposed to 6 month smoke. the whole toponPa-scored version is shown. arrow 
edge indicates a positive relationship, while ball and stick edge indicates a negative relationship (includes causal and correlative statements). nodes are 
colored by nPa score; yellow indicates inferred increase and blue indicates inferred decrease. darker colors denote higher magnitude scores. leading 
nodes contribute to 80% of the network score and are denoted by their shapes outlined in gray. nodes added within this section of the network during the 
NVC process are labeled in red. Nodes boxed in yellow reflect prediction of Il17 cytokines.
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networks. Keeping networks up-to-date with the constant 
stream of published literature is difficult for the small team 
of scientists who created the networks. Crowdsourcing this 
effort through the Bionet website allows for a diverse group 
of international scientists to share in this effort to collect rel-
evant literature and note missing areas in a network using each 
individual’s expertise and biological perspective. This process 
allows the community as a whole to benefit from up-to- 
date networks.
The main incentive for participants, according to a survey, 
was the learning process, and although educating the commu-
nity about BEL and network biology is an excellent outcome 
of the NVC, there were many challenges associated with this 
large, crowdsourced effort to edit the networks. These chal-
lenges included clearly defining and communicating rules and 
boundaries up front in a way that everyone can consistently 
follow, the follow-up effort required to edit the changes made 
to the networks to ensure consistency and adherence to the 
network framework rules, and the creation of accurate BEL 
statements capturing the biology stated in a publication.
An idea for future challenges is to separate knowledge 
creation from network construction. Adding new and relevant 
edges to a network was a heavily incentivized portion of the 
challenge and is an important mechanism for filling knowl-
edge gaps in the network and maintaining the networks with 
newer information from the literature. While the crowd par-
ticipants performed well at identifying relevant literature and 
representing key ideas in BEL, it was challenging for partici-
pants to select and add mechanistic, nonredundant paths that 
were well integrated with the rest of the network, especially 
for the larger networks. As seen from the network statistics, 
the crowd contributed to the number of nodes and edges but 
not necessarily to changing the topology of the network. Sep-
arating the curation and network building portions of the task 
could provide several advantages. For example, BEL evidences 
could be voted on by the crowd for accuracy and relevance and 
refined prior to incorporation into a network. It is difficult to 
edit evidences and statements once they are connected into a 
network, as all neighboring edges and all individual evidences 
supporting the same edge are affected. Moreover, evidences 
could be more readily shared across networks where applica-
ble, and evidences that are highly relevant, but not the most 
streamlined, direct connection within a given network, could 
be omitted from the network but retained for other applica-
tions. Making the challenge tasks more manageable and nar-
rowly defined in this manner could potentially attract more 
participants as well as increase the quality and value of the 
resulting networks and associated knowledge. Every year, as 
more biological experts participate in the challenge and more 
literature is published, the networks can be kept up-to-date 
with the current understanding of the biology contained in 
these networks.
Networks can be used in toxicity and drug discovery 
applications. In addition to application as a tool to understand 
signaling pathways regulating a disease process, biological 
networks can be used to predict active mechanisms driving 
measured biological changes based on a knowledgebase of 
known regulators of these measured changes. In this study, 
we use network scoring to infer upstream mechanisms known 
to regulate measured gene changes applied to three datasets. 
Networks that contain these mechanisms can then be scored 
to infer perturbation of biological processes represented by the 
networks in a quantitative manner. In the GSE28464 study, 
mutated HRASV12 was expressed in fibroblasts and acti-
vation of senescence and cell cycle was inferred by network 
scoring of the transcriptomics data. These results were consis-
tent with experimental expectations of HRASV12, inducing 
senescence and cell cycle arrest.36 This example illustrates the 
ability of the network scoring approach to infer known active 
mechanisms using transcriptomics data. Novel mechanisms 
predicted to be active from transcriptomics data as a result of a 
treatment could also be identified in biological networks using 
this approach.
A major advantage of this network-based transcrip-
tomics data scoring approach is the ability to quantitatively 
compare treatments and time points within a dataset within 
discrete biological processes. In the E-MTAB-3150 dataset, 
the effects of smoke, pMRTP, switch to pMRTP, and cessa-
tion were quantified on the biological process and mechanistic 
level through network and mechanism scores. Network scor-
ing indicated that smoke impacted lung biology captured by 
networks more than pMRTP, switch to pMRTP, or cessation 
and with a greater magnitude over time. pMRTP appeared 
to impact lung biology less than smoke, based on the lower 
pMRTP vs sham network scores and fewer networks scor-
ing significantly. Switching from smoke to pMRTP or ces-
sation showed a decrease in network perturbation compared 
with sham group over time. Additionally, scoring mechanisms 
within the network gives insights on which mechanisms are 
predicted to induce gene expression changes observed in the 
dataset. Il1 receptor signaling was predicted to impact mac-
rophage activation the most in early time points with smoke 
treatment, followed by an increased impact of Irak4 and 
Myd88 activity on macrophage activation in later time points 
(Fig. 5). Il1r1/MyD88 signaling has been shown to contrib-
ute to elastase-induced lung inflammation and emphysema,37 
and although there are no publications implicating Irak4 in 
emphysema or COPD, a recent conference poster reported 
MyD88/Irak4 promotion of lung fibrosis in a mouse model 
of COPD.38 This network approach can potentially high-
light novel mechanisms such as Irak4 that drive disease and 
increase our understanding of COPD progression. Findings 
such as these could lead to a list of potential biomarkers or 
novel targets that could then be confirmed in multiple datasets 
in the primary disease tissue and narrowed down by aspects 
of ease of targetability and low off-target effects to identify 
ideal targets. Additionally, the quantitative aspect to network 
scoring can be used in toxicity testing to rank the impact of 
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different treatments and study dosing and time effects for a 
particular perturbation.
Another advantage of the network approach is the 
ability to glean information from a dataset with a low tran-
scriptomics signal. Similar to the E-MTAB-3150 dataset, 
GSE52509 contained data from smoke-exposed mouse lungs 
for four and six months; however, this dataset had a much 
lower transcriptomics signal. This difference in signal could 
be attributed to a larger variation in the data, or potentially 
the lower dosage and duration per day of smoke exposure 
in GSE52509 compared with the E-MTAB-3150 dataset. 
In the E-MTAB-3150 study, mice were exposed to smoke 
2.4 times longer per day at 1.5 times higher concentration. 
Similar types of networks and leading nodes were inferred 
in both studies to be activated in processes relevant to CS 
exposure, and they matched experimental end points of pig-
mented macrophage and Th17 counts in E-MTAB-3150 and 
GSE52509 studies, respectively.
Although the networks focus on lung- and COPD-
relevant context and were scored on lung datasets, these net-
works can apply to other disesases and tissues. The networks 
include edges that are based on literature from lung-relevant 
cell types such as fibroblasts, smooth muscle, and immune 
cells; these cell types are not specific to lung but can apply to 
many other tissues and disease contexts. The networks to be 
scored should be evaluated based on the context of the data-
set. For the GSE28464 dataset, only the senescence and cell 
cycle networks were scored, while the immune networks were 
not scored since the experiment was performed in fibroblasts 
and not immune cells. Since many of the pathways that the 
networks describe such as canonical MAPK and NFKB sig-
naling are conserved across tissues, these networks provide an 
important resource that can be built on to include context-
specific mechanisms according to scientists’ needs.
conclusion
The computable biological language BEL allows for encod-
ing of scientific literature with high granularity and is well 
suited for sharing mechanistic biology in a network context. 
The NVC takes advantage of the well-defined nature and ease 
of use of BEL to allow the scientific community to verify, 
enhance, and use these networks. These networks can then 
be used for toxicological and drug discovery applications. We 
illustrated one way to use these networks through quantitative 
network scoring based on transcriptomics data. Mechanisms 
were inferred from the data and could be quantitatively com-
pared within a dataset, leading to insights in disease-driving 
mechanisms and toxicity assessment.
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Abstract
Neurodegenerative diseases are chronic debilitating conditions, characterized by
progressive loss of neurons that represent a significant health care burden as the global eld-
erly population continues to grow. Over the past decade, high-throughput technologies
such as the Affymetrix GeneChip microarrays have provided new perspectives into the path-
omechanisms underlying neurodegeneration. Public transcriptomic data repositories,
namely Gene Expression Omnibus and curated ArrayExpress, enable researchers to con-
duct integrative meta-analysis; increasing the power to detect differentially regulated genes
in disease and explore patterns of gene dysregulation across biologically related studies.
The reliability of retrospective, large-scale integrative analyses depends on an appropriate
combination of related datasets, in turn requiring detailed meta-annotations capturing the
experimental setup. In most cases, we observe huge variation in compliance to defined
standards for submitted metadata in public databases. Much of the information to complete,
or refine meta-annotations are distributed in the associated publications. For example, tissue
preparation or comorbidity information is frequently described in an article’s supplementary
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tables. Several value-added databases have employed additional manual efforts to over-
come this limitation. However, none of these databases explicate annotations that distin-
guish human and animal models in neurodegeneration context. Therefore, adopting a more
specific disease focus, in combination with dedicated disease ontologies, will better em-
power the selection of comparable studies with refined annotations to address the research
question at hand. In this article, we describe the detailed development of NeuroTransDB, a
manually curated database containing metadata annotations for neurodegenerative studies.
The database contains more than 20 dimensions of metadata annotations within 31 mouse,
5 rat and 45 human studies, defined in collaboration with domain disease experts. We eluci-
date the step-by-step guidelines used to critically prioritize studies from public archives and
their metadata curation and discuss the key challenges encountered. Curated metadata for
Alzheimer’s disease gene expression studies are available for download.
Database URL: www.scai.fraunhofer.de/NeuroTransDB.html
Background
Considerable effort by the global research community has
been dedicated to addressing a limited understanding of the
pathogenic events underlying neurodegenerative disease
(NDD) (1, 2). The cumulative output of these efforts has es-
tablished an increased amount of deposited molecular data
and published knowledge. As life expectancy continues to
rise and treatment options for NDD remain limited, there is
an increasing urgency to translate this amassed molecular
data into biomarker tools for early diagnosis; to open the
possibility of disease altering and preventative therapy (3,
4). Furthermore, biomarkers aiding the decision-making
process for therapies targeting specific pathophysiological
mechanisms will help to address the high drug attrition rate
in the NDD pharmaceutical industry. Informatic efforts to
facilitate the integration and interrogation of the distributed
molecular data legacy for NDD can enable a systematic and
objective prioritization of molecular protagonists and there-
fore potential biomarkers in NDD (5–8).
In this direction, we have previously developed a seman-
tic framework, called NeuroRDF (9), for integration of
heterogeneous molecular data types, extracted from bio-
medical literature, transcriptomic repositories and bespoke
databases. NeuroRDF enables researchers to formulate
biological questions that relate to the interplay of different
facets of molecular biology as a formalized query. Even
today, the most abundant source of quantitative molecular
data remains transcriptomic data, which can support hy-
pothesis-free, elucidation of biological function (10). When
the same biological function is replicated in additional ex-
pression data sets, it increases the plausibility of the
derived hypothesis (11).
The inaccessibility of the brain is a significant barrier
to molecular analysis of NDD and this frequently limits
the availability of samples from post-mortem tissue (12,
13). This is evident when simply comparing the availabil-
ity of NDD studies to other disease domains, like cancer
(14), in public archives such as Gene Expression
Omnibus (GEO) (15) and ArrayExpress (16) (see
Supplementary Figure S1). For instance, GEO contains
157 NDD studies in contrast to 16,910 cancer studies.
Therefore, animal models are an important complement
to human-derived samples but are at best an incomplete re-
flection of the human conditions. Assessing the biological
complementarity of studies is important when considering
a meta-analysis. Such an assessment can be a cumbersome
process as searching in these public repositories is princi-
pally based on free text. Additionally, limited adoption of
controlled vocabularies, such as the Experimental Factor
Ontology (EFO) (17), to describe the metadata fields and
lack of compliance to defined standards (18) has contrib-
uted to the dilemma. This has resulted in metadata being
scattered as unstructured prose in public databases and as
additional annotations, widely distributed in originating
publications. Moreover, applying automated methods to
retrieve information from these databases could comprom-
ise on the accuracy. On the other hand, capturing missing
annotations through the manual curation can incur huge
costs of trained labour.
Capturing the associated metadata in a standardized
and precise fashion will empower integrative analysis by
helping to control sources of variability that do not relate
to the hypothesis under investigation (11, 19–21). Ober
et al. (22) have reported on differing gene-expression pat-
terns related to gender and suggest gender-specific gene
architectures that underlay pathological phenotypes. Li
et al. (23) observed distinct expression patterns, strongly
correlated with tissue pH of the studied subjects; these pat-
terns are not random but dependent on the cause of death:
brief or prolonged agonal states. Thus, studies enriched
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with metadata annotations provide the power to obtain
more precise differential estimates.
Related work
Numerous approaches have been proposed to tackle the
problem of identifying relevant gene-expression studies
and annotating metadata information resulting in several
databases, web servers and data exploration tools. These
(value added) databases differ from one another based on
their objectives, information content and mode of query.
AnnotCompute (24) is an information discovery plat-
form that allows effective querying and grouping of similar
experiments from ArrayExpress, based on conceptual dis-
similarity. The dissimilarity measure used, Jaccard dis-
tance, which is derived from the MAGE-TAB fields
submitted by the data owners. Another tool, Microarray
Retriever (MaRe) (25) enables simultaneous querying and
batch retrieval from both GEO and ArrayExpress for a
range of common attributes (e.g. authors, species)
(MAGE-TAB is a submission template, tab-delimited, for
loading functional genomics data into ArrayExpress.
https://www.ebi.ac.uk/fgpt/magetab/help/). GEOmetadb
(26) is a downloadable database of structured GEO meta-
data with programmatic querying libraries in both R and
MATLAB. However, all the above-mentioned resources
suffer from a common limitation: they rely completely on
the submitted data and do not provide solutions for miss-
ing metadata information.
Several value-added databases invest manual curation
effort to enrich metadata information for gene-expression
studies. Many Microbe Microarrays Database (M3D) (27)
contains manually curated metadata, retrieved from the
originating publications, for three microbial species, con-
ducted on Affymetrix platforms. Similarly, the Oncomine
database (28) contains extensive, standardized and curated
human cancer microarray data. A-MADMAN (19); an
open source web application, mediates batch retrieval and
reannotation of Affymetrix experiments contained in GEO
for integrative analyses. Microarray meta-analysis data-
base (M2DB) (11) contains curated single-channel human
Affymetrix experiments (from GEO, ArrayExpress and lit-
erature); categorized into five clinical characteristics, repre-
senting disease state and sample origin. However,
experiments with missing link to the published paper in
GEO and ArrayExpress were excluded. A substantial pau-
city of sample associated gender information in GEO and
ArrayExpress motivated Buckberry et al. (29) to develop a
R package, massiR (MicroArray Sample Sex Identifier) to
label the missing and mislabelled samples retrospectively
with gender information, based on data from Y chromo-
some probes. Apart from publicly available resources,
there are various commercial products that contain manu-
ally curated transcriptomic metadata: NextBio, Genevesti-
gator and InSilicoDB (30) (http://www.nextbio.com/b/
nextbioCorp.nb and https://genevestigator.com/gv/).
However, none of the above databases are optimized to
capture detailed metadata specific to neurodegenerative
disease. In addition, these databases fail to handle species-
specific annotations; especially treatments applied on ani-
mal models to partially explicate or treat human-related
NDD mechanisms, which may strongly contribute to in-
crease the predictive power of translating preclinical results
in NDD drug trials.
Here, we describe the detailed development of
NeuroTransDB, a manually curated database containing
metadata annotations for neurodegenerative studies and
an enabling resource for supporting integrative studies
across human, mouse and rat species. The participation of
our group, at Fraunhofer Institute SCAI, in projects funded
by the Neuroallianz Consortium (a part of the BioPharma
initiative of the German Ministry of Education and
Research) and the evident lack of a comprehensive NDD
specific metadata archive has motivated us to develop
Neurodegenerative Transcriptomic DataBase
(NeuroTransDB) (http://www.neuroallianz.de/en/mission.
html). This database now contains more than 20 dimen-
sions of metadata annotations for human studies, as well
as mouse and rat models, defined in agreement with dis-
ease experts. To demonstrate our approach, we chose to
highlight Alzheimer’s disease for this publication because it
depicts a wide spectrum of the possible annotations across
different types of metadata in neurodegeneration.
Additionally, we have applied the same approach to all
publicly available Parkinson’s and Epilepsy studies, which
shows that the overall approach is unspecific to the disease.
However, the curated data for these two diseases will be
released in the future under the terms of a Neuroallianz
agreement. The database is updated every six months using
highly trained curators. An interactive graphical user inter-
face to access this data is currently being developed as part
of the AETIONOMY IMI project (http://www.aetionomy.
eu).
Curation of gene-expression studies:
prerequisites, key issues and solutions
This section discusses the workflow we followed to re-
trieve relevant gene-expression datasets and to generate
detailed metadata annotations for each study (Figure 1).
First, we retrieved all functional genomics studies from
GEO and ArrayExpress that reference Alzheimer’s dis-
ease (AD) or a set of AD synonyms, along with the pro-
vided metadata (cf. Data Retrieval section). Each study
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was then prioritised (cf. Experiment Prioritization sec-
tion) based on the disease relevancy, experimental type
and sample source. Only studies in the top prioritization
category were subjected to rigorous, semiautomated
metadata curation (cf. Metadata Curation section).
Annotations are standardized by reference to controlled
vocabularies for each extracted metadata dimension (cf.
Normalization of Metadata Annotations section). The
curated Alzheimer’s data is stored in NeuroTransDB, but
in principle the proposed workflow can be applied with
little adaptation to any disease indication, especially
NDD.
Primary data resources
Together the GEO and ArrayExpress databases constitute
a wealth of gene expression studies and are commonly
reused for validating new hypotheses and identifying novel
signatures through meta-analysis by multi-data integration
(11). GEO is the largest public repository of functional
genomic data; maintained by the National Center for
Biotechnology Information (NCBI) in the USA.
ArrayExpress is the European counterpart of GEO and
consists of manually curated experimental information im-
ported from GEO, in addition to the data that are directly
submitted by the researchers. To support reuse of the de-
posited studies, each repository adheres to annotation
standards for submission of transcriptomic data:
‘Minimum Information about a Microarray Experiment’
(MIAME) and ‘Minimum Information about a high-
throughput nucleotide SEQuencing Experiment’
(MINSEQE) (http://fged.org/projects/miame/ and http://
www.fged.org/projects/minseqe/). GEO allows data sub-
mission in Excel, SOFT or MINiML format and
ArrayExpress as MAGE-TAB through Annotare webform
tool (http://www.ncbi.nlm.nih.gov/geo/info/submission.
html and http://www.ebi.ac.uk/arrayexpress/submit/over-
view.html).
Curation team
An obvious prerequisite for any curation process is to have
access to specially trained personnel, who understand the
key attributes required to adequately describe an expres-
sion experiment and are able to complete these attributes
by reference to appropriate resources (31). Such individ-
uals are known as biocurators. We assembled a team of
candidate biocurators who have adequate biological ex-
perience. Each biocurator underwent extensive training in
the fundamentals of curation, including the basics of gene
expression study design, outlined by experts, scientists and
disease experts. Clear curation guidelines (see Experiment
Prioritization and Metadata Curation section) and a
weekly meeting of the biocurators with one of the experts
ensured good quality, consistency, and uniformity in cur-
ation procedure. In addition, this provided an opportunity
to get feedback from the biocurators for improving and
updating the defined guidelines. To keep abreast and elim-
inate any bias, the curated data was regularly exchanged
between them for good interannotator agreement. The ex-
perts resolve any disagreement that may arise between the
curators.
Data retrieval
Putative AD studies were programmatically retrieved from
GEO and ArrayExpress by applying a recall-optimized
keyword search approach, cf. Figure 2. The keywords in-
clude a set of AD synonyms such as ‘Alzheimer’,
‘Alzheimer’s’ or ‘AD’ in combination with a species filter.
Since ArrayExpress imports and curates the majority of
GEO experiments, we firstly queried the former through
its REST service (http://www.ebi.ac.uk/arrayexpress/help/
programmatic_access.html). Conjointly, we further
queried GEO using the eSearch Entrez Programming
Utilities (E-utils) service to fetch additional identifiers
(IDs), which were not picked up by the previous query
(http://www.ncbi.nlm.nih.gov/geo/info/geo_paccess.html).
The final list of unified experiment IDs was downloaded
Data Retrieval
Experiment Priorizaon
Manual meta-data curaon
Normalizaon
Priority 1
Priority 2
Storage in NeuroTransDB
Figure 1. Overall workflow for curation of gene expression studies
related to neurodegeneration from public archives. The first step in-
volves automated retrieval of gene expression studies (along with
metadata) from public archives such as GEO, and ArrayExpress. The
related studies were further assigned to one of the two prioritization
classes (priority 1 or priority 2), based on the specific experimental vari-
ables. Next, manual curation was applied to capture missing metadata
information on priority 1 studies. All the harvested metadata was nor-
malized using standard vocabularies. Both raw and normalized data are
stored in NeuroTransDB.
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(along with their metadata) and stored in
NeuroTransDB. Metadata information was captured
from Sample and Data Relationship Format (SDRF) file
of ArrayExpress and SOFT file of GEO (https://www.ebi.
ac.uk/fgpt/magetab/help/creating_a_sdrf.html and http://
www.ncbi.nlm.nih.gov/geo/info/soft.html). The above-
described steps are fully automated; enabling an auto-
matic update procedure we run every 6 months to obtain
new published studies.
Experiment prioritization
For integrative meta-analysis, combining studies that ad-
dress the same objectives could minimize biases from co-
hort selection (inclusion and exclusion criteria) and other
design effects. Anatomical and functional heterogeneity
arising from experimental sample source, imposes yet an-
other challenge for integrative analysis. Moreover, key-
word-based, recall optimized retrieval of experiments does
not guarantee its clinical relevancy to the queried indica-
tion or organism. Thus, we propose a straightforward bin-
ning approach to select potentially eligible studies for AD
as illustrated in Figure 3.
Firstly, we identified experiments relevant to AD indica-
tion, if not relevant we mark them as unrelated (referred as
AD3 in the database). Relevancy is defined on the basis of
the experiment’s characteristics: investigation on AD
mechanism, AD associated mechanism, AD genes or con-
tains samples that belong to direct or implicated effects of
or on AD. For example, GSE4757 is relevant to AD since it
investigates the role of neurofibrillary tangle formation in
Alzheimer patients between normal and affected neurons.
The retained AD-related experiment IDs were manually
classified by biocurators into one of the two-prioritization
categories (cf. Figure 3). To support this process, a set of
classification rules were devised that capture two import-
ant considerations: organism specificity and source of the
samples used in the study. Although curation with regards
to these considerations is of obvious importance, no previ-
ously published guidelines were available for reference. To
our knowledge, this is the first work where such a guide-
line has been explicitly detailed. A simplified description of
the classification rules adopted for AD disease prioritiza-
tion is provided below:
Priority 1
• Experiments that study AD pathophysiology in in vivo
systems
• Studies containing samples from:
– Human AD patients such as blood, brain tissue,
serum, etc.
– Animal model samples such as mouse brain tissue or
rat brain, e.g. C57BL/6 mice, Sprague–Dawley rat, etc.
– Animal models modified to study the role of an AD
gene (knock-out models), or AD mechanism (trans-
fected models), or diet/drug treatments (treated mod-
els), such as TgAPP23, APLP2-KO mice, etc.
• Experiments containing only healthy/normal samples
from human/mouse/rat that are a part of a bigger study
investigating AD
Priority 2
• Experiments that study AD pathophysiology in in vitro
systems
Keyword search for human, mouse, and rat:
“Alzheimer”,  “Alzheimer’s”, or “AD”
eSearch E-uls service
Parse XML ﬁle for experiment IDs
Storage in NeuroTransDB
REST Service
Parse XML ﬁle for experiment IDs
Fetch the SOFT ﬁle using experiment 
IDs and parse meta-data annotaons
Fetch the SDRF ﬁle using experiment 
IDs and parse meta-data annotaons
Figure 2. Automated data retrieval of Alzheimer’s Disease specific gene expression studies from ArrayExpress and GEO. Here, the dotted line
represents the sequence of query performed. Alzheimer’s disease specific experiment IDs were automatically retrieved from GEO and ArrayExpress,
using keywords, through eSearch and REST service respectively. Metadata information was extracted by automatically parsing sample information
files (SDRF and SOFT) of these experiment IDs.
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• Studies containing samples from derived or cultures
sources:
– Cell lines
– Pluripotent cells
– Stem cells
Incorrect organism or disease specificity
Although the experiment retrieval step was restricted to a
specific organism and disease conditions, we observed dif-
fering levels of specificity. For example, some mouse stud-
ies were retrieved when querying for human studies.
Similarly, we obtained experiments for related diseases
such as Parkinson’s disease, or diabetes, when querying for
AD. Therefore, during study prioritization it was import-
ant to confirm the species of origin and relevancy of the
study to AD. It’s also possible that keyword-based retrieval
may miss AD studies due to incorrect disease or organism
tagging. However, we did not perform an exhaustive
search for such falsely ignored studies, since it would re-
quire immense human effort.
Ambiguous species designation
In some studies, human cells such as embryonic stem cells
are injected into animal models and post-mortem samples
from these animal models are extracted for transcriptomic
analysis (e.g. GSE32658 experiment in GEO). Such a study
could arguably be classified as either human priority 2 or
mouse priority 1. After several discussions, we concluded
to prioritize such experiments based on the organism from
which the final sample was extracted. In this case,
although the mouse was grafted with human tissue, we pri-
oritized it to mouse priority 1.
Superseries redundancy
During prioritization, we retrieved several superseries ex-
periments from GEO. Manual inspection revealed that not
all the subseries IDs of these superseries experiments were
retrieved (see Data Retrieval section) (A SuperSeries is sim-
ply a wrapper to group of related Series (typically
described in a single publication). It facilitates access to the
entire dataset, and establishes a convenient reference
entry that can be quoted in the publication (definition
provided by the GEO team, as of 27 October 2014) and a
subseries is an experiment that is a part of superseries.).
With careful manual inspection, we included missing
subseries, further subjected to priorization. Conversely,
if the inclusion of superseries resulted in the duplication
of experiments, we removed the duplicates. Having assigned
priority categories to all retrieved AD studies, further meta-
data curation was focused on the priority 1 studies.
Metadata curation steps are described below.
Metadata curation
Precisely and comprehensively capturing the accessory in-
formation for a transcriptomic study as meta-annotations,
is an important precursor to identification of comparable
experiments that address the biological question at hand.
Unfortunately, the current, general, submission standards
do not cater to the needs of metadata annotations, specific
to a disease domain, during submission. In subsequent
Query downloaded experiment IDs 
from NeuroTransDB
Sample source
Alzheimer’s 
Disease 
relevancy?
Mark as unrelated
In vivo studies In vitro studies
Priority 1
Human paents 
Animal models
Knock out/transfected/treated 
Animal models for AD patho-
physiology
Priority 2
Cell lines
Stem cells 
Pluripotent cells
Yes
No
Figure 3. Experiment prioritization for metadata curation in NeuroTransDB. All the downloaded Alzheimer’s Disease experiments were first checked
for their disease relevancy. Those experiments which were falsely retrieved, are marked as unrelated. The remaining experiments were classified
into one of two priority classes based on the experiment type: In vivo or In vitro studies. For priority 1, we considered direct/primary samples from
human or animal models such as brain tissue, blood, etc. Experiments that were conducted on derived sample sources such as cell lines, were put
into priority 2 class.
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sections, we discuss the metadata curation for NDD and
key issues faced during the process.
Metadata annotation fields
We assembled a list of metadata annotations determined to
be important for evaluating NDD studies in a process
involving consultation by NDD domain experts. All the
metadata fields were categorized as organism attributes
and sample annotations, based on their relevancy to organ-
ism or sample source. Table 1 provides detailed descrip-
tions of curated metadata fields including examples for
human, mouse and rat.
Several animal models and in vitro systems have been
defined that partially mimic the human diseased condi-
tions. Animal models provide experimentally tractable sys-
tems for interrogating NDD, however, not all animal
models faithfully mimic human pathophysiology. A dedi-
cated set of meta-annotation was defined for NDD animal
models to support assessments of inter-study comparability
and translatability to human disease, cf. Table 2 These
fields were defined with assistance from biologists and dis-
ease experts from industry.
Metadata curation workflow
To capture all the relevant meta-annotations, we designed
a semiautomated curation workflow, illustrated in
Figure 4. Firstly, we automatically retrieved all the avail-
able meta-annotations from GEO and ArrayExpress (cf.
Figure 2). Annotations were captured in an Excel template
as shown in Supplementary Figure S2 (A) and confirmed
by our trained curators to rectify any inaccuracies.
To capture incomplete and newly defined meta-annota-
tions, we followed a two-step approach. First, we check if
the required meta-annotation entries are directly available
in GEO, GEO2R or ArrayExpress (http://www.ncbi.nlm.
nih.gov/geo/geo2r/). Where the required information is
complete, we directly update NeuroTransDB, otherwise
we move to a second step to manually harvest information
for missing annotations. Missing information is retrieved
from the originating publications and associated
Supplementary files. When necessary, corresponding au-
thors were contacted to request missing entries. The list of
experiment IDs where we contacted the authors for further
information, along with reason of contact (priority 1 ex-
periments only) are provided in Supplementary Table S1.
In most cases, the corresponding author or one of the coau-
thors responded to our queries; whereas, in few other cases
the email addresses no longer remained valid. In the event
that the authors do not respond or we were unable to con-
tact them, information in primarily deposited database is
used as the final authorative source. Once all the relevant
data was captured, we updated the annotations in
NeuroTransDB. If needed, we updated our automated re-
trieval iteratively.
To demonstrate the metadata curation process, here we
relate our experience with study GSE36980 that includes a
total of 79 samples. Common MIAME annotations such as
gender, age and sample tissue were automatically captured
from ArrayExpress and GEO. The associated publication
contained further useful information on the enrolled
patients, namely: disease stage, post mortem interval be-
fore sample extraction and preservation, pathological
diagnosis and whether the patient suffered from
comorbidities such as diabetes. This information was
located in Supplementary File S2 of the associated publica-
tion (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128
707/bin/supp_bht101_bht101supp_table2.xls). However,
lack of a common ID to enable mapping between the sam-
ple entries in GEO and the associated Supplementary File
S2 impeded curation. For example, sample GSM907797 in
GEO is annotated as being derived from a 95-year-old fe-
male patient. However, in their Supplementary file, there
are two entries that contain information for patients with
same age and gender. The ‘No.’ column, assumed to be pa-
tient ID, in the Supplementary file was not helpful for
mapping, since it was not mentioned in GEO. Thus, we
contacted the authors for the missing link. They provided
us an additional Excel sheet where the GEO sample ID
was mapped to the ‘No.’ column in the Supplementary file
(cf. Supplementary Figure S2 (B) and (C)). As a conse-
quence, we achieved a 28.5% increase in the missing meta-
data information (cf. Table 1 for total number of fields)
after contacting the authors.
Automated meta-annotation retrieval challenges
During automated retrieval of metadata fields, we
observed several alternate representations of information
for certain annotation types in the archives. For example,
age information can be provided in the Characteristics sec-
tion of GEO or ArrayExpress as ‘age: 57 years’ or ‘Stage
IV, male, 57 years’ and so on. We attempted to
prenormalize these diverse representations and automatic-
ally extract the correct information, however, due to the
heterogeneity in data representation, manual curation was
still required.
Although ArrayExpress and GEO provide program-
matic access to their meta-annotations, much essential in-
formation appears in fields meant for general categories.
For example, information about the sample source and
clinical disease presentation appear in the sample title
‘PBMC mRNA from Alzheimer’s disease patient 2’.
Adhering to the standard submission protocol for data
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Table 1. Detailed description of Neurodegenerative disease metadata fields outlined for human, mouse and rat
Annotation type Metadata fields Description of the annotation Relevancy for NDD Examples References
Organism
attributes
Age Age of the organism Main factor for predisposition to
disease
84 years, 9 months (32–35)
Gender Gender of the organism Possible disproportionate effect
arising from difference in anat-
omy and hormonal
composition
Male, female (36, 37)
Phenotype Clinical phenotypes of the or-
ganism from which the sam-
ple was extracted
Supports comparative analysis
for underlying pathomechan-
isms based on the observable/
measurable characteristics
Healthy control,
early incipient
(38)
Behavioural
Effect
Description of behavioural
changes occurring in organ-
ism due to treatment or other
effects
Impact of developed drug or
other environmental factors to
treat or reduce the disease/dis-
ease symptoms
Reduced agitation/
aggression
(39, 40)
Disease type The disease occurrence is due
to hereditary or effect of en-
vironmental factors
To distinguish the genetic vari-
ability and complexity be-
tween the two types during
analysis
Sporadic, familial (41)
Stage Disease stage of the organism
from which the sample was
extracted
Capability to distinguish severity
of the affected disease
Incipient, severe,
BRAAK II
(42)
Cause of
death
Reason for the organism’s
death
To determine if Alzheimer’s dis-
ease or its associated comor-
bidities are major contributors
to death rate
Respiratory disorder (43)
Comorbidity Existence of another disease
other than Alzheimer’s
To determine the impact of an-
other disease on Alzheimer’s
disease aetiology and
progression
Type 2 diabetes (44, 45)
Sample
annotations
Post mortem
duration
(PMD)
Duration from death till the
sample extraction from the
dead organism
To assess quality and reliability
of the sample obtained by
measuring RNA integrity that
is influenced by natural deg-
radation of the sample after
death
2.5 hours (46, 47)
pH pH value of the extracted post-
mortem sample
Indicator of agonal status and
RNA integrity
6 (48–50)
Functional
effect
Description of functional ef-
fects observed
Observed changes such as gene
expression, post-translation,
or pathway due to external
effects
Decreased expres-
sion of BDNF
gene, reduced Ab
toxicity
(51, 52)
Brain region Brain region of the extracted
sample
Provides information of patho-
genesis and disease progres-
sion, as AD does not affect all
the brain regions
simultaneously
Hippocampus (53, 54)
Cell and cell
parts
Type of cells or cell parts ex-
tracted from the sample for
analysis (if any)
To determine cell type specific
expression influencing patho-
genesis and regional
vulnerability
Synaptoneurosome,
neurons and
astrocyte
(55, 56)
Body Fluid Type of body fluid used for
analysis
Could serve as biomarkers for
early diagnosis and therapy
monitoring
CSF, blood (57–59)
The table provides a list of metadata fields, confirmed by disease experts, critical for NDD meta-analysis. The selected fields are classified as organism attributes
and sample annotations based on their relevancy to organism or sample source.
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entry, this information should appear in the
‘Characteristics column’ of ArrayExpress and GEO. Again
inconsistent adherence to annotation standards means that
manual inspection is needed to capture correct and com-
plete information from these archives.
Accessing linked publications
For annotation information that is not directly available
from the source repositories, we refer to the associated full
text publications. However, not all deposited studies link
to an associated publication in PubMed, contributing to a
Table 2. Detailed description of additional metadata fields, defined specifically for mouse and rat models
Annotation type Metadata fields Description of the
annotation
Relevancy for NDD Examples References
Organism
attributes
Physical injury Method used to cause brain
injury in animal models
Consideration for analysing
plaque formation in animal
models to mimic disease
symptoms in human
Traumatic brain injury,
ischemia reperfusion
injury
(60, 61)
Type of
treatment
Description of chemical,
drug, genetic or diet
treatment
Consideration for determining
the effect of treatment on
animal models either to
mimic or treat the disease/
symptoms
Long-term pioglitazone,
BDNF treated
(62, 63)
Dosage Detailed description of the
dosage associated with
“type of treatment”
description
Consideration of the right
quantity of the substance for
determining the effect on
animal models either to
mimic or treat the disease/
symptoms
Total polyphenol 6mg/
kg/day, received
drinking water with-
out ACE inhibitor
(64, 65)
Mouse/rat
strain name
Mouse model official or
author given name
To determine the effect of dif-
ferent manipulated animal
models in recapitulating key
AD features capable of
extrapolating to human
studies
C57BL/6-129 hybrid,
Sprague–Dawley rat
(66, 67)
Mouse/rat
weight
Weight of the animal model
during analysis
Establishing a causative link to
metabolic disruption
100–150 g (68)
These additional metadata fields are defined by disease experts as critical for translating mouse/rat model outcomes to human, in the field of neurodegenerative
diseases.
Go to GEO, AE or 
GEO2R page
Captured 
all 
relevant 
data?
Read associated 
publicaon
Update the curators 
excel sheet
Yes
Automacally extract the 
relevant  meta-data ﬁelds  and 
pre-ﬁll the curaon excel sheets
No
Data also 
available in 
preﬁlled 
columns?
No
Yes
Improve pre-ﬁller method
if possible
NeuroTransDB
Figure 4. Semi-automated workflow for metadata curation. Automatically extracted metadata fields are rechecked by the curators. To capture the
missing fields, curators browse through GEO, ArrayExpress (AE) or GEO2R experiment’s description pages. For cases where the information is still
incomplete, associated fulltext publications and their associated supplementary material are read. All the extracted metadata annotations are stored
in NeuroTransDB. Intermediately, if feasible, automated extraction leverages on curator’s experience for improvement. This process is carried out
half yearly.
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significant loss of information while curating. We at-
tempted to overcome this by searching for an associated
article using the study title with search engines such as
SCAIView and/or Google (http://www.scaiview.com and
https://www.google.com). Supplementary Figure S3 shows
the percentage of articles that were retrieved with different
search strategies. We are aware that not all the experi-
ments in these databases are associated with published art-
icle (14%), but for 9% of the experiments (prioritized as 1)
we were able to link them to publications through a title
search. We strongly encourage study depositors to provide
PubMed annotation whenever available to allow enhanced
meta-annotation. Additionally, database owners should
find a more robust way to update their resources.
Duplication and inconsistent sample counts
We observed differences in sample counts for some experi-
ments between ArrayExpress and GEO, when downloaded
automatically. For example, GSE49160 contained 36 sam-
ples in GEO and 72 samples in ArrayExpress. Following
closer inspection at several similar experiments, we found
that ArrayExpress duplicates sample IDs to provide separ-
ate links to different raw file formats or large raw files split
into smaller ones (57%), processed raw files (17%), separ-
ate entry for each channel in double channel arrays (14%)
and replicates (12%) (cf. Supplementary Figure S4); more-
over, the duplicated samples mostly represented the same
annotation information. Since, we used sample IDs as a
unique entry in our database, the duplicated IDs were
replaced with the last entry from the archive, in
NeuroTransDB, as read by our algorithm; thus a risk of
loosing the raw file or other non-duplicated annotation
information.
Apart from duplication, occasionally some samples
were missing in one archive relative to the other. For ex-
ample, GSE47038 had some additional samples in
ArrayExpress, which were not present in GEO. When we
contacted the ArrayExpress team, they suggested that the
experiment entry could be out of sync, since each entry
from GEO is uploaded into ArrayExpress only once and is
not updated if GEO deletes some samples later. However,
they have now corrected the entry. This demonstrates a
need for periodic review of study records in each database.
Missing RAW filenames
Public transcriptomic archives provide a gateway for the
search and retrieval of studies for subsequent analysis out-
side of the platform. Therefore, one has to obtain the link
between a sample’s raw file name and corresponding
phenotype. However, this is not the case when applying
automated downloads. The majority of the raw file names
present in public archives contain syntactical errors such as
surrounded by brackets or separated by comma; moreover,
such entries could be normalized through a simple script.
In cases where no information about sample’s raw file
name is provided, manual intervention is required to link
sample’s raw file to its respective sample. This clearly indi-
cates the need for standardization of the database entries
for automation and to prevent loss of information.
Incorrect and incomplete metadata information
We also observed inconsistent meta-annotations between a
study deposited in an archive and the information in the linked
publication. In GEO for experiment GSE2880, the sample de-
scription page states that male Wistar rats have been used for
the study. However, when we looked into the associated full
text article, in the Methods section, the authors clearly men-
tion using female Wistar rats (69). We are still waiting for the
author’s reply to correct the gender information for this entry.
Another example is GSE18838, we observe that the ratio of
male to female patients provided in GEO (male/female: 19/9)
is different from that reported in the Supplementary file (male/
female: 18/10); additionally, Supplementary Table S2 provides
detailed challenges faced during mapping of age and gender
information to samples. When searched in ArrayExpress, this
experiment has been removed from the database, for un-
known reasons. In yet another example, GSE36980, the age
information for sample GSM907823 and GSM907823 vary
between GEO (84 and 81 years, respectively) and
ArrayExpress (74 and 86 years, respectively). From these
anecdotal experiences, it is evident that one has to spend
immense effort to obtain correct metadata information.
Database owners and the submitters have to take utmost care
to provide the correct data for reproducibility.
Information extraction from chained references
One further time consuming task included looking follow-
ing chains of references to previous publications for human
and animal model information such as mouse name, cross
breeding steps applied and human subject information. In
some cases, we had to tediously trace back 5–6 cross-
referred publications to obtain the original source of
information.
Normalization of metadata annotations
Meta-annotation involved the curation team extracting the
original text as provided in GEO/ArrayExpress or in the
published literature. We observed many different ways to
express information for each annotation field, with obvi-
ously ramifications for accurate and efficient querying of
NeuroTransDB. In an effort to standardize entries for dif-
ferent annotation fields specific controlled vocabularies
were adopted during curation.
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Age and gender normalization
We observed several different ways of representing age
such as ‘24 yrs’, ‘25 yo’ and ‘236 2 years old’. All age val-
ues were standardised by converting to simple decimal
numbers, e.g. 24.00 for 24 years. Similarly for gender, we
used a consistent representation of ‘M’ and ‘F’. As an ex-
ample, gender information for GSE33528 samples were re-
ported in the associated article (40) as ‘70% of the
participants were women’. Here, we annotated the infor-
mation as ‘70% female’. Although the annotations such as
ranges (e.g. ‘236 2 years old’), ratios (male/female: 19/9),
or percentages (70% female) (40) are study-level annota-
tions, they were provided as sample level annotations; as
they do not contribute to reasonable cohort selection we
did not normalize them.
Phenotype, brain region and stage normalization
Disease phenotype and stage information contributes to
specific details of clinical manifestations whereas the tissue
source (hereafter brain region) caters to the sample origin.
For all the curated phenotype mentions (human), we gener-
ated a binning scheme: diseased, control or treated. These
binned terms were further mapped to controlled vocabula-
ries provided by Alzheimer’s Disease Ontology (ADO)
(32). Other annotated terms that are not specific to AD
were mapped to the Human Disease Ontology (33),
Medical Subject Headings (MESH), Medicinal Dictionary
for Regulatory Activities (MEDDRA) and Systematized
Nomenclature of Medicine - Clinical Terms (SNOMED-
CT) (34) ontologies (http://bioportal.bioontology.org/
ontologies/MESH and http://bioportal.bioontology.org/
ontologies/MEDDRA). This caters the need to query sam-
ples at a more abstract level, for downstream analysis. In
total, for AD, we obtained 481 phenotype mentions as-
signed to at least one entry in the bins generated. Similarly,
all the stage mentions (117 terms) were mapped to ADO,
and ONTOAD (35). Mentions of brain region (41 unique
terms) were tagged to Brain Region and Cell Type
Terminology (BRCT) (http://bioportal.bioontology.org/
ontologies/BRCT?p¼summary). Please refer to
Supplementary File S2 for detailed mapping of human an-
notation terms to controlled vocabularies.
Normalization of animal models
Similar to human phenotype normalization, we have nor-
malized mouse and rat phenotype terms to EFO and
SNOMED-CT. Different treatment procedures have been
used to generate animal models that capture specific as-
pects of human diseases. At times, the incomplete nature of
the models could lead to inadequate or misinterpretation
of results. Thus, it is necessary to know the experimental
procedures used on these animal models. To enhance this
interpretation, we have binned all the captured animal
model information, during the metadata curation, to a
higher level of abstraction, further mapped to EFO, the
National Cancer Institute Thesaurus (36), and the
BioAssay Ontology (37). In addition, we mapped mouse
and rat names to EFO, Jackson Laboratory database iden-
tifiers, and Sage Bionetworks Synapse Ontology (http://jax-
mice.jax.org/query/f?p¼205:1:0 and http://bioportal.
bioontology.org/ontologies/SYN). This provides more
flexibility during querying of samples from specifically
treated animal models. Please refer to Supplementary Files
S3 and S4 for mapping of mouse and rat-related terms to
controlled vocabularies.
For some of the metadata terms, there were no con-
trolled vocabularies available, e.g. ‘Vehicle #1:non-
transgenic’ or ‘BDNF-treated’, describes that the mouse is
non-transgenic and a vehicle in the former case, while in
the second case it is specific gene treatment. Such terms
were mapped to either of the phenotype’s controlled vo-
cabulary. In case of human stage mentions, specific stages
such as Braak II or cognitive scores, such as CERAD,
MMSE, etc. could not be mapped to any staging controlled
vocabulary as most of the ontologies used higher level of
staging, namely Braak. Moreover, in most of the ontolo-
gies cognitive tests are not classified under staging, but ra-
ther as cognitive tests. This has prompted us to generate a
more detailed hierarchical representation of the above-
mentioned binning schemes, which will be published
separately as ontology, specifically for neurodegenerative
gene expression studies. However, for current version, we
stick to the already available controlled vocabularies, in
addition to our internal classification.
Curation results and discussion
Compliance to standards
Authors tend to provide minimum information as required
by the guidelines in archives; publishing major part of the
experimental metadata annotations in associated publica-
tion. To test, whether the authors adhere to the minimum
compliant standards, we performed an assessment of the
complaint scores provided by ArrayExpress, the highest
score being 5, for Alzheimer’s studies. Figure 5 shows the
trend in distribution of retrieved AD experiments (see Data
Retrieval section) in ArrayExpress, based on the published
MIAME and MINSEQE scores (for human, mouse and rat
experiments). We observe the trend of submission is con-
centrated around the score of 4, showing that the submit-
ted data are not fully MIAME or MINSEQE compliant;
leading to variable levels of information stored in these
archives.
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To conclude that not all the submitters’ abide 100% by
the compliant standards, we investigated if this trend is
same for all other disease domains; we chose one among the
most studied cancer disease, Lung Cancer, and generated
similar results to AD. Supplementary Figure S5 shows the
distribution of compliant standards across Lung Cancer
studies. From this observation, we show that the loss of in-
formation follow the same pattern across all submissions
(varying mostly around score of 4). As a result, automated
retrieval and meta-analysis is impeded, due to lack of infor-
mation availability. Details of the experiment IDs investi-
gated for AD and Lung Cancer, along with compliant scores
is provided in Supplementary File S1.
Retrieval and prioritization of indication specific
studies from GEO and ArrayExpress
Retrieval of experiment IDs using a keyword search (cf.
Data Retrieval section) also acquires false positive experi-
ments. Any non-disease specific experiment performed by
an author named ‘Alzheimer’ is also retrieved when search-
ing for AD specific experiments. For example, E-MTAB-
2584 aims to investigate neuronal gp130 regulation in
mechanonociception but was retrieved for AD since one of
its author’s name is Alzheimer. Moreover, we also ob-
tained experiments for related diseases such as Epilepsy, or
Breast Cancer, when querying for AD. For example,
GSE6771, and GSE6773 are Epilepsy studies; GSE33500
belongs to Nasu Hakola Disease; all these studies were
retrieved when queried for Alzheimer. Incorrect organism
specificity was also noticed during prioritization. For ex-
ample, GSE5281 was retrieved as rat study although it
belonged to human. Similarly, GSE2866 was retrieved as
mouse study but it belonged to zebra fish. Although incor-
rectly identified studies are not too high, this still indicates
the need to include organism and disease specificity filter
during prioritization. Additionally, we manually identified
a few experiments that were not retrieved using these key-
words, which were also included in the database.
Further on, just by applying these two filter criteria does
not assure that all retained experiments were specific to
AD. For example, there could be some experiments that
aim at a certain pathway that are also relevant in the area
of neurodegeneration, but the experiment submitted to the
repository does not deal with AD pathology. As a conse-
quence, additional disease relevancy conditions were
included before prioritization (cf. Experiment Prioritization
section). An overview of all the retrieved AD experiments,
categorized to one of the priority classes is shown in
Figure 6. In addition, a list of priority 1 experiments (for
human, mouse and rat) is provided in Supplementary file
S5. This figure indicates that nearly 20% of the retrieved
studies are in any case not related to AD. On the other
hand, to identify the remaining 80% of the experiments
(prioritized as 1 and 2) we need massive manual filtering by
trained personnel. Only if the archives take an initiative to
apply such a structured classification for all uploaded ex-
periments, individual time-cost can be reduced to a greater
extent.
Some experiments contain cell lines or other disease sam-
ples in addition to Alzheimer’s patient samples. Experiment
GSE26927 additionally contain samples from patients suffer-
ing from Parkinson’s disease, multiple sclerosis, etc. To be
able to query only AD related samples for integrative
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Figure 5. Distribution of MIAME and MINSEQE scores for all automatically retrieved Alzheimer’s Disease gene expression experiments in
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analysis, we additionally included priority information at
sample level. For example, we tagged Alzheimer’s disease
samples to AD1 whereas multiple sclerosis samples to MS1.
Please refer to the README.txt file for various priority no-
tations used.
Metadata curation
The underlying metadata information for any gene expres-
sion study has been underrepresented and thus is largely
under-utilized. To perform large-scale analysis, associated
annotations are of utmost importance. With the availabil-
ity of detailed annotation information, one is capable of se-
lecting studies that focus on a particular attribute, such as
stage or gender. Each priority class has a specific set of
fields for curation; some fields are organism dependent.
After prioritization of experiments (cf. Experiment
Prioritization section), we expect to have 100% coverage
of essential clinical and relational parameters during man-
ual metadata curation for priority 1 studies. For example,
age, gender, phenotype and stage are basic experimental
variables for human studies. Additionally, in case of ani-
mal models, mouse and rat strain names are important for
translational pipelines, as some strains are highly specific
models for human NDD while others not (38). Irrespective
of the organisms, samples mapped to their corresponding
raw file identifiers are vital for running large-scale analysis.
However, as shown in Figure 7, this does not hold true for
human studies. From Figure 7, it is evident that even after
performing thorough curation, we cannot achieve 100% in
capturing information for these five basic metadata fields,
a fact that is largely due to patient data privacy regula-
tions. Similar is the case with mouse and rat information,
see Supplementary Figure S6. Moreover, information
related to animal models are much more scare, obstructing
automated retrieval. Hence, manual curation accuracy is
highly dependent on information availability, as curators
cannot harvest information for annotation fields that are
not available. On the contrary, the level of detail also de-
pends on the type or aim of the experiment carried out.
The authors and database owners obviously need to focus
on the qualitative aspect of the experimental information,
especially the phenotype of the sample, to allow normal-
ized access for beginners, with standard prose, in order to
support a robust computational analysis across all studies
in ArrayExpress and GEO.
We selected five of the most common metadata fields
(common to any disease domain such as age, gender, pheno-
type, stage and raw filename) and carried out a trend analysis
of information availability versus time. Figure 8 (A) shows
the trend over time for the metadata information provided in
the archives versus the number of annotation fields that can
be harvested after manual curation for human AD priority 1
experiments. Although a bit obscure, we can observe that the
level of information submitted to the databases remains al-
most stable in the last decade (between 2 and 4 metadata
fields). Moreover, with manual curation support, we were
able to capture the majority of the remaining metadata from
associated publications, Figure 8 (B) shows the shift in the
mean value of the metadata availability. However, the trend
is recently declining since the authors submit relatively lesser
level of detailed information than in former times in the asso-
ciated publications.
The incompleteness of metadata annotations contrib-
uted to a substantial increase in curation workload through
an increased need for publication reading. This leads to a
steep increase of the cost of the trained personal for cur-
ation. Overall, for the prioritization and metadata curation
of AD gene expression studies, we spent about 1 year of
four biocurators effort (working 10 h/week). This does not
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include the expert’s effort, who constantly provided guid-
ance and monitored the curation work during the same
duration.
Accessing NeuroTransDB
Metadata annotations for priority 1 AD gene expression
studies for human, mouse and rat organisms, from GEO
and ArrayExpress, are stored as MySQL tables separately;
downloadable as dump files at Fraunhofer SCAI File
Transfer Protocol (FTP) website: http://www.scai.
fraunhofer.de/NeuroTransDB.html. Please refer to the
README.txt for details of how to install and use MySQL
dumps. Additionally, these tables are provided as Excel
files to allow users to use the curated information in their
preferred tools/interface. Currently, the data is in its non-
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normalized form. Normalized data, tagged with standard
ontologies (cf. Normalization of Metadata Annotations
section), will be made available through the
AETIONOMY Knowledge Base. Currently, we have pro-
vided human priority 1 studies normalized using our in-
ternal binning scheme. Half yearly updates are planned.
Our ultimate goal is to make NeuroTransDB a comprehen-
sive resource for researchers working on large-scale meta-
analysis in the field of neurodegenerative diseases.
Conclusion and future directions
NeuroTransDB fills the gap for large-scale meta-analysis
on publicly available gene-expression studies in the field of
neurodegeneration. It joins bits of missing metadata infor-
mation, scattered in public archives and associated publi-
cations, into a consistent, easily accessible and regularly
updated data resource. Additionally, in this paper, we have
systematically specified key issues encountered during se-
lection of relevant gene expression studies from public
archives, along with their associated metadata informa-
tion. We observed a huge lack of structured metadata in
these archives, hampering automated large-scale reusabil-
ity on a usable level of abstraction. We present here recom-
mendations, as guidelines, for prioritizing relevant studies
and a step-by-step protocol for metadata curation. The
challenges faced in the course of the development of these
guidelines have been pointed out, and the huge manual ef-
fort has been made explicit.
The work presented here has listed metadata fields, which
have been generated based on disease expert consultation.
They are highly important for choosing the right subsets of
expression studies to answer complex biological questions
underlying a diseased pathology. Some additional fields are
included for animal models studies to allow maximal use for
translational research. For all the manually curated fields, we
describe normalization strategies in an attempt to provide
standards for more robust automated querying and interoper-
ability. Our results show the amount of information that is
scattered in various resources, requiring extensive manual ef-
fort to capture the same. Additionally, we report that even
with comprehensive manual harvesting, we were not able to
capture 100% of information to fill for the basic annotation
fields. We demonstrate convincingly that data availability de-
pends largely on the meticulousness of the submitters.
Additionally, it also depends on the aim of the experiment
carried out. On an average, considering all the retrieved AD
experiments, the submitters provide about 60% of the most
basic metadata information. The outlined guidelines could be
of significant value to other researchers working on gene-ex-
pression studies. The described key issues we faced during
such a curation work could influence the data submission
and data storage architecture of public repositories.
Subsequently, we plan to extend the curation pipeline
to other NDD diseases namely, Huntington’s disease. A
more gene-expression specific ontology will be built based
on the curated annotations for selecting a subset of studies
for meta-analyses. Although, microarray studies are the
major contributors to the public repositories, RNA-Seq
data are rapidly growing. We comprehend that it will be
necessary for us to identify all the relevant RNA-Seq stud-
ies, since their large storage space has contributed to dis-
perse nature of the available raw data.
Supplementary Data
Supplementary data are available at Database Online.
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